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ABSTRACT 
MATTHEW ALLAN HORWITZ: COMPLEXITY-BUILDING TRANFORMATIONS ENABLED BY 
BRØNSTED BASE ORGANOCATALYSIS 
AND 
PROGRESS TOWARD THE TOTAL SYNTHESIS OF THE VERATRUM ALKALOIDS JERVINE, 
CYCLOPAMINE, AND VERATRAMINE 
(Under the direction of Jeffrey S. Johnson) 
 
I.  Asymmetric Organocatalytic Reductive Coupling Reactions between Isatins and 
Aldehydes 
 
A fully organic phosphite-mediated stereoselective reductive coupling reaction between 
isatins and aldehydes was developed. A Pudovik-phospha-Brook sequence was used to invert the 
polarity of the isatin, which allowed the formation of an enolate intermediate. Subsequent aldol-
type addition into aldehydes provided a new carbon-carbon bond and two new stereocenters with 
high yields and stereoselectivities using a chiral triaminoiminophosphorane organocatalyst. Using 
this novel umpolung reaction, chemically differentiated diols were formed and a new two-electron 
pathway for reductive coupling of carbonyl reaction partners was demonstrated.  
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II. Asymmetric Organocatalytic Reductive Coupling Reactions between Benzylidene 
Pyruvates and Aldehydes 
 
Utilizing the previously developed two-election reductive coupling mechanism, dimethyl 
phosphite was used as an organic reductant to reductively couple benzylidene pyruvates and 
aldehydes. Though a larger number of selectivity issues were present in this case, the desired mode 
of carbonyl coupling was enabled in a stereoselective fashion using a chiral 
triaryliminophosphorane catalyst. Using this reaction manifold, a range of highly functionalized 
stereodyads were generated in high diastereoselectivity, enantioselectivity, and yield. The reaction 
was demonstrated to work on gram scale. 
	
III. Phosphazene-catalyzed Desymmetrization of Cyclohexadienones by Intramolecular 
Dithiane Addition 
 
A phosphazene-catalyzed desymmetrization reaction of dithiane-tethered 
cyclohexadienones is established. Using the ester-bound dithiane nucleophile, a conjugate addition 
reaction was found to be possible using catalytic P2-tBu phosphazene base. A series of products 
containing two nascent stereocenters was synthesized in a racemic sense. Chiral iminophosphorane 
catalysts were studied but were found to not give enantioenrichment in the product. Deprotection 
of the dithiane and desulfurization were studied but proved unsuccessful. An independent synthesis 
of the a-ketolactone that would result from dithiane deprotection also failed using an oxidative 
deacylation strategy, suggesting an inherent product stability issue. 
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IV. Diastereoselective Organocatalytic Addition of a-Angelica Lactone to b-Halo-a-
ketoesters 
 
A diastereoselective addition of a-angelica lactone to b-halo-a-ketoesters is discussed. 
Using commercial quinidine as an organocatalyst, three contiguous stereocenters were set in a 
relative sense. The scope of the reaction demonstrated that high diastereoselectivity was possible 
in several cases with either a b-bromo or b-chloro substituent on the a-ketoester, though yields 
were moderate. A stereochemical model was developed to explain the observed outcome. Though 
a-angelica lactones are most commonly nucleophilic at the g-position, this reaction was found to 
proceed with an observed a-nucleophilicity of the a-angelica lactone. Hydrogenation of the 
product was found to result in a diastereoselective formation of a fourth stereocenter by delivery 
of hydrogen to the least hindered face of the alkene.  
	
 
V. Progress Toward the Total Synthesis of the Veratrum Alkaloids Jervine, 
Cyclopamine, and Veratramine 
 
Efforts toward a de novo total synthesis of the Veratrum alkaloids jervine, cyclopamine, 
and veratramine are presented. A novel synthetic approach relying on oxidative dearomatization 
of a tyrosine derivative and local desymmetrization of a cyclohexadienone was developed. Starting 
vi 
	
from a known racemic b-methyltyrosine derivative with two stereocenters set in a relative sense, 
a third stereocenter in the E ring of jervine and cyclopamine was conveniently set with a 
borohydride reduction. The oxidative dearomatization sequence was found to lead to the desired 
6-5 framework necessary for the DE ring system of jervine and cyclopamine, but a competitive 
cyclization process necessitated further revisions to the route.  
 
 
VI. Enantio- and Diastereoselective Organocatalytic Conjugate Additions of 
Nitroalkanes to Enone Diesters 
 
A conjugate addition of nitroalkanes to enone diester electrophiles was used to provide two 
new stereocenters in polyfunctionalized products. A one-pot procedure for the synthesis of the 
starting materials from diazo compounds and Wittig reagents was developed and used to generate 
a wide range of substrates. A triaryliminophosphorane organocatalyst enabled high 
stereoselectivity in the conjugate addition reaction. Reduction of the nitro group and 
diastereoselective cyclization led to the formation of a third stereocenter in the lactam products. 
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CHAPTER ONE: 
ASYMMETRIC ORGANOCATALYTIC REDUCTIVE COUPLING REACTIONS BETWEEN 
ISATINS AND ALDEHYDES* 
 
1.1 Introduction 
 The synthetic toolbox that is available to organic chemists is constantly expanding as a 
result of innovation in reaction methodology. Consquently, new avenues in the field of natural 
product synthesis are developing, which in turn will lead to a larger amount of biological screening 
and translational applications. Retrosynthetic analysis in natural product synthesis relies on 
polarity relationships, which are related to the placement of carbon-heteroatom bonds in target 
molecules. While many canonical reactions (including additions into carbonyls, enolate chemistry, 
and conjugate additions) rely on traditional polarity relationships, a larger synthetic toolbox 
invoking umpolung (polarity reversal) reactions would allow a plethora of new approaches in 
natural product synthesis. Traditional polarity relationships in retrosynthetic analysis allow 
consonant disconnections, while umpolung relationships allow dissonant disconnections. One of 
the most common dissonant disconnections is a 1,2-diol motif, which can be achieved through a 
reductive coupling of carbonyl reaction partners. Well-established methods for accomplishing this 
transformation normally require stoichiometric or superstoichiometric amounts of metal reagents, 
and result in non-stereoselective formation of non-chemically differentiated diols. Here, we 
																																								 																				
*	Reprinted in part with permission from The Royal Society of Chemistry. Horwitz, M. A.; 
Tanaka, N.; Yokosaka, T.; Uraguchi, D.; Johnson, J. S.; Ooi, T. Chem. Sci. 2015, 6, 6086. – 
Published by The Royal Society of Chemistry. 
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develop a reductive coupling reaction between isatins and aldehydes using commercial 
dialkylphosphites as the organic reductant and a chiral triaminoiminophosphorane catalyst to 
establish the two new stereocenters with high diastereo- and enantioselectivity.  
1.2 Background 
1.2.1 Extant Approaches to Reductive Coupling of Carbonyls 
Reductive coupling of unsaturated functional groups has enabled the rapid construction of 
new chemical bonds in a large number of reaction manifolds. In addition to the bonds created 
through this process, the stereochemistry that results from the formation of new tetrahedral centers 
adds value to the process. Under the umbrella of carbonyl reductive coupling process lie several 
mechanistic categories.1 The pinacol reaction makes manifest the ketyl radical coupling 
mechanistic pathway. Utilization of low-valent metals in this transformation has enabled this 
single-electron mechanism to proceed in many different contexts.2-6  For example, low-valent 
titanium species can be utilized to promote pinacol couplings between distinct aldehyde reaction 
partners. In a foundational example from the Yamamoto group, the chiral chromium complex 
TBOxCrCl was used to enable the homocoupling of aldehydes in high yields and stereoselectivities 
(Scheme 1-1).4w In 2009, Duan and coworkers were able to obtain the cross-coupled diol as the 
major product of a pinacol reaction (Scheme 1-2).4x 
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Scheme 1-1.	Yamamoto’s Stereoselective Homocoupling of Aldehydes 
 
 
Scheme 1-2.	Pinacol Coupling with Distinct Aldehyde Partners 
 
 
However, a broader perspective of these advances highlights a number of common 
shortcomings: stoichiometric or superstoichiometric metal reagents are generally needed (with a 
few exceptions).4n-4r  Moreover, the nature of the mechanism can render it difficult to control both 
chemoselectivity (homo- versus cross-coupling) and stereoselectivity, and the lack of 
differentiation of the nascent alcohols can be nettlesome. These precedents collectively informed 
our interest in developing an alternative, potentially generalizable reductive coupling strategy that 
utilizes a polar two-electron reaction mechanism for addressing the aforementioned issues. The 
purpose of this research direction is to detail a new base-catalyzed cross coupling of carbonyls 
mediated by an economical organic reductant, diethyl phosphite; the stereochemical outcome of 
this multicomponent process is precisely controlled by a chiral triaminoiminophosphorane (Figure 
1-1a).7,8 
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Figure 1-1.	Stereoselective Reductive Coupling Reactions 
 
1.2.2 Precedents for Phosphite-mediated Reductive Coupling 
At the outset, we envisaged the possibility of catalytic generation of an a-oxycarbanion 
from a carbonyl substrate and its rapid and selective trapping with another carbonyl compound to 
form 1,2-diols. For substantiating this hypothesis, polarity reversal of a particular carbonyl group 
is of critical importance and we sought to take advantage of the phosphonate–phosphate (phospha-
Brook) rearrangement to achieve this requisite process. Thus, a base-catalyzed sequence of 
Pudovik addition and phosphonate–phosphate rearrangement between ketone 1.1 and dialkyl 
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phosphite was projected to lead to carbanion 1.2. The interception of this key intermediate by 
aldehyde 1.3 would afford mono-protected diol 1.4 through dialkoxyphosphinyl migration (Figure 
1-1b).9  
The overall electron flow proposed in the phosphite-mediated reductive coupling was a 
conceptual outgrowth of extant mechanistic precedents utilizing the Pudovik reaction (Scheme 1-
3a) and the phosphonate-phosphate (phospha-Brook) rearrangement (Scheme 1-3b). In 2011, 
Nakamura applied these motifs in a Pudovik-phospha-Brook-protonation cascade that provided 
enantioenriched phosphates in high yield using commercial quinine as the Brønsted basic 
organocatalyst (Scheme 1-4a).9e Following this development, the Ooi and Johnson groups reported 
a phospha-Brook-aldol sequence that allowed a carbon-carbon bond formation to give two 
adjacent stereocenters with good yields and excellent stereselectivities (Scheme 1-4b).9c The 
Terada group subsequently developed a Pudovik-phospha-Brook-addition sequence that allowed 
an intramolecular cyclization to proceed in a racemic sense with P2-tBu phosphazene (Scheme 1-
4c).9d 
Scheme 1-3.	Pudovik Reaction and Phospha-Brook Rearrangement 
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Scheme 1-4.	Mechanistic Precedents for the Title Reaction 
 
 
A crucial departure from prior art is the fully intermolecular nature of the coupling and the 
need for the phosphite to exhibit complete selectivity between the two carbonyl reactants. We 
reasoned that the crucial chemoselectivity issue underlying this mechanistic framework, viz. the 
selective generation of a-oxycarbanion 1.2 from ketone 1.1, would be ensured by the inherent 
reversibility of the Pudovik reaction and the reluctance of the aldehyde Pudovik product to undergo 
phospha-Brook rearrangement. In addition, absolute stereochemical guidance in the C–C bond-
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forming event could be provided by the conjugate acid of a suitable chiral base. In providing the 
conceptual blueprint for this scenario, we focused our attention on the exceptional electrophilicity 
and utility of a-dicarbonyls.9d–g,10 
1.3 Results and Discussion 
1.3.1 Development of Racemic Phosphite-mediated Reductive Coupling Reaction 
 Steps were initially taken to assess the feasibility of the proposed reaction in a racemic 
sense using achiral bases such as potassium tert-butoxide (KOtBu). Initial trials with diethyl 
phosphite as the stoichiometric reductant indicated that the reaction proceeds most cleanly and 
efficiently when a protecting group is used on the isatin. Benzyl, allyl, and methyl protecting 
groups were examined using 20 mol % KOtBu in THF at 0 ºC (Table 1-1, (±)-1.4a–(±)-1.4c). 
Under these conditions, the reactions were complete in minutes with no observable intermediates 
(if the aldehyde is omitted from the reaction, the Pudovik-phospha-Brook product can be observed, 
however).9f These experiments revealed that the benzyl protecting group provided the highest 
isolated yield and diastereoselectivity. We subsequently verified that para-tolualdehyde is not 
capable of phospha-Brook rearrangement when treated with diethyl phosphite and 20 mol % 
KOtBu: only the Pudovik adduct was observed, implying that it is the isatin that is undergoing 
polarity reversal as we expected. We then briefly studied the scope of the racemic reaction. The 
reaction gives consistently good yields for various aryl aldehydes incorporating substituents of 
different electronic properties (Table 1-1, (±)-1.4d–(±)-1.4g). At the current level of optimization, 
alkyl aldehydes and Boc-protected imine electrophiles were not well tolerated and only provided 
messy reactions.11 The substitution pattern of the isatin was also examined; we found that the 
racemic reaction is reasonably flexible in terms of isatin electronics ((±)-1.4h–(±)-1.4k). 
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Table 1-1.	Three Component Reductive Coupling: Racemica 
 
	
a All reactions were run on 0.2 mmol scale, using 1.1 equiv of dialkylphosphite and 5.0 
equivalents of aldehyde. % Yields refer to isolated yields. All dr and % yield values are the 
averages of two trials. Reactions were run until complete as adjudged by TLC. b % Yield 
determined by crude 1H NMR spectroscopy using mesitylene as an internal standard.  Products 
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derived from apparent retro-reaction significantly diminished the isolated yield; therefore, this 
substrate was not selected for further study.  
1.3.2 Development of Asymmetric Reaction 
 Efforts were next directed to the development of the enantioselective variant.12 We were 
encouraged to find that when we used the chiral iminophosphorane (C1), we obtained the 
secondary phosphate 1.4a with appreciable enantioenrichment (er 89.5:10.5), although the 
diastereoselectivity was poor (Table 1-2, entry 1). Gratifyingly, we found that upon lowering the 
temperature to -78 ºC, phosphate 1.4a was obtained in 82% yield, 15:1 diastereoselectivity and an 
er of 96.5:3.5 (entry 2). Using the same temperature, we proceeded to evaluate the effect of the 
catalyst structure (entries 3 to 6), but ultimately concluded that a-branching in ligand substituent 
R is essential for promoting the desired transformations and the valine-derived iminophosphorane 
C1 was optimal in terms of stereoselectivity and chemical yield. 
1.3.3 Crossover Experiments Probing the Reversibility of Asymmetric Reaction 
 The disparity between the stereoselectivities at 0 ºC and -78 ºC prompted us to investigate 
the reversibility of the carbon-carbon bond formation via crossover experiments in that 
temperature range (Table 1-3). When racemic phosphate (±)-1.4a was subjected to standard 
conditions in the presence of 4-fluorobenzaldehyde, significant incorporation of that component 
in the form of phosphate 1.4a–F was observed at 0 ºC and 40 ºC, but no crossover was observed 
at -78 ºC. These data support the hypothesis that the increase in enantioselectivity at -78 ºC is not 
only a consequence of more rigorous facial discrimination of both substrates but also shutting 
down a stereoablative retro-aldol process that is operative at higher temperatures. 
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Table 1-2.	Optimization of the Catalytic Asymmetric Reductive Couplinga 
 
	
entry T (°C) catalyst dr er % conv. 
1 0 C1 3.4:1 89.5:10.5 96 
2 –78 C1 15:1 96.5:3.5 82 
3 –78 C2 n.a. n.a. 18 
4 –78 C3 n.a. n.a. 15 
5 –78 C4 n.a. n.a. 12 
6 –78 C5 7.9:1 86:14 80 
a All reactions were conducted on a 0.1 mmol scale, using 1.1 equiv of dialkylphosphite and 5.0 
equiv of ArCHO. Argon was used to purge the reaction flasks. All dr, er, and % conversion 
values are the average of two trials. n.a. = not analyzed. 
1.3.4 Substrate Scope for Asymmetric Reaction 
 Using the optimized conditions, we evaluated the scope of the asymmetric reaction by 
initially looking at various isatins. While electron-deficient 5-halogenated isatins were well 
accommodated under the optimized conditions, use of dimethyl phosphite was indispensable for 
completion of the reactions with 5-methyl and methoxy isatins probably because of the slow 
phospha-Brook rearrangement (Table 1-4, 1.4h–1.4m).13 6-Chloro and 7-fluoro isatins were also 
smoothly converted into the reductive coupling products of high stereochemical purity using 
appropriate phosphite (1-4n and 1-4o). 
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Table 1-3.	Crossover Experiments Establish Reversibilitya 
 
	
entry T (°C) catalyst dr er % conv. 
1 0 C1 3.4:1 89.5:10.5 96 
2 –78 C1 15:1 96.5:3.5 82 
3 –78 C2 n.a. n.a. 18 
4 –78 C3 n.a. n.a. 15 
5 –78 C4 n.a. n.a. 12 
6 –78 C5 7.9:1 86:14 80 
a Product distributions were determined by 1H NMR analysis (800 MHz) of the crude mixture. 
n.a. = not analyzed. 
For exploration of aldehyde generality, we selected 5-bromo isatin as a coupling partner in 
consideration of its high reactivity and advantage of having an additional functional handle. As 
included in Table 1-4, various para substituted aromatic aldehydes were tolerated and relatively 
electron rich aldehydes exhibited higher reactivity and selectivity (1.4p–1.4t). Hetero-substituents 
at the meta-position slightly affected the stereochemical outcome (1.4u–1.4w). For sterically 
demanding ortho-substituted aldehydes, dimethyl phosphite was needed to accelerate the reaction 
and virtually complete stereocontrol could be achieved (1.4x–1.4z). 
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Table 1-4.	Scope of Asymmetric Reductive Coupling Reaction with Isatins and Aldehydesa 
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Table 1-4, cont. 
 
a All reactions were conducted on a 0.1 mmol scale, using 1.1 equiv of dialkylphosphite and 5.0 
equiv of ArCHO. Argon was used to purge the reaction flasks. % Yields refer to isolated yields. 
All dr, er, and % yield values are the average of two trials. b 15 mol % of catalyst was used. c 2.2 
equiv of dialkylphosphite was used. 
1.3.5 Determination of Absolute Configuration 
 The absolute stereochemistry furnished in the product series was determined by an X-ray 
diffraction study of phosphate 1.4j (Figure 1-2).14 
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Figure 1-2.	ORTEP Diagram of 1.4ja 
 
a Ellipsoids displayed at 50% probability. Calculated hydrogen atoms except for that attached to 
the stereogenic carbon atom are omitted for clarity. Black: carbon, Red: oxygen, Purple: 
phosphorous, Blue: nitrogen, Vermilion: bromine, White: hydrogen. 
1.4 Conclusion 
 In summary, we have developed a highly stereoselective, fully organic multicomponent 
coupling reaction between isatins and aldehydes with dialkyl phosphite as an economical 
reductant. The advantages of extending the reductive coupling into a two-electron manifold are 
manifest, and the mechanistic framework established herein may be applicable to other 
stereoselective reductive carbon–carbon bond constructions. 
1.5 Experimental Details 
Methods: Infrared (IR) spectra were obtained using an Jasco 460 Plus Fourier transform infrared 
spectrometer or a Shimadzu IRAffinity-1 spectrometer. Magnetic resonance spectra (1H, 13C, 19F, 
and 31P NMR) were recorded on a Bruker model DRX 400 (1H NMR at 400 MHz, 13C NMR at 
101 MHz, 19F NMR at 376 MHz, and 31P NMR at 162 MHz), a Bruker model DRX 600 (1H NMR 
at 600 MHz, 13C NMR at 151 MHz, and 31P NMR at 243 MHz), a JEOL JNM-ECS400 (1H NMR 
at 400 MHz, 19F NMR at 376 MHz, and 31P NMR at 162 MHz), ECA-800 (1H NMR at 800 MHz), 
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a Bruker AVANCE III-OneBay500 (13C NMR at 126 MHz) spectrometer with solvent resonance 
as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 13C NMR: CDCl3 at 77.16 ppm), or 
benzotrifluoride (19F NMR: -64.0 ppm) and H3PO4 (31P NMR: 0.0 ppm) resonances as the external 
standard. 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, br = broad, 
d = doublet, dd = doublet of doublet, t = triplet, dt = doublet of triplet, m = multiplet), coupling 
constants (Hz), and integration. High resolution mass spectra were obtained with a Thermo Fisher 
Scientific Exactive, FinniganTM LTQ-ICR FTTM, or Micromass Quattro II (triple quad) instrument 
with nanoelectrospray ionization (all samples prepared in methanol). Melting points were obtained 
using a Stanford Research Systems OptiMelt MPA100 or Thomas Hoover UniMelt Capillary 
Melting Point Apparatus. Analytical thin layer chromatography was carried out using Whatman 
0.25 mm silica gel 60 plates, Sorbent Technologies 0.20 mm Silica Gel TLC plates, or Merck 
precoated TLC plates (silica gel 60 GF254, 0.25 mm). Visualization was allowed by UV light, 
phosphomolybdic acid in ethanol, or aqueous ceric ammonium nitrate solution. HPLC analysis 
was performed on a Shimadzu SPD-M20A PDA detector with a Shimadzu SPD20AD eluent 
system using DAICEL CHIRALPAK IA or AD3 columns (ϕ 4.6 mm x 250 mm, constant flow at 
1.00 mL/min), using hexane, 2-propanol, and ethanol as eluents. To perform HPLC trials at 4 ºC, 
a Shimadzu LC-2010C HT unit was used. Asymmetric reactions were carried out under an 
atmosphere of argon, in oven-dried glass with magnetic stirring, using a UC Reactor (Techno 
Sigma) or a PSL-1810 (EYELA) reactor. Purification of the reaction products was carried out by 
using Siliaflash-P60 silica gel (40-63 µm) purchased from Silicycle, or silica gel 60 (spherical, 40-
50 µm) from Kanto Chemical Co., Inc. Yields refer to isolated yields after flash column 
chromatography; some samples contain residual minor diastereomers. Since all results are the 
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averages of two trials, the stereochemical outcomes listed in the above tables may not exactly 
match those represented in the NMR and HPLC data below. 
Materials: Tetrahydrofuran (THF) was supplied from Kanto Chemical Co., Inc. as “Dehydrated 
solvent system” and further purified by passing through neutral alumina under nitrogen 
atmosphere. Isatins were purchased from Acros Organics or Wako Chemical Co. and alkylated 
according to literature procedures.15 Triaminoiminophosphorane catalysts C1-C5 were prepared 
according to literature procedures.8b Commercially available dimethyl phosphite, diethyl 
phosphite, and diisopropyl phosphite were distilled using a Kügelrohr apparatus prior to use. 
Commerically available aldehydes were freshly distilled directly before the reactions. Potassium 
tert-butoxide was purchased from Sigma Aldrich and used as is. 
Experimental Procedures: 
General procedure for the three component reaction using KOtBu: 
 
To a stirred solution of isatin derivative (0.20 mmol), diethyl phosphite (30.4 mg, 0.22 mmol, 1.1 
equiv) and aldehyde (1.0 mmol, 5.0 equiv) in THF (2.0 mL) at 0 °C was added KOtBu (2.2 mg, 
0.02 mmol, 10 mol %). The reaction was allowed to proceed at the same temperature and was 
followed by TLC. Once the isatin was fully consumed (typically 5-10 minutes), the reaction 
mixture was quenched with saturated aqueous NH4Cl, and extracted twice with EtOAc. The 
combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in 
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vacuo.  The residue was purified by silica gel column chromatography to give the desired products 
1.4. 
 1-Benzyl-3-((((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-3-hydroxyindolin-2-one 
((±)-1.4a):  
The title compound was prepared according to general procedure. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 5.73 (major diastereomer) and δ 4.44 (minor 
diastereomer). White solid (mp 166-167 °C); 1H NMR (400 MHz, CDCl3) d 7.73 (d, J = 7.2 Hz, 
1H), 7.07-7.18 (m, 5H), 6.89-6.94 (m, 4H), 6.56 (d, J = 7.6 Hz, 2H), 6.37 (d, J = 7.6 Hz, 1H), 5.77 
(d, J = 8.8 Hz, 1H), 4.98 (d, J = 16.0 Hz, 1H), 4.38 (s, 1H), 4.28 (d, J = 16.0 Hz, 1H), 3.97-4.22 
(m, 4H), 2.30 (s, 3H), 1.30 (t, J = 6.8 Hz, 3H), 1.22 (t, J = 6.8 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 175.0, 143.3, 138.7, 134.8, 131.1 (d, J = 3.6), 130.1, 128.7, 128.4, 127.9, 127.2, 126.6, 
126.5, 126.3, 123.0, 109.4, 83.6 (d, J = 5.7 Hz), 79.1 (d, J = 4.5 Hz), 64.5 (d, J = 5.7 Hz), 64.3 (d, 
J = 5.9 Hz), 43.7, 21.3, 16.1 (d, J = 7.2 Hz), 16.0 (d, J = 6.9 Hz); 31P NMR (162 MHz, CDCl3) δ 
-0.3; IR (thin film) ν 3420, 2928, 1721, 1615, 1469, 1368, 1250, 1123, 1081, 1029, 909 cm-1; 
HRMS (ESI+) cald for C27H30NO6P 496.1889 (M+H+) found 496.1893. TLC (2:1 
EtOAc/Hexanes): Rf = 0.33.  
1-Allyl-3-((((diethyl-l3-oxidanyl)(l1-oxidanyl)phosphoryl)oxy)(p-
tolyl)methyl)-3-hydroxyindolin-2-one ((±)-1.4b):  
The title compound was prepared according to general procedure. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
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mixture by comparison of the resonances at δ 6.58 (minor diastereomer) and δ 6.53 (major 
diastereomer). Clear oil; 1H NMR (600 MHz, CDCl3) d 7.71 (d, J = 7.3 Hz, 1H), 7.30-7.27 (m, 
1H), 7.16-7.13 (m, 1H), 6.91 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.56 (d, J = 7.7 Hz, 
1H), 5.72 (d, J = 8.6 Hz, 1H), 5.28-5.22 (m, 1H), 4.87 (d, J = 10.4 Hz, 1H), 4.48-4.44 (m, 2H), 
4.29-4.20 (m, 2H), 4.14-4.01 (m, 2H), 3.78-3.75 (m, 1H), 2.24 (s, 3H), 1.35-1.29 (m, 3H), 1.28-
1.20 (m, 3H); 13C NMR (151 MHz, CDCl3) δ 174.5, 143.2, 138.7, 130.9, 130.4, 130.0, 128.4, 
127.6, 126.2, 122.8, 118.1, 116.8, 109.0, 83.5 (d, J = 5.6 Hz), 79.3 (d, J = 4.5 Hz), 64.5 (d, J = 5.7 
Hz), 64.3 (d, J = 5.9 Hz), 42.0, 21.0, 16.1-16.0 (m, 2C); 31P NMR (162 MHz, CDCl3) δ 0.23; IR 
(thin film) ν 3288, 2984, 1725, 1614, 1469, 1368, 1257, 1029, 754, 663 cm-1; HRMS (ESI+) cald 
for C23H28NNaO6P 468.155197 (M+Na+) found 468.1565. TLC (2:1 EtOAc/Hexanes): Rf = 0.17. 
 3-((((diethyl-l3-oxidanyl)(l1-oxidanyl)phosphoryl)oxy)(p-
tolyl)methyl)-3-hydroxy-1-methylindolin-2-one ((±)-1.4c):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 6.59 (minor diastereomer) and δ 6.51 (major diastereomer). The product was found 
to be unstable to silica gel chromatography.The percent yield was calculated by 1H NMR 
spectroscopy using mesitylene as an internal standard. 
1-Benzyl-3-((4-bromophenyl)(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)methyl)-3-hydroxyindolin-2-one ((±)-
1.4d):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
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resonances at δ 4.92 (minor diastereomer) and δ 4.83 (minor diastereomer). White solid (mp 168-
169 °C); 1H NMR (400 MHz, CDCl3) d 7.73 (d, J = 7.2 Hz, 1H), 7.16-7.26 (m, 6H), 7.11 (t, J = 
7.6 Hz, 1H), 6.89 (d, J = 8.0 Hz, 2H), 6.55-6.57 (m, 2H), 6.42 (d, J = 8.0 Hz, 1H), 5.78 (d, J = 8.8 
Hz, 1H), 5.00 (d, J = 16.0 Hz, 1H), 4.71 (s, 1H), 4.28 (d, J = 16.0 Hz, 1H), 3.94-4.25 (m, 4H), 1.29 
(t, J = 6.8 Hz, 3H), 1.20 (t, J = 6.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.8, 143.2, 134.6, 
133.3 (d, JP-C = 3.5 Hz), 131.2, 130.3, 129.7 ,128.7, 127.5, 126.5, 126.3, 126.0, 123.2, 123.1, 109.5, 
82.9 (d, J = 5.7 Hz), 78.9 (d, J = 4.7 Hz), 64.6 (d, J = 5.6 Hz), 64.4 (d, J = 5.6 Hz), 43.8, 16.1 (d, 
J = 7.2 Hz), 16.0 (d, J = 6.6 Hz); 31P NMR (243 MHz, CDCl3) δ -0.6; IR (thin film) ν 3403, 2984, 
1720, 1614, 1489, 1369, 1252, 1029, 1008, 972 cm-1; HRMS (ESI+) cald for C26H27BrNO6P 
560.0838 (M+H+) found 560.0820. TLC (2:1 EtOAc/Hexanes): Rf = 0.33.  
 1-Benzyl-3-((((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(4-methoxyphenyl)methyl)-3-
hydroxyindolin-2-one ((±)-1.4e):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.76 (major diastereomer) and δ 5.71 (minor diastereomer).White solid (mp 157-
158 °C); 1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 7.2 Hz, 1H), 7.05-7.21 (m, 5H), 6.91 (d, J = 
8.4 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H), 6.48 (d, J = 7.6 Hz, 2H), 6.37 (d, J = 7.6 Hz, 1H), 5.78 (d, J 
= 8.8 Hz, 1H), 4.99 (d, J = 16.0 Hz, 1H), 4.76 (s, 1H), 4.24 (d, J = 16.0 Hz, 1H), 3.91-4.21 (m, 
4H), 3.73 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H), 1.20 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
174.9, 160.1, 143.3, 134.7, 130.1, 129.4, 128.4, 127.3, 126.5, 126.4, 126.3, 126.2 (d, J = 4.1 Hz), 
123.0, 113.4, 109.4, 83.4 (d, J = 6.2 Hz), 79.2 (d, J = 5.0 Hz), 64.4 (d, J = 5.6 Hz), 64.3 (d, J = 5.6 
Hz), 55.1, 43.6, 16.1 (d, J = 7.2 Hz), 16.0 (d, J = 6.9 Hz); 31P NMR (243 MHz, CDCl3) δ -0.5; IR 
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(thin film) ν 3416, 2983, 2931, 1721, 1614, 1515, 1441, 1368, 1251, 1028 cm-1; HRMS (ESI+) 
cald for C27H30NO7P 512.1838 (M+H+) found 512.1803. TLC (2:1 EtOAc/Hexanes): Rf = 0.19. 
 1-benzyl-3-((((diethyl-l3-oxidanyl)(l1-oxidanyl)phosphoryl)oxy)(m-
tolyl)methyl)-3-hydroxyindolin-2-one ((±)-1.4f): 
The title compound was prepared according to general procedure. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.24 (major diastereomer) and δ 4.46 (minor 
diastereomer). White solid (mp 109-110 °C); 1H NMR (400 MHz, CDCl3) d 7.75 (d, J = 6.8 Hz, 
1H), 6.89-7.19 (m, 7H), 6.82 (s, 1H), 6.78 (d, J = 7.6 Hz, 1H), 6.45 (d, J = 7.6 Hz, 2H), 6.33 (d, J 
= 7.6 Hz, 1H), 5.77 (d, J = 8.4 Hz, 1H), 4.96 (d, J = 16.4 Hz, 1H), 4.89 (br-s, 1H), 3.95-4.27 (m, 
5H), 2.10 (s, 3H), 1.26 (t, J = 6.8 Hz, 3H), 1.19 (t, J = 6.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
174.9, 143.3, 137.7, 134.7, 133.9 (d, J = 3.0 Hz), 130.0, 129.7, 128.7, 128.6, 127.9, 127.2, 126.4, 
126.3, 126.3, 125.0, 123.0, 109.4, 83.7 (d, J = 6.0 Hz), 79.2 (d, J = 4.5 Hz), 64.5 (d, J = 6.0 Hz), 
64.4 (d, J = 6.0 Hz), 43.6, 21.2, 16.1 (d, J = 6.0 Hz), 16.0 (d, JP-C = 7.6 Hz); 31P NMR (162 MHz, 
CDCl3) δ -0.6; IR (thin film) ν 3290, 1724, 1614, 1468, 1366, 1251, 1028, 753, 699 cm-1; HRMS 
(ESI+) cald for C27H30NO6P 496.1889 (M+H+) found 496.1815. TLC (2:1 EtOAc/Hexanes): Rf = 
0.25. 
 1-benzyl-3-((((diethyl-l3-oxidanyl)(l1-oxidanyl)phosphoryl)oxy)(o-
tolyl)methyl)-3-hydroxyindolin-2-one ((±)-1.4g): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 4.86 (major diastereomer) and δ 4.54 (minor diastereomer).White solid (mp 170-
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171 °C); 1H NMR (400 MHz, CDCl3) d 7.69 (d, J = 7.2 Hz, 1H), 7.04-7.26 (m, 7H), 6.82 (t, J = 
7.6 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 6.39-6.46 (m, 3H), 6.13 (d, J = 8.8 Hz, 1H), 5.06 (d, J = 16.0 
Hz, 1H), 4.61 (s, 1H), 3.88-4.22 (m, 5H), 2.45 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 6.8 Hz, 
3H); 13C NMR (151 MHz, CDCl3) 175.0, 143.4, 137.4, 134.8, 132.7 (d, J = 4.5 Hz), 130.5, 130.2, 
128.9, 128.7, 127.8, 127.2, 126.6, 126.4, 126.3, 125.5, 123.1, 109.4, 79.1 (d, J = 4.5 Hz), 78.9 (d, 
J = 6.0 Hz), 64.3 (d, 4.5 Hz), 64.1 (d, 6.0 Hz), 43.7, 19.8, 16.0 (d, J = 7.6 Hz), 15.9 (d, J = 7.6 Hz); 
31P NMR (162 MHz, CDCl3) δ -0.5; IR (thin film) ν 3264, 2982, 2341, 1716, 1613, 1468, 1362, 
1241, 1016, 753 cm-1; HRMS (ESI+) cald for C27H30NO6P 496.1889 (M+H+) found 496.1812. 
TLC (2:1 EtOAc/Hexanes): Rf = 0.29. 
 1-Benzyl-3-((((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-methoxy-3-
hydroxyindolin-2-one ((±)-1.4k):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 6.24 (minor diastereomer) and δ 6.15 (major diastereomer). White solid (mp 128-
129 °C); 1H NMR (400 MHz, CDCl3) d 7.35 (d, J = 2.4 Hz, 1H), 7.05-7.26 (m, 3H), 6.90-6.95 
(m, 4H), 6.67 (dd, J = 8.0, 2.4 Hz, 1H), 6.52 (d, J = 7.6 Hz, 2H), 6.25 (d, J = 8.8 Hz, 1H), 5.77 (d, 
J = 8.8 Hz, 1H), 4.95 (d, J = 16.0 Hz, 1H), 4.76 (s, 1H), 3.91-4.25 (m, 5H), 3.79 (s, 3H), 2.30 (s, 
3H), 1.29 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 6.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.7, 156.1, 
138.7, 136.5, 134.9, 131.1 (d, J = 3.8 Hz), 128.7, 128.4, 128.0, 127.7, 127.2, 126.6, 114.6, 113.4, 
109.8, 83.6 (d, J = 5.6 Hz), 79.5 (d, J = 4.4 Hz), 64.4 (d, J = 5.6 Hz), 64.3 (d, J = 6.0 Hz), 55.8, 
43.8, 21.3, 16.1 (d, J =6.8 Hz), 16.0 (d, J = 6.8 Hz); 31P NMR (243 MHz, CDCl3) δ -0.3; IR (thin 
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film) ν 3402, 2986, 1717, 1605, 1494, 1370, 1351, 1253, 1183, 1028 cm-1; HRMS (ESI+) cald for 
C28H32NO7P 526.1995 (M+H+) found 526.1944. TLC (2:1 EtOAc/Hexanes): Rf = 0.19. 
General procedure for three component reaction using chiral iminophosphorane: 
 
An oven-dried test tube was evacuated and filled with argon, then charged sequentially with the 
isatin substrate and THF (0.5 mL), followed by the dialkylphosphite and the aldehyde. THF (0.5 
mL) was then added and used to wash the residual solids on the sides of the test tube to the bottom. 
The reaction was stirred at -78 ºC in a cryogenic cooling apparatus, then the iminophosphorane 
catalyst C1 was added. The reaction was then stirred at -78 ºC and monitored by TLC until the 
reaction was complete. Trifluoroacetic acid in toluene (40µL of a 0.5 M solution) was added to 
quench the reaction and the reaction was concentrated on a rotatory evaporator. The crude 
materials thusly obtained were purified using flash column chromatography, with a gradient from 
1:1 hexanes/EtOAc to 1:2 hexanes/EtOAc. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-fluoro-3-
hydroxyindolin-2-one (1.4h):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.79 (major diastereomer) and δ 5.70 (minor diastereomer). White solid; 1H NMR 
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(400 MHz, CDCl3) d 7.50 (dd, J = 2.8, 7.8 Hz, 1H), 7.18-6.84 (m, 8H), 6.51 (d, J = 7.3 Hz, 2H), 
6.28 (d, J = 4.1 Hz, 1H), 5.79 (d, J = 8.7 Hz, 1H), 4.98 (d, J = 16.0 Hz, 1H), 4.28-4.09 (m, 3H), 
4.04-3.97 (m, 2H), 2.31 (s, 3H), 1.34-1.29 (m, 3H), 1.25-1.18 (m, 3H); 13C NMR (126 MHz, 
CDCl3) d 174.8, 160.2, 158.3, 139.2 (d, J = 1.8 Hz), 138.9, 134.5, 130.8, 128.8, 128.5, 127.8, 
127.4, 126.6, 116.3 (d, J = 23.6 Hz), 114.4 (d, J = 25.0 Hz, 110.0 (d, J = 8.2 Hz), 83.4 (d, J = 5.5 
hz), 79.4 (d, J = 4.6 Hz), 64.6 (d, J = 5.5 Hz), 64.4 (d, J = 5.5 Hz), 43.8, 21.3, 16.1 (d, J = 7.3 Hz), 
16.0 (d, J = 7.3 Hz); 31P NMR (162 MHz, CDCl3) d 0.48. 19F NMR (376 MHz, CDCl3) d -119.6. 
IR (thin film) ν 3275, 2980, 2247, 1715, 1620, 1485, 1258, 1177, 1007, 903 cm-1. HRMS (ESI): 
Calcd. For C27H29FNNaO6P ([M+Na+]): 536.1614, found 536.1605. HPLC Chiralpak IA column, 
Hex/iPrOH/EtOH = 95:4:1, flow rate = 1.0 mL/min, λ = 210 nm, 28.5 min (minor isomer), 44.2 
min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.38. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-chloro-3-
hydroxyindolin-2-one (1.4i):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.80 (major diastereomer) and δ 5.72 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.72 (s, 1H), 7.22-6.91 (m, 8H), 6.50 (d, J = 7.3 Hz, 2H), 6.27 (d, J = 8.2 Hz, 
1H), 5.78 (d, J = 9.2 Hz, 1H), 4.97 (d, J = 16.0 Hz, 1H), 4.28-4.10 (m, 3H), 4.05-3.95 (m, 2H), 
2.32 (s, 3H), 1.35-1.29 (m, 3H), 1.26-1.17 (m, 3H); 13C NMR (126 MHz, CDCl3) d 174.7, 141.9, 
139.0, 134.5, 130.9, 130.0, 128.9, 128.8, 128.6, 128.5, 128.4, 128.0, 127.5, 126.8, 126.7, 110.5, 
83.4  (d, J = 6.4 Hz), 79.4 (d, J = 4.6 Hz), 64.8 (d, J = 5.5 Hz), 64.6 (d, J = 6.4 Hz), 43.9, 21.4, 
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16.2 (d, J = 8.6 Hz); 31P NMR (162 MHz, CDCl3) d 0.51. IR (thin film) ν 3269, 2988, 2245, 1726, 
1613, 1483, 1254, 1173, 1007, 783 cm-1. HRMS (ESI): Calcd. For C27H29ClNNaO6P ([M+Na+]): 
522.1319, found 552.1309. HPLC Chiralpak IA column, Hex/iPrOH/EtOH = 95:4:1, flow rate = 
1.0 mL/min, λ = 210 nm, 28.8 min (minor isomer), 43.3 min (major isomer). TLC (1:4 
EtOAc/Hexanes): Rf = 0.41. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-bromo-3-
hydroxyindolin-2-one (1.4j): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.78 (major diastereomer) and δ 5.69 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.84 (d, J = 1.8 Hz, 1H), 7.31-6.90 (m, 7H), 6.50 (d, J = 7.8 Hz, 2H), 6.23 
(d, J = 8.7 Hz, 1H), 5.77 (d, J = 8.7 Hz, 1H), 4.96 (d, J = 16.0 Hz, 1H), 4.29-4.11 (m, 3H), 4.05-
3.95 (m, 2H), 2.32 (s, 3H), 1.37-1.30 (m, 3H), 1.25-1.17 (m, 3H); 13C NMR (126 MHz, CDCl3) 
174.6, 142.4, 139.1, 134.4, 133.0, 130.9 (2C), 130.8, 129.6, 129.0, 128.0, 127.5, 126.7, 115.8, 
111.0, 83.4 (d, J = 6.4 Hz), 79.4 (d, J = 4.6 Hz), 64.8 (d, J = 5.5 Hz), 64.6 (d, J = 5.5 Hz), 43.9, 
21.5, 16.2 (d, J = 7.3 Hz), 16.1 (d, J = 6.4 Hz); 31P NMR (162 MHz, CDCl3) d 0.67. IR (thin film) 
ν 3293, 2983, 2909, 2245, 1726, 1609, 1479, 1248, 1028, 733 cm-1. HRMS (ESI): Calcd. For 
C27H29BrNNaO6P ([M+Na+]): 596.0814, found 596.0809. HPLC Chiralpak IA column, 
Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 nm, 11.3 min (minor isomer), 15.3 min (major 
isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.44. 
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(R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-methoxy-3-
hydroxyindolin-2-one (1.4l):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.77 (major diastereomer) and δ 5.74 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.36 (d, J = 2.3 Hz, 1H), 7.22-6.92 (m, 7H), 6.69 (dd, J = 8.6 Hz, 2.5 Hz, 
1H), 6.54 (d, J = 7.3 Hz, 2H), 6.28 (d, J = 8.9 Hz, 1H), 5.77 (d, J = 8.7 Hz, 1H), 4.99 (d, J = 16.0 
Hz, 1H), 4.40 (br, 1H), 4.25 (d, J = 16.0 Hz, 1H), 3.81 (s, 3H), 3.78 (d, J = 11.4 Hz, 3H), 3.64 (d, 
J = 11.5 Hz, 3H), 2.31 (s, 3H); 13C NMR (126 MHz, CDCl3) d 174.9, 152.2, 138.9, 136.8, 135.0, 
131.2, 128.9, 128.7, 128.5, 128.1, 127.7, 127.3, 127.1, 126.7, 114.7, 113.7, 110.0, 83.9 (d, J = 5.5 
Hz), 79.5 (d, J = 4.6 Hz), 56.0, 54.8 (d, J = 5.5 Hz), 54.6 (d, J = 6.4 Hz), 43.9, 21.4; 31P NMR 
(162 MHz, CDCl3) d 2.55. IR (thin film) ν 3300, 2951, 2243, 1713, 1605, 1487, 1258, 1163, 1026, 
810 cm-1. HRMS (ESI): Calcd. For C26H28NNaO7P ([M+Na+]): 520.1501, found 520.1499. HPLC 
Chiralpak IA column, Hex/iPrOH/EtOH = 90:5:5, flow rate = 1.0 mL/min, λ = 210 nm, 34.2 min 
(minor isomer), 45.4 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.17. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-5-methyl-3-
hydroxyindolin-2-one (1.4m):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.76 (major diastereomer) and δ 5.72 (minor diastereomer). White solid; 1H NMR 
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(400 MHz, CDCl3) d 7.54, 7.17-6.91 (m, 8H), 6.54 (d, J = 6.1 Hz, 2H), 6.27 (d, J = 7.8 Hz, 1H), 
5.75 (d, J = 8.7 Hz, 1H), 4.26 (d, J = 16.0 Hz, 1H), 3.74 (d, J = 11.0 Hz, 3H), 3.66 (d, J = 11.4 Hz, 
3H), 2.36 (s, 3H), 2.31 (s, 3H); 13C NMR (126 MHz, CDCl3) d 175.1, 141.0, 138.9, 135.0, 132.7, 
131.2 (d, J = 3.6 Hz), 130.5, 128.9, 128.5, 128.1, 127.3, 127.1, 126.7, 126.4, 109.3, 84.0 (d, J = 
6.4 Hz), 79.2 (d, J = 5.5 Hz), 54.8 (d, J = 5.5 Hz), 54.6 (d, J = 5.5 Hz), 43.8, 21.4, 21.3; 31P NMR 
(162 MHz, CDCl3) d 2.55. IR (thin film) ν 3337, 2924, 2851, 2243, 2116, 1715, 1620, 1493, 1260, 
1032 cm-1. HRMS (ESI): Calcd. For C26H28NNaO6P ([M+Na+]): 504.1552, found 504.1547. 
HPLC Chiralpak IA column, Hex/iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 210 nm, 13.4 min 
(minor isomer), 16.5 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.23. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-6-chloro-3-
hydroxyindolin-2-one (1.4n):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.80 (major diastereomer) and δ 5.74 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.66 (d, J = 7.8 Hz, 1H), 7.16-7.20 (m, 1H), 7.08-7.12 (m, 3H), 6.97 (d, J = 
7.8 Hz, 2H), 6.90 (d, J  = 8.5 Hz, 2H), 6.53 (d, 7.3 Hz, 2H), 6.38 (d, 1.8 Hz, 1H), 5.77 (d, J = 9.2 
Hz, 1H), 4.98 (d, J = 16.0 Hz, 1H), 4.24 (d, J = 16.5 Hz, 1H), 3.76 (d, J = 11.4 Hz, 3H), 3.65 (d, J 
= 11.4 Hz 3H), 2.32 (s, 3H); 13C NMR (126 MHz, CDCl3) d 175.1, 144.7, 139.2, 136.1, 134.3, 
130.8 (d, J = 2.36 Hz), 129.1, 128.7, 127.9, 127.6, 127.5, 126.7, 125.0, 123.1, 83.8 (d, J = 4.1 Hz), 
78.9 (d, J = 2.9 Hz), 54.9 (d, J = 11.7 Hz), 43.9, 21.5; 31P NMR (162 MHz, CDCl3) d 2.55. HRMS 
(ESI): Calcd. For C25H25ClNNaO6P ([M+Na+]): 524.1006, found 524.1003. IR (thin film) ν 3302, 
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2957, 2247, 1726, 1609, 1454, 1252, 1180, 1025, 731 cm-1. HPLC Chiralpak IA column, 
Hex/iPrOH = 90.9:9.1, flow rate = 1.0 mL/min, λ = 210 nm, 20.5 min (minor isomer), 30.6 min 
(major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.41. 
 (R)-1-Benzyl-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(p-tolyl)methyl)-7-fluoro-3-
hydroxyindolin-2-one (1.4o):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.75 (major diastereomer) and δ 5.67 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) 7.55-7.53 (m, 1H), 7.18-7.04 (m, 4H), 6.99-6.86 (m, 5H), 6.70 (d, J = 7.3 Hz, 
2H), 5.74 (d, J = 8.7 Hz, 1H), 4.91 (d, J = 16.0 Hz, 1H), 4.59 (d, J = 16.0 Hz, 1H), 4.21-4.15 (m, 
2H), 4.10-3.96 (m, 2H), 2.28 (s, 3H), 1.32-1.27 (m, 3H), 1.23-1.19 (m, 3H) ; 13C NMR (126 MHz, 
CDCl3) d 174.7, 148.3, 146.3, 139.0, 136.2, 130.7 (d, J = 3.6 Hz), 129.6 (d, J = 8.2 Hz), 128.9, 
128.4, 127.9, 127.2, 126.8 (d, J = 1.8 Hz), 123.9 (d, J = 6.4 Hz), 122.4 (d, J = 3.6 Hz), 118.5, 
118.4, 79.1-79.1 (m), 64.6 (d, J = 5.5 Hz), 64.5 (d, J = 5.5 Hz), 45.3 (d, J = 4.5 Hz), 21.4, 16.2-
16.0 (m, 2C); 31P NMR (162 MHz, CDCl3) d 0.46; 19F NMR (376 MHz, CDCl3) d -133.6. IR 
(thin film) ν 3296, 2986, 2237, 1730, 1632, 1487, 1248, 1022, 910, 733 cm-1. HRMS (ESI): Calcd. 
For C27H29FNNaO6P ([M+Na+]): 536.1614, found 536.1608. HPLC Chiralpak IA column, 
Hex/iPrOH/EtOH = 85:5:10, flow rate = 1.0 mL/min, λ = 210 nm, 9.3 min (minor isomer), 12.5 
min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.38. 
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(R)-1-Benzyl-5-bromo-3-((S)-(((diethyl3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(4-fluorophenyl)methyl)-3-
hydroxyindolin-2-one (1.4p): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.81 (major diastereomer) and δ 5.75 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.83 (d, J = 1.84 Hz, 1H), 7.33-6.81 (m, 8H), 6.54 (d, J = 7.4 Hz, 2H), 6.29 
(d, J = 8.7 Hz, 1H), 4.91 (d, J = 16.0 Hz, 1H), 4.89 (br s, 1H), 4.28 (d, J = 16.5 Hz, 1H), 4.25-4.13 
(m, 2H), 4.06-3.95 (m, 2H), 1.80 (br, 1H), 1.38-1.31 (m, 3H), 1.25-1.18 (m, 3H); 13C NMR (126 
MHz, CDCl3) d 174.5, 164.2, 162.2, 142.4, 134.3, 133.2, 130.0 (d, J = 8.2 Hz), 129.6, 128.8, 127.8, 
126.6, 115.9, 115.3 (d, J = 21.8 Hz), 111.1, 82.7 (d, J = 6.4 Hz), 79.3 (d, J = 4.6 Hz), 64.9 (d, J = 
5.5 Hz), 64.9 (d, J = 5.5 Hz), 64.6 (d, J = 5.5 Hz), 43.9, 16.3 (d, J = 13.4 Hz), 16.1 (d, J = 6.3 Hz); 
31P NMR (162 MHz, CDCl3) d  0.27; 19F NMR (376 MHz, CDCl3) d -111.6. IR (thin film) ν 
3252, 2986, 2245, 1726, 1607, 1510, 1479, 1346, 1229, 1022 cm-1. HRMS (ESI): Calcd. For 
C26H26BrFNNaO6P ([M+Na+]): 600.0563, found 600.0552. HPLC Chiralpak IA column, 
Hex/iPrOH/EtOH = 95:4:1, flow rate = 1.0 mL/min, λ = 210 nm, 29.6 min (minor isomer), 43.8 
min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.45. 
 (R)-1-Benzyl-5-bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(4-iodophenyl)methyl)-3-
hydroxyindolin-2-one (1.4q):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
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resonances at δ 5.76 (major diastereomer) and δ 5.69 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.83 (d, J = 1.8 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.32-7.23 (m, 4H), 6.78 
(d, J = 8.7 Hz, 2H), 6.56-6.54 (m, 2H), 6.28 (d, J = 8.7 Hz, 1H), 5.75 (d, J = 8.7 Hz, 1H), 4.99 (d, 
J = 16.0 Hz, 1H), 4.28-4.15 (m, 3H), 4.07-3.99 (m, 2H), 1.38-1.35 (m, 3H), 1.26-1.19 (m, 3H); 
13C NMR (126 MHz, CDCl3) d 174.3, 142.4, 137.5, 134.2, 133.6, 133.2, 129.8, 129.6, 128.3, 
127.8, 126.6, 115.9, 111.2, 95.5, 82.8 (d, J = 5.5 Hz), 79.1 (d, J = 5.3 Hz), 65.0 (d, J = 6.4 Hz), 
64.7 (d, J = 4.6 Hz), 44.0, 16.3-16.1 (m, 2C); 31P NMR (162 MHz, CDCl3) d 0.56. IR (thin film) 
ν 3291, 2980, 2243, 1730, 1607, 1481, 1371, 1254, 1024, 910 cm-1. HRMS (ESI): Calcd. For 
C26H26BrINNaO6P ([M+Na+]): 707.9623, found 707.9618. HPLC Chiralpak AD3 column, 
Hex/EtOH = 88:12 (4 ºC), flow rate = 1.0 mL/min, λ = 210 nm, 18.9 min (minor isomer), 29.7 min 
(major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.47. 
 (R)-1-Benzyl-5-bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(phenyl)methyl)-3-hydroxyindolin-2-one 
(1.4r): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.82 (major diastereomer) and δ 5.77 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.86 (s, 1H), 7.32-7.26 (m, 3H), 7.18-7.14 (m, 3H), 7.11-7.04 (m, 4H), 6.46 
(d, J = 7.8 Hz, 2H), 6.21 (d, J = 8.2 Hz, 1H), 5.81 (d, J = 9.2 Hz, 1H), 5.06 (br, 1H), 4.90 (d, J = 
16.5 Hz, 1H), 4.29-4.11 (m, 2H), 4.05-3.98 (m, 2H), 1.36-1.30 (m, 3H), 1.26-1.16 (m, 3H); 13C 
NMR (126 MHz, CDCl3) d 174.5, 142.4, 134.4, 133.9, 133.0, 129.6, 129.2, 128.8, 128.7 (d, J = 
2.7 Hz), 128.3, 128.1, 127.5, 126.6, 115.8, 111.1, 83.5 (d, J = 6.4 Hz), 79.4 (d, J = 4.6 Hz), 64.9 
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(d, J = 5.5 Hz), 65.6 (d, J = 5.5 Hz), 43.9, 16.3-16.1 (m, 2C); 31P NMR (162 MHz, 
CDCl3) d  0.48. HRMS (ESI): Calcd. For C26H27BrNNaO6P ([M+Na+]): 582.0657, found 
582.0652. IR (thin film) ν 3283, 2978, 2247, 1726, 1715, 1607, 1454, 1348, 1254, 725 cm-1. 
HPLC Chiralpak IA column, Hex/iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 210 nm, 18.1 min 
(minor isomer), 28.0 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.44. 
(R)-1-Benzyl-5-bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(4-(methylthio)phenyl)methyl)-3-
hydroxyindolin-2-one (1.4s): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.78 (major diastereomer) and δ 5.71 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.85 (d, J = 1.8 Hz, 1H), 7.30-6.93 (m, 8H), 6.47-6.45 (m, 2H), 6.24 (d, J = 
8.2 Hz, 1H), 5.77 (d, J = 9.2 Hz, 1H), 5.77 (d, J = 9.2 Hz, 1H), 5.01 (d, J = 16.0 Hz, 1H), 4.30-
4.13 (m, 3H), 4.06-3.95 (m, 2H), 2.42 (s, 3H), 1.38-1.35 (m, 3H), 1.25-1.18 (m, 3H); 13C NMR 
(126 MHz, CDCl3) d 174.5, 142.4, 134.2, 133.1, 130.2, 130.2, 129.6, 128.9, 128.8, 128.6, 128.5, 
127.7, 126.5, 125.4, 115.8, 111.1, 83.2 (d, J = 5.5 Hz), 79.3 (d, J = 4.6 Hz), 64.9 (d, J = 5.5 Hz), 
64.6 (d, J = 5.5 Hz), 43.9, 16.3 (d, J = 7.3 Hz), 16.1 (d, J = 6.4 Hz); 31P NMR (162 MHz, 
CDCl3) d 0.54. HRMS (ESI): Calcd. For C27H29BrNNaO6PS ([M+Na+]): 628.0534, found 
628.0526. IR (thin film) ν 3306, 2986, 2247, 1730, 1607, 1483, 1250, 1134, 1020, 731 cm-1. HPLC 
Chiralpak IA column, Hex/iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 210 nm, 13.7 min (minor 
isomer), 20.7 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.42. 
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(R)-1-benzyl-5-Bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(4-methoxyphenyl)methyl)-3-
hydroxyindolin-2-one (1.4t): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.78 (major diastereomer) and δ 5.71 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.84 (d, J = 1.8 Hz), 7.31-7.07 (m, 4H), 6.94 (d, J = 9.2 Hz, 2H), 6.67 (d, J 
= 8.7 Hz, 2H), 6.47 (d, J = 7.8 Hz, 2H), 6.24 (d, J = 8.7 Hz, 1H), 5.76 (d, J = 9.2 Hz, 1H), 4.98 (d, 
J = 16.5 Hz, 1H), 4.88 (br, 1H), 4.28-4.14 (m, 3H), 4.05-3.98 (m, 2H), 3.76 (s, 3H), 1.38-1.34 (m, 
3H), 1.25-1.21 (m, 3H); 13C NMR (126 MHz, CDCl3) d 174.5, 160.3, 142.5, 134.3, 133.0, 129.5, 
129.4, 128.6, 127.6, 126.6, 115.8, 113.7, 111.0, 83.2 (d, J = 5.5 Hz), 79.4 (d, J = 4.6 Hz), 64.8 (d, 
J = 5.5 Hz), 64.6 (d, J = 5.5 Hz), 55.2, 43.8, 16.3 (d, J = 7.3 Hz), 16.1 (d, J = 6.4 Hz); 31P NMR 
(162 MHz, CDCl3) d 0.83. IR (thin film) ν 3314, 2976, 2353, 2245, 1730, 1613, 1514, 1485, 1250, 
1024 cm-1. HRMS (ESI): Calcd. For C27H29BrNNaO7P ([M+Na+]): 612.0763, found 612.0754. 
HPLC Chiralpak IA column, Hex/iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 210 nm, 13.4 min 
(minor isomer), 18.9 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.39. 
(R)-1-Benzyl-5-bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(m-tolyl)methyl)-3-hydroxyindolin-2-one 
(1.4u):  
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.76 (major diastereomer) and δ 5.71 (minor diastereomer). White solid; 1H NMR 
32 
	
(400 MHz, CDCl3) d 7.83 (d, J = 1.8 Hz, 1H), 7.32-7.02 (m, 6H), 6.86 (s, 1H), 6.80 (d, J = 7.8 Hz, 
1H), 6.45 (d, J = 7.3 Hz, 2H), 6.2 (d, J = 8.0 Hz, 1H), 5.75 (d, J = 8.7 Hz, 1H), 4.94 (d, J = 16.5 
Hz, 1H), 4.86 (br, 1H), 4.30-4.12 (m, 3H), 4.07-3.98 (m, 2H), 2.16 (s, 3H), 1.38-1.31 (m, 3H), 
1.26-1.18 (m, 3H); 13C NMR (126 MHz, CDCl3) d 174.5, 142.5, 138.0, 134.5, 133.7, 133.0, 130.0, 
129.6, 128.8, 128.2, 127.6, 126.5, 125.0, 115.8, 111.0, 83.5 (d, J = 5.5 Hz), 79.4 (d, J = 3.6 Hz), 
64.9 (d, J = 6.4 Hz), 64.6 (d, J = 8.6 Hz), 43.9, 21.4, 16.3 (d, J = 7.3 Hz), 16.1 (d, J = 6.4 Hz); 31P 
NMR (162 MHz, CDCl3) d 0.67. IR (thin film) ν 3266, 2932, 2934, 1730, 1714, 1609, 1454, 1250, 
1130, 1020 cm-1. HRMS (ESI): Calcd. For C27H29BrNNaO6P ([M+Na+]): 596.0814, found 
596.0795. HPLC Chiralpak IA column, Hex/iPrOH = 90.9:9.1, flow rate = 1.0 mL/min, λ = 210 
nm, 14.5 min (minor isomer), 24.7 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.45. 
(R)-1-Benzyl-5-bromo-3-((S)-(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(3-(methylthio)phenyl)methyl)-3-
hydroxyindolin-2-one (1.4v): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.78 (major diastereomer) and δ 5.72 (minor diastereomer).White solid; 1H NMR 
(400 MHz, CDCl3) d 7.87 (s, 1H), 7.30-7.03 (m, 7H), 6.87-6.81 (m, 1H), 6.49 (d, J = 7.3 Hz, 2H), 
6.24 (d, J = 8.7 Hz, 1H), 5.78 (d, J = 8.7 Hz, 1H), 5.09 (br, 1H), 4.93 (d, J = 16.5 Hz, 1H), 4.31-
4.13 (m, 3H), 4.07-3.98 (m, 2H), 2.14 (s, 3H), 1.38-1.34 (m, 3H), 1.25-1.21 (m, 3H); 13C NMR 
(126 MHz, CDCl3) d 174.4, 142.4, 139.1, 134.7 (2C), 134.3, 133.0, 129.6, 128.9, 128.5, 127.9, 
127.6, 126.5, 125.0, 124.9, 115.8, 111.2, 83.1 (d, J = 5.5 Hz), 79.3 (d, J = 4.6 Hz), 64.9 (d, J = 6.4 
Hz), 64.7 (d, J = 6.4 Hz), 43.9, 16.3 (d, J = 6.4 Hz), 16.1 (d, J = 6.4 Hz), 15.6; 31P NMR (162 
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MHz, CDCl3) d  0.48. HRMS (ESI): Calcd. For C27H29BrNNaO6PS ([M+Na+]): 628.0534, found 
628.0530. IR (thin film) ν 3256, 2984, 2363, 1730, 1607, 1479, 1256, 1018, 972, 895 cm-1. HPLC 
Chiralpak IA column, Hex/iPrOH = 90.9:9.1, flow rate = 1.0 mL/min, λ = 210 nm, 19.4 min (minor 
isomer), 34.1 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.41. 
(R)-3-((S)-Benzo[d][1,3]dioxol-5-yl(((diethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)methyl)-1-benzyl-5-bromo-3-
hydroxyindolin-2-one (1.4w): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 5.72 (major diastereomer) and δ 5.64 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.80 (d, J = 1.8 Hz, 1H), 7.38-7.14 (m, 4H), 6.64-6.59 (m, 4H), 6.40 (s, 1H), 
6.32 (d, J = 8.7 Hz, 1H), 5.89 (d, J = 1.4 Hz, 1H), 5.88 (d, J = 1.4 Hz, 1H), 5.71 (d, J = 8.7 Hz, 
1H), 5.01 (d, J = 16.0 Hz, 1H), 4.31-4.13 (m, 3H), 4.08-3.97 (m, 2H), 1.40-1.32 (m, 3H), 1.27-
1.20 (m, 3H); 13C NMR (126 MHz, CDCl3) d 174.5, 148.4 (d, J = 1.8 Hz), 147.5, 142.5, 134.6, 
133.1, 129.5, 128.7, 127.7, 126.8, 122.4, 115.9, 111.0, 108.2, 108.1, 101.3, 83.3 (d, J = 5.5 Hz), 
79.4 (d, J = 4.6 Hz), 64.9, 64.7, 43.9, 16.3 (d, J = 7.3 Hz), 16.1 (d, J = 7.3 Hz); 31P NMR (162 
MHz, CDCl3) d 0.56. HRMS (ESI): Calcd. For C27H27BrNNaO8P ([M+Na+]): 626.0555, found 
626.0550. IR (thin film) ν 3281, 2990, 2249, 1726, 1609, 1483, 1445, 1244, 1018, 733 cm-1. 
HPLC Chiralpak IA column, Hex/iPrOH = 90.9:9.1, flow rate = 1.0 mL/min, λ = 210 nm, 26.2min 
(minor isomer), 43.4 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.39. 
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(R)-1-Benzyl-5-bromo-3-((S)-(((dimethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(2-fluorophenyl)methyl)-3-
hydroxyindolin-2-one (1.4x): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 6.21 (major diastereomer) and δ 6.16 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.71 (s, 1H), 7.35-6.90 (m, 10H), 6.65 (d, J = 7.3 Hz, 2H), 6.35 (d, J = 8.2 
Hz, 1H), 6.14 (d, J = 9.2 Hz, 1H), 5.01 (d, J = 16.5 Hz, 1H), 4.33 (d, J = 16.0 Hz, 1H), 3.75 (d, J 
= 11.4 Hz, 3H), 3.68 (d, J = 11.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) d 174.1, 161.0, 159.0, 
142.5, 134.6, 133.4, 131.2 (d, 8.3 Hz), 129.6, 128.9, 127.7, 126.7, 124.1 (d, J = 3.6 Hz), 121.5 (d, 
J = 3.6 Hz), 121.4 (d, J = 3.6 Hz), 115.9, 115.8, 111.1, 78.5 (d, J = 5.5 Hz), 76.0-75.9 (m, 1C), 
55.0 (d, J = 6.4 Hz), 54.9 (d, J = 6.4 Hz), 44.0; 31P NMR (162 MHz, CDCl3) d 2.39; 19F NMR 
(376 MHz, CDCl3) d -114.0.  IR (thin film) ν 3273, 2355, 1730, 1609, 1483, 1454, 1344, 1263, 
1180, 1028 cm-1. HRMS (ESI): Calcd. For C24H22BrFNNaO6P ([M+Na+]): 572.0250, found 
572.0245. HPLC Chiralpak IA column, Hex/iPrOH/EtOH = 93:5:2 (4 ºC), flow rate = 1.0 mL/min, 
λ = 210 nm, 76.3 min (minor isomer), 92.1 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 
0.42. 
(R)-1-Benzyl-5-bromo-3-((S)-(((dimethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(o-tolyl)methyl)-3-hydroxyindolin-2-one 
(1.4y): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
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resonances at δ 6.15 (major diastereomer) and δ 6.04 (minor diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 7.81 (s, 1H), 7.34-7.06 (m, 6H), 6.90-6.87 (m, 1H), 6.69 (d, J = 8.2 Hz, 1H), 
6.42 (d, J = 6.9 Hz, 2H), 6.30-6.28 (m, 1H), 6.14 (d, J = 8.7 Hz, 1H), 5.05 (d, J = 16.0 Hz, 1H), 
4.18 (d, J = 16.5 Hz, 1H), 3.74 (dd, J = 11.5 Hz, 1.8 Hz, 3H), 3.57 (dd, J = 11.4 Hz, 1.4 Hz, 3H), 
2.44 (s, 3H); 13C NMR (126 MHz, CDCl3) d 174.7, 142.6, 137.6, 134.4, 133.2, 132.4 (d, J = 2.7 
Hz), 130.8, 129.8, 129.3, 128.9, 128.7, 127.7, 127.5, 126.4, 125.9, 116.0, 111.0, 79.2 (d, J = 6.4 
Hz), 79.0 (d, J = 6.4 Hz), 54.8 (d, J = 5.5 Hz), 54.5 (d, J = 5.5 Hz), 43.9, 19.8; 31P NMR (162 
MHz, CDCl3) d 2.60. IR (thin film) ν 3204, 2957, 2245, 1725, 1607, 1454, 1346, 1223, 1003, 812 
cm-1. HRMS (ESI): Calcd. For C25H25BrNNaO6P ([M+Na+]): 596.0501, found 596.0495. HPLC 
Chiralpak IA column, Hex/iPrOH = 90.9:9.1, flow rate = 1.0 mL/min, λ = 210 nm, 15.9 min (minor 
isomer), 21.6 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.40. 
(R)-1-Benzyl-5-bromo-3-((S)-(((dimethyl-l3-oxidanyl)(l1-
oxidanyl)phosphoryl)oxy)(naphthalen-1-yl)methyl)-3-
hydroxyindolin-2-one (4z): 
The title compound was prepared according to general procedure. The diastereomeric ratio was 
determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the 
resonances at δ 6.41 (minor diastereomer) and δ 6.17 (major diastereomer). White solid; 1H NMR 
(400 MHz, CDCl3) d 8.29 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 2.3 Hz, 1H), 7.82 (dd, J = 5.0, 8.2 Hz, 
2H), 7.59-7.51 (m, 1H), 7.49-7.46 (m, 1H), 7.30 (dd, J = 1.4, 8.7 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 
7.09-7.05 (m, 2H), 6.96-6.93 (m, 2H), 6.76 (d, J = 8.7 Hz, 1H), 6.22 (d, J = 8.2 Hz, 1H), 6.12, (m, 
2H), 4.81 (d, J = 16.0 Hz, 1H), 4.65 (br, 1H), 4.01 (d, J = 16.0 Hz, 1H), 3.75 (dd, J = 1.8, 9.6 Hz, 
3H), 3.57 (d, J = 11.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) d 174.3, 142.7, 134.3, 133.5, 133.2, 
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130.8, 130.0, 129.7, 129.6, 129.0, 128.8, 128.7, 128.6, 127.5, 127.0, 126.6, 126.4, 126.2, 124.7, 
123.5, 115.9, 110.9, 79.4 (d, J = 4.5 Hz), 55.0 (d, J = 5.5 Hz), 54.7 (d, J = 6.4 Hz), 43.9; 31P NMR 
(162 MHz, CDCl3) 2.84. IR (thin film) ν 3277, 2955, 2247, 1730, 1609, 1481, 1260, 1175, 1026, 
731 cm-1. HRMS (ESI): Calcd. For C28H25BrNNaO6P ([M+Na+]): 604.0501, found 604.0496. 
HPLC Chiralpak IA column, Hex/iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 210 nm, 16.3 min 
(minor isomer), 30.0 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.38. 
Details of crossover experiment: 
 Three oven-dried test tubes were evacuated and filled with argon, then charged sequentially 
with the cross pinacol product (±)-1.4a and THF (0.5 mL), followed by 4-fluorobenzaldehyde (4.0 
equiv). THF (0.5mL) was then added and used to collect residual solids on the sides of the test 
tube. The reaction was stirred at 0 ºC, or -40 ºC, or -78 ºC in an appropriate cooling apparatus, then 
the iminophosphorane catalyst C1 was added. The reaction was then stirred at the same 
temperatures and monitored by TLC until the reaction was complete. Trifluoroacetic acid in 
toluene (40µL of a 0.5 M solution) was added to quench the reaction and the reaction was 
concentrated on a rotatory evaporator.  
Analysis of crossover experiment: 
 The reactions were analyzed by 1H NMR spectroscopy on an 800 MHz spectrometer.  The 
1H NMR trace show below details the results of the above crossover experiment. The trace on 
bottom shows racemic starting material (3.2:1 dr, 1.4a). The major and minor diastereomer peaks 
of the starting material are identified with red wedges. As the temperature is increased from -78 
ºC to -40 ºC, crossover starts to occur; the major and minor diastereomers of the crossover product 
are identified with green wedges. Additionally, at 0 ºC the dr of the starting material was observed 
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to sharply increase; we attribute this to a relatively rapid retro reaction of the minor diastereomer 
of starting material (which could also be responsible for the low diastereoselectivity of crossover 
product at that temperature). These results suggest that the crossover process shuts down between 
-40 ºC and -78 ºC. 
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CHAPTER TWO: 
ASYMMETRIC ORGANOCATALYTIC REDUCTIVE COUPLING REACTIONS BETWEEN 
BENZYLIDENE PYRUVATES AND ALDEHYDES† 
 
2.1 Introduction 
 Following the development of the asymmetric organocatalytic reductive coupling reaction 
between isatins and aldehydes, we sought to extend the same mechanistic manifold to a wider 
array of chemical systems. The eventual endpoint of these developments would be arriving at a 
catalytic asymmetric system that is capable of furnishing the core of natural products. With this 
goal in mind, we aimed to utilize more complex substrates than we did in our initial work. In the 
work presented in this chapter, the mechanistic framework from Chapter One is further developed 
in order to advance the state of the reaction using a new substrate class. While more selectivity 
issues were present in this new system, we were ultimately able to resolve them by deploying a 
chiral triaryliminophosphorane organocatalyst, allowing a stereocontrolled reductive coupling 
reaction between benzylidene pyruvates and aldehydes. 
 
 
 
																																								 																				
† Reprinted in part with permission from Horwitz, M. A.; Zavesky, B. P.; Martinez-Alvarado, J. 
I.; Johnson, J. S. Org. Lett. 2016, 18, 36. Copyright 2016 American Chemical Society.	
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2.2 Background 
2.2.1 Extension of the Phosphite-mediated Reductive Coupling Mechanism to Benzylidene 
Pyruvates and Aldehydes 
 The reductive union of two prochiral starting materials into products bearing vicinal 
stereogenic centers builds molecular complexity and as such is an actively sought transformation 
in chemical synthesis. Pinacol-type reductive coupling reactions deliver vicinal diols,1-5 but 
drawbacks remain. Commonly used single-electron transfer methods rely on stoichiometric 
amounts of low-valent metal3n-3r and stereocontrol can be challenging.5b,5c In the methodologies 
that have successfully achieved selectivity in the reductive coupling reaction, the challenge of 
achieving orthogonal reactivity in downstream transformations of the vicinal alcohols remains.3g 
Some of these issues were addressed in Chapter One through the use of a base-catalyzed, phosphite 
mediated asymmetric reductive coupling of two different carbonyls.6,7 In this mechanistic 
manifold, a Pudovik addition of a dialkylphosphite to an isatin triggers phospha-Brook 
rearrangement and subsequent catalyst controlled trapping of the resultant enolate with an 
aldehyde.6-9 In this chapter, we extend this reaction framework and report a highly stereoselective 
phosphite-mediated reductive coupling reaction between benzylidene pyruvates and aryl 
aldehydes (Scheme 2-1). 
2.2.2 Chemoselectivity Challenges Associated with Phosphite-mediated Reductive Coupling 
of Benzylidene Pyruvates and Aldehydes 
 Our goal of introducing a higher level of functionality into the product carries with it 
challenges not faced in our prior work (Scheme 2-2). In order to achieve a stereoselective cross-
coupled product from ambident benzylidene pyruvates and aryl aldehydes, it is necessary to be 
able to control (a) the chemoselectivity of the phosphite addition (pyruvate vs. aldehyde; Scheme 
2-3a),10 (b) the regioselectivity of the phosphite addition (1,2- vs. 1,4-addition; Scheme 2-3b),11 
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(c) the nucleophilicity of the nascent enolate (a- vs. g-trapping; Scheme 2-3c),12 (d) the 
chemoselectivity of the enolate trap (proton vs. pyruvate vs. aldehyde; Scheme  
Scheme 2-1.	Asymmetric Reductive Multicomponent Reactions 
		
 
2-3d),12,13 and (e) the stereoselectivity of the enolate addition into the aryl aldehyde. Fortunately, 
the relative electron deficiency of the benzylidene pyruvates made the chemo- and regioselectivity 
issues manageable. Furthermore, the chiral triaryliminophosphoranes developed by Dixon and 
coworkers14 guided the stereodefining C-C bond construction with excellent levels of diastereo- 
and enantiocontrol. 
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Scheme 2-2.	Chemoselectivity Issues 
	
2.3 Results and Discussion 
2.3.1 Discovery and Optimization of Asymmetric Reaction 
 Initially, we studied the dimethyl phosphite-mediated reductive coupling of benzylidene 
pyruvate 1a with para-bromobenzaldehyde (Table 2-1). Using 10 mol %  KOtBu at 0 ºC, the 
reaction was complete in minutes and hydroxy phosphate 2a was formed exclusively (1.2:1 dr). 
Having found that the enolate formed by the Pudovik-phospha-Brook sequence was both 
nucleophilic at the correct position and capable of being trapped by aryl aldehydes, we turned our 
attention to the development of the asymmetric variant. 
Scheme 2-3.	Precedents for Undesired Modes of Reactivity 
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In our previous experience with this type of reductive coupling reaction, we demonstrated through 
crossover experiments that a stereoablative retro aldol process becomes possible somewhere in the 
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cryogenic range;7 therefore, we sought to carry out the reactions at as low a temperature as 
possible. We observed that cinchona alkaloid-derived thiourea catalysts were not basic enough to 
permit the reaction to proceed at cryogenic temperatures, which caused us to move toward other 
catalyst families. The evaluation of chiral triaryliminophosphorane C1 revealed that after 48 h at 
-60 ºC, the starting material was completely consumed and a 6:1 ratio of products was obtained 
arising from aldehyde trapping (2.2a) relative to proton trapping (2.3a), the former with a 
diastereomer ratio of 13:1. This encouraging result led us to synthesize and evaluate catalyst C2, 
which gave a >20:1 ratio of 2.2a:2.3a, with 17:1 dr and 97:3 er. 
2.3.2 Scope of Reaction 
 The application of catalyst C2 to a broader range of reaction partners was then 
undertaken (Table 2-2).  The reaction proceeds with electron-withdrawing groups on the 
benzylidene pyruvate; placing the electron-withdrawing group on the ortho (2.2f, 2.2g) or para 
(2.2b-2.2d) positions on the benzylidene pyruvate led to comparable yields and 
stereoselectivities to the unsubstituted case, but we found that using a meta-bromo benzylidene 
pyruvate gave only 5.4:1 dr. Additionally, while substrates with meta and para electron-
withdrawing groups gave upwards of 96:4 er, we observed enantioselectivities of 90.5:9.5 for 
2.2f and 93:7 for 2.2g (o-bromo and o-fluoro, respectively). Using a 4-methyl substituted 
benzylidene pyruvate we observed that the reaction was complete in 24 h (2.2h), though with 
stronger electron-donating groups on the ring, the reaction is slower likely due to depressed rate 
of Pudovik addition (2.2i-2.2j). 
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Table 2-1.	Reaction Optimization for Reductive Coupling Reaction with Benzylidene Pyruvates 
 
 
entry temp (°C) catalyst dr er 2.2a:2.3a 
1a 0 KOtBu 1.2:1 50:50 100:0 
2b –60 C1 13:1 9:91 6:1 
3b –60 C2 17:1 97:3 >20:1 
a Reaction was conducted on 1.0 mmol scale, using 1.1 equiv of dimethylphosphite and 5.0 equiv 
of ArCHO; reaction was complete in minutes. b Reactions were conducted on 0.2 mmol scale, 
using 1.1 equiv of dimethylphosphite and 5.0 equiv of ArCHO. Reactions were run for 24 h. 
Using the 2-thienylidene pyruvate gave 2.2k in >20:1 dr, with 87% yield and 92:8 er, but extending 
the conjugation of the starting material as in 2.2l gave 14:1 dr and 92:8 er, with 74% yield. The 
reaction was found to proceed with other electron-deficient aryl aldehydes as well (2.2m-2.2r), 
either in the para or meta position, although there was a noticeable drop in stereoselectivity with 
para-nitrobenzaldehyde. We attempted to use benzaldehyde as a coupling partner, but observed 
that the major product formed in that reaction was 2.3.15 
 
 
 
 
 
48 
	
Table 2-2.	Scope of Asymmetric Reductive Coupling Reaction with Benzylidene Pyruvates and 
Aldehydesa 
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Table 2-2, cont.	
 
a All reactions were conducted on 0.1 mmol scale, using 1.1 equiv of dimethyl phosphite and 5.0 
equiv of ArCHO. % yields refer to isolated yields. All dr, er, and % yields are the averages of 
two trials. b Reaction time = 48 h. 
2.3.2 Gram-scale Reductive Coupling Reaction 
 The asymmetric reductive coupling reaction on gram scale works comparably to those 
reactions conducted on smaller scale.  Figure 2 illustrates the conversion of 1 g of 1a to 1.88 g of 
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the derived coupled product 2a with >20:1 dr and 97.5:2.5 er after a single recrystallization. An x-
ray diffraction study of this material revealed the absolute configuration of the coupled product to 
be (1R,2R) (Scheme 2-4). 
Scheme 2-4.	Asymmetric Reductive Coupling Reaction on Gram-Scale and X-Ray Diffraction 
Study of 2.2aa 
 
 
a The reaction was conducted using 1.1 equiv of dimethyl phosphite and 5.0 equiv of ArCHO. % 
yield refers to isolated yield. Reaction was run for 24 h. 
2.4  Conclusion 
 The work described in this chapter expands on the organic reductant-based organocatalytic 
reductive coupling developed in Chapter One.  The title process exhibits high levels of chemo- 
and stereoselectivity in the face of multiple potential reaction pathways.  Specifically, this work 
presents new possibilities for the coupling partners that can participate in this reaction.  
2.5 Experimental Details 
Methods: Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier transform infrared 
spectrometer. Proton and carbon magnetic resonance spectra (1H NMR, 13C NMR, 19F NMR and 
31P NMR) were recorded on a Bruker model DRX 400 or 600 (1H NMR at 400 MHz or 600 MHz, 
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13C NMR at 101 MHz or 151 MHz, 19F NMR at 376 MHz and 31P NMR at 162 MHz or 243 MHz), 
or a Bruker AVANCE III-OneBay500 (13C NMR at 235 MHz) spectrometer with solvent 
resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 13C NMR: CDCl3 at 77.0 
ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, br-s = broad 
singlet, d = doublet, dd = doublet of doublets, t = triplet, m = multiplet), coupling constants (Hz), 
and integration. High resolution mass spectra were obtained with a Thermo Fisher Scientific 
Exactive or FinniganTM LTQ-ICR FTTM (all samples prepared in methanol). Melting points were 
obtained using a Thomas Hoover UniMelt Capillary Melting Point Apparatus. Analytical thin layer 
chromatography was carried out using Whatman 0.25 mm silica gel 60 plates, Sorbent 
Technologies 0.20 mm Silica Gel TLC plates. Visualization was allowed by UV light, 
phosphomolybdic acid in ethanol, or aqueous ceric ammonium nitrate solution. HPLC analysis 
was performed on a Perkin Elmer flexar photodiode array (PDA) system equipped with Daicel IA, 
IC, AD, and OD-H columns. Asymmetric reactions were carried out in a Thermo NESLAB CB-
80 immersive cryogenic cooler with stirring. Purification of the reaction products was carried out 
by using Siliaflash-P60 silica gel (40- 63µm) purchased from Silicycle. Yields refer to isolated 
yields after flash column chromatography; some samples contain residual minor diastereomers. 
Since all results are the averages of two trials, the stereoisomer ratios listed in the tables may not 
exactly match those represented in the NMR and HPLC data below. 
Materials: Tetrahydrofuran (THF) was passed through a column of neutral alumina under 
nitrogen prior to use. Benzylidene pyruvates were prepared according to literature procedures.16 
Triaryliminophosphorane catalysts C1-C2 were prepared according to literature procedures.14 
Commercially available dimethyl phosphite and potassium tert-butoxide were used as received. 
Commercially available liquid aldehydes were freshly distilled directly before the reactions. The 
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literature method for the racemic three-component coupling was used to generate racemic 
standards.7 
Experimental Procedures: 
General procedure for three component reaction using chiral iminophosphorane: 
 A test tube was charged sequentially with dimethyl phosphite (0.11 mmol, 1.1 equiv), 
aldehyde (0.5 mmol, 5.0 equiv), and a–keto ester (0.1 mmol, 1.0 equiv), followed by THF (1.0 
mL), which was used to wash the residual solids and liquids on the sides of the test tube to the 
bottom. The reaction was stirred at -60 ºC in a cryogenic cooling apparatus for 30 minutes, then 
the iminophosphorane catalyst C2 was added. The reaction was then stirred at -60 ºC and 
monitored by TLC until the reaction was complete. The crude reaction mixture was then flowed 
through a short silica plug and flushed through with diethyl ether, then concentrated in vacuo. The 
crude materials thusly obtained were purified using flash column chromatography, with a gradient 
from 60:40 hexanes/EtOAc to 40:60 hexanes/EtOAc. 
Characterization data for new compounds: 
Methyl (R,E)-2-((R)-(4-
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-hydroxy-
4-phenylbut-3-enoate (2.2a):  
The title compound was prepared according to the general procedure; the reaction was allowed to 
proceed for 24 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of 
the crude reaction mixture by comparison of the resonances at δ 6.46 (major diastereomer) and δ 
6.18 (minor diastereomer). White solid (40.1 mg), mp 136-137 °C (decomp); 1H NMR (400 MHz, 
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CDCl3) δ 7.52 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 7.38-7.28 (m, 5H), 7.04 (d, J = 16.0 
Hz, 1H), 6.47 (d, 16.0 Hz, 1H), 5.71 (d, J = 9.6 Hz, 1H), 3.78 (s, 3H), 3.59 (d, J = 11.2 Hz, 3H), 
3.49 (d, J = 11.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.1, 135.9, 134.3 (d, J = 2.4 Hz), 
132.7, 131.4, 129.6, 128.7, 128.3, 126.9, 126.0, 123.4, 81.5 (d, J = 5.4 Hz), 80.3 (d, J = 6.5 Hz), 
54.6 (d, J = 6.0 Hz), 54.3 (d, J = 6.0 Hz), 53.5; 31P NMR (243 MHz, CDCl3) δ 0.97. IR (thin film) 
ν 2917, 2360, 1741, 1489, 1257, 1034, 906, 852, 507 cm-1. HRMS (ESI): Calcd. For C20H22BrO7P 
([M+H+]): 485.0359, found 485.0367. HPLC Chiralpak OD-H column, Hex/iPrOH = 95:5, flow 
rate = 1.0 mL/min, λ = 210 nm, 18.1 min (minor isomer), 25.0 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.13. [a]D = -14.9 (c = 3.0, CH2Cl2). 
Methyl (R,E)-4-(4-bromophenyl)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2- 
hydroxybut-3-enoate (2.2b): The title compound was prepared 
according to the general procedure; the reaction was allowed to proceed for 48 h. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.46 (major diastereomer) and δ 6.18 (minor 
diastereomer). White solid (45.3 mg), mp 148-153 °C; 1H NMR (600 MHz, CDCl3) δ 7.51 (d, J = 
8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.33-7.30 (m, 4H), 6.96 (d, J = 15.7 Hz, 1H), 6.47 (d, J = 
15.7 Hz, 1H), 5.69 (d, J = 9.6 Hz, 1H), 3.78 (s, 3H), 3.58 (d, J = 11.4 Hz, 3H), 3.48 (d, J = 11.4 
Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 171.9, 134.8, 134.1 (d, J = 2.3 Hz), 131.9, 131.5, 131.4, 
129.5, 128.4, 126.9, 123.5, 122.1, 81.3 (d, J = 5.4 Hz), 80.2 (d, J = 6.5 Hz), 54.6 (d, J = 6.0 Hz), 
54.3 (d, J = 6.0 Hz), 53.6; 31P NMR (243 MHz, CDCl3) δ 0.96. IR (thin film) ν 2954, 1742, 1590, 
1488, 1251, 1149, 1036, 1009, 905, 851 cm-1. HRMS (ESI): Calcd. For C20H21Br2O7P ([M+H+]): 
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562.9464, found 562.9475. HPLC Chiralpak IA column, Hex/iPrOH = 97:3, flow rate = 1.0 
mL/min, λ = 210 nm, 42.0 min (minor isomer), 53.0 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.14. [a]D = -10.2 (c = 4.6, CH2Cl2). 
Methyl (R,E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-4-(4- 
chlorophenyl)-2-hydroxybut-3-enoate (2.2c): The title 
compound was prepared according to the general procedure; the reaction was allowed to proceed 
for 48 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude 
reaction mixture by comparison of the resonances at δ 6.45 (major diastereomer) and δ 6.16 (minor 
diastereomer). White solid (44.4 mg), mp 137-141 °C; 1H NMR (600 MHz, CDCl3) δ 7.51 (d, J = 
8.5 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 7.33-7.30 (m, 4H), 6.98 (d, J = 15.7 Hz, 1H), 6.46 (d, J = 
15.7 Hz, 1H), 5.70 (d, J = 9.8 Hz, 1H), 3.79 (s, 3H), 3.58 (d, J = 11.2 Hz, 3H), 3.48 (d, J = 11.4 
Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 171.9, 134.4, 134.1 (d, J = 2.6 Hz), 133.9, 131.5, 131.4, 
129.5, 128.9, 128.1, 126.7, 123.5, 81.4 (d, J = 5.3 Hz), 80.2 (d, J = 6.6 Hz), 54.6 (d, J = 6.2 Hz), 
54.3 (d, J = 6.2 Hz), 53.6; 31P NMR (243 MHz, CDCl3) δ 0.99. IR (thin film) ν 1740, 1492, 1249, 
1036 cm-1. HRMS (ESI): Calcd. For C20H21BrClO7P ([M+H+]): 518.9970, found 518.9976. 
HPLC Chiralpak IA column, Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 nm, 28.8 min 
(minor isomer), 62.8 min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.36. [a]D = -5.5 (c = 
2.9, CH2Cl2). 
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Methyl (R,E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxy-4-(4-(trifluoromethyl)phenyl)but-3-enoate (2.2d): 
The title compound was prepared according to the general 
procedure; the reaction was allowed to proceed for 48 h. The diastereomeric ratio was determined 
by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances 
at δ 6.59 (major diastereomer) and δ 6.30 (minor diastereomer). White solid (40.9 mg), mp 134-
140 °C; 1H NMR (600 MHz, CDCl3) δ 7.60 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 7.52 (d, 
J = 8.4 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 16.0 Hz, 1H), 6.58 (d, J = 15.7 Hz, 1H), 5.72 
(d, J = 102. Hz, 1H), 3.79 (s, 3H), 9. 3.59 (d, J = 11.4 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C 
NMR (151 MHz, CDCl3) δ 171.8, 139.4, 134.0 (d, J = 2.3 Hz), 131.5, 131.4, 130.1, 129.9, 129.5, 
128.8, 127.0, 125.7 (q, J = 3.9 Hz), 123.5, 81.3 (d, J = 5.3 Hz), 80.3 (d, J = 6.5 Hz), 54.6 (d, J = 
6.0 Hz, 54.3 (d, J = 6.3 Hz), 53.6; 31P NMR (243 MHz, CDCl3) δ 0.95; 19F NMR (376 MHz, 
CDCl3) δ -62.6. IR (thin film) ν 1739, 1326, 1123, 1045 cm-1. HRMS (ESI): Calcd. For 
C21H21BrF3O7P ([M+H+]): 553.0233, found 553.0244. HPLC Chiralpak IA column, Hex/iPrOH = 
95:5, flow rate = 1.0 mL/min, λ = 210 nm, 22.3 min (minor isomer), 51.9 min (major isomer). 
TLC (1:1 EtOAc/Hexanes): Rf = 0.32. [a]D = -6.6 (c = 3.6, CH2Cl2). 
Methyl (R,E)-4-(3-bromophenyl)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxybut-3-enoate (2.2e): The title compound was prepared 
according to the general procedure; the reaction was allowed to 
proceed for 48 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of 
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the crude reaction mixture by comparison of the resonances at δ 6.48 (major diastereomer) and δ 
5.05 (minor diastereomer). White solid (42.9 mg), mp 128-131 °C; 1H NMR (600 MHz, CDCl3) 
δ 7.59 (s, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 7.31 (d, 
J = 8.3 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 6.96 (d, J = 15.6 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 5.69 
(d, J = 9.6 Hz, 1H), 3.79 (s, 3H), 3.60 (d, J = 11.4 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C NMR 
(151 MHz, CDCl3) δ 171.9, 138.1, 134.1 (d, J = 2.4 Hz), 131.5, 131.4, 131.1, 130.3, 129.7, 129.5, 
127.6, 125.5, 123.5, 122.9, 81.4 (d, J = 5.6 Hz), 80.2 (d, J = 6.6 Hz), 54.6 (d, J = 6.0 Hz), 54.3 (d, 
J = 5.9 Hz), 53.6; 31P NMR (243 MHz, CDCl3) δ 0.97. IR (thin film) ν 2955, 2349, 1742, 1591, 
1563, 1269, 1153, 1037, 1067, 905 cm-1. HRMS (ESI): Calcd. For C20H21Br2O7P 
([M+H+]):562.9464, found 562.9476. HPLC Chiralpak IA column, Hex/iPrOH = 95:5, flow rate 
= 1.0 mL/min, λ = 210 nm, 28.5 min (minor isomer), 63.1 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.30. [a]D = -2.4 (c = 2.8, CH2Cl2). 
Methyl (R,E)-4-(2-bromophenyl)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxybut-3-enoate (2.2f): The title compound was prepared 
according to the general procedure; the reaction was allowed to 
proceed for 24 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of 
the crude reaction mixture by comparison of the resonances at δ 6.44 (major diastereomer) and δ 
6.09 (minor diastereomer). White solid (40.9 mg), mp 122-126 °C; 1H NMR (600 MHz, CDCl3) 
δ 7.64 (d, J = 7.7 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 15.6 Hz, 
1H), 7.35-7.31 (m, 3H), 7.15 (t, J = 7.5 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 5.72 (d, J = 9.9 Hz, 
1H), 3.79 (s, 3H), 3.64 (d, J = 11.2 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 171.8, 135.9, 134.1 (d, J = 2.6 Hz), 133.0, 131.6, 131.4, 129.6, 129.5, 129.2, 127.7, 
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127.5, 124.0, 123.5, 81.2 (d, J = 5.6 Hz), 80.4 (d, J = 6.3 Hz), 54.7 (d, J = 6.5 Hz), 54.3 (d, J = 6.2 
Hz), 53.6; 31P NMR (243 MHz, CDCl3) δ 0.83. IR (thin film) ν 1741, 1268, 1028, 553 cm-1. 
HRMS (ESI): Calcd. For C20H21Br2O7P ([M+H+]): 562.9464, found 562.9474. HPLC Chiralpak 
IA column, Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 nm, 23.7 min (minor isomer), 57.3 
min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.27. [a]D = +6.6 (c = 3.5, CH2Cl2). 
Methyl (R,E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-4-(2- 
fluorophenyl)-2-hydroxybut-3-enoate (2.2g): The title compound 
was prepared according to the general procedure; the reaction was allowed to proceed for 24 h. 
The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.54 (major diastereomer) and δ 6.68 (minor 
diastereomer). White solid (36.2 mg), mp 126-130 °C; 1H NMR (600 MHz, CDCl3) δ 7.54-7.50 
(m, 2H), 7.33 (d, J = 8.3 Hz, 2H), 7.29-7.24 (m, 1H), 7.19 (d, J = 15.9 Hz, 1H), 7.14 (t, J = 7.3 
Hz, 1H), 7.08-7.05 (m, 1H), 6.58 (d, J = 15.6 Hz, 1H), 5.71 (d, J = 9.6 Hz, 1H), 3.78 (s, 3H), 3.62 
(d, J = 11.4 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 171.9, 161.2, 
159.6, 134.2 (d, J = 1.8 Hz), 131.4, 129.6, 128.7 (d, J = 5.0 Hz), 128.1 (d, J = 3.2 Hz), 125.5 (d, J 
= 3.2 Hz), 124.3 (d, J = 3.5 Hz), 123.7 (d, J = 12.1 Hz), 123.4, 115.9 (d, J = 22.0 Hz), 81.4 (d, J = 
5.3 Hz), 80.4 (d, J = 6.6 Hz), 54.6 (d, J = 5.7 Hz), 54.3 (d, J = 6.5 Hz), 53.5; 31P NMR (243 MHz, 
CDCl3) δ 0.86; 19F NMR (376 MHz, CDCl3) δ -117.0. IR (thin film) ν 3649, 3956, 1748, 1507, 
1489, 1457, 1289, 1270, 1231, 1039 cm-1. HRMS (ESI): Calcd. For C20H21BrFO7P ([M+H+]): 
503.0265, found 503.0272. HPLC Chiralpak IA column, Hex/iPrOH = 96:4, flow rate = 1.0 
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mL/min, λ = 210 nm, 34.1 min (minor isomer), 87.9 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.25. [a]D = -1.0 (c = 4.0, CH2Cl2). 
Methyl (R,E)-2-((R)-(4-
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxy-4-(p-tolyl)but-3-enoate (2.2h): The title compound 
was prepared according to the general procedure; the reaction 
was allowed to proceed for 24 h. The diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture by comparison of the resonances at δ 6.37 
(major diastereomer) and δ 6.54 (minor diastereomer). White solid (42.7 mg), mp 129 
°C (decomp); 1H NMR (600 MHz, CDCl3) δ 7.51 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 
7.33 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 6.99 (d, J = 15.6 Hz, 1H), 6.41 (d, J = 15.6 Hz, 
1H), 5.70 (d, J = 9.6 Hz), 3.77 (s, 3H), 3.59 (d, J = 11.4 Hz, 3H), 3.48 (d, J = 11.4 Hz, 3H), 2.36 
(s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.1, 138.2, 134.3 (d, J = 2.4 Hz), 133.1, 132.5, 131.4, 
129.6, 129.4, 126.8, 125.0, 123.3, 81.5 (d, J = 5.4 Hz), 80.3 (d, J = 6.6 Hz), 54.6 (d, J = 6.0 Hz), 
54.3 (d, J = 6.0 Hz), 53.4 21.3; 31P NMR (243 MHz, CDCl3) δ 0.95. IR (thin film) ν 3853, 3649, 
3345, 2954, 2854, 2360, 1741, 1593, 1514, 1488 cm-1. HRMS (ESI): Calcd. For C21H24BrO7P 
([M+H+]): 499.0516, found 499.0524. HPLC Chiralpak IC column, Hex/iPrOH = 90:10, flow rate 
= 1.0 mL/min, λ = 210 nm, 27.0 min (minor isomer), 58.0 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.29. [a]D = -24.2 (c = 4.0, CH2Cl2). 
Methyl (R,E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxy-4-(4-methoxyphenyl)but-3-enoate (2.2i): The title 
59 
	
compound was prepared according to the general procedure; the reaction was allowed to proceed 
for 48 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude 
reaction mixture by comparison of the resonances at δ 6.31 (major diastereomer) and δ 6.55 (minor 
diastereomer). White solid (31.3 mg), mp 115-129 °C; 1H NMR (600 MHz, CDCl3) δ 7.51 (d, J = 
8.5 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 15.7 Hz, 1H), 6.88 (d, 
J = 8.7 Hz, 2H), 6.32 (d, J = 15.7 Hz, 1H), 5.70 (d, J = 9.6 Hz, 1H), 3.83 (s, 3H), 3.77 (s, 3H), 3.59 
(d, J = 11.4 Hz, 3H), 3.48 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.2, 159.7, 134.3 
(d, J = 2.1 Hz), 132.1, 131.4, 129.6, 128.6, 128.1, 123.7, 123.3, 114.1, 81.5 (d, J = 5.6 Hz), 80.2 
(d, J = 6.6 Hz), 55.3, 54.6 (d, J = 6.0 Hz), 54.3 (d, J = 6.2 Hz), 53.4; 31P NMR (243 MHz, CDCl3) 
δ 0.96. IR (thin film) ν 2955, 1740, 1606, 1513, 1488, 1456, 1253, 1176, 1032, 1008 cm-1. HRMS 
(ESI): Calcd. For C21H24BrO8P ([M+H+]): 515.0465, found 515.0472. HPLC Chiralpak IA 
column, Hex/iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 210 nm, 18.6 min (minor isomer), 36.6 
min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.09. [a]D = -30.4 (c = 2.5, CH2Cl2). 
Methyl (R,E)-4-(benzo[d][1,3]dioxol-5-yl)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-
hydroxybut-3-enoate (2.2j): The title compound was prepared 
according to the general procedure; the reaction was allowed to 
proceed for 48 h. The diastereomeric ratio was determined by 1H NMR spectroscopic analysis of 
the crude reaction mixture by comparison of the resonances at δ 6.28 (major diastereomer) and δ 
6.51 (minor diastereomer). White solid (31.5 mg), mp 118-120 °C; 1H NMR (600 MHz, CDCl3) 
δ 7.50 (d, J = 8.5 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 1.5 Hz, 1H), 6.92 (d, J = 15.7 Hz, 
1H), 6.89 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.28 (d, J = 15.6 Hz, 1H), 5.98 (s, 2H), 
5.68 (d, J = 9.6 Hz, 1H), 3.77 (s, 3H), 3.61 (d, J = 10.8 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C 
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NMR (151 MHz, CDCl3) δ 172.1, 148.1, 147.7, 134.3, 132.3, 131.4, 130.3, 129.6, 124.1, 123.4, 
121.8, 108.4, 106.0, 101.2, 81.5 (d, J = 5.4 Hz), 80.2 (d, J = 6.6 Hz), 54.6 (d, J = 6.0 Hz), 54.3 (d, 
J = 6.0 Hz), 53.4; 31P NMR (243 MHz, CDCl3) δ 0.94. IR (thin film) ν 1740, 1490, 1446, 1252, 
1037, 852 cm-1. HRMS (ESI): Calcd. For C21H22BrO9P ([M+H+]): 529.0258, found 529.0267. 
HPLC Chiralpak OD-H column, Hex/iPrOH = 97:3, flow rate = 1.0 mL/min, λ = 210 nm, 41.4 
min (minor isomer), 47.7 min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.31. [a]D = -14.7 
(c = 2.1, CH2Cl2). 
Methyl (R,E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-hydroxy-4-
(thiophen-2-yl)but-3-enoate (2.2k): The title compound was 
prepared according to the general procedure; the reaction was 
allowed to proceed for 24 h. The diastereomeric ratio was determined by 1H NMR spectroscopic 
analysis of the crude reaction mixture by comparison of the resonances at δ 6.26 (major 
diastereomer) and δ 6.03 (minor diastereomer). White solid (43.0 mg), mp 119-124 °C; 1H NMR 
(600 MHz, CDCl3) δ 7.51 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 5.4 Hz, 1H), 
7.15 (d, J = 15.0 Hz, 1H), 7.05 (d, J = 3.0 Hz, 1H), 6.99 (dd, J = 3.6 Hz, 1.8 Hz), 6.27 (d, J = 15.0 
Hz, 1H), 5.65 (d, J = 9.6 Hz, 1H), 3.78 (s, 3H), 3.63 (d, J = 10.8 Hz, 3H), 3.50 (d, J = 11.4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 171.9, 140.8, 134.2, 131.4, 129.6, 127.6, 127.0, 126.0, 125.3, 
125.2, 123.4, 81.5 (d, J = 4.4 Hz), 80.0 (d, J = 5.6 Hz), 54.6 (d, J = 4.8 Hz), 54.3 (d, J = 4.9 Hz), 
53.5; 31P NMR (243 MHz, CDCl3) δ 0.95. IR (thin film) ν 3323, 2954, 2360, 1741, 1488, 1435, 
1261, 1203, 1146, 1036 cm-1. HRMS (ESI): Calcd. For C18H20BrO7PS ([M+H+]): 490.9923, found 
490.9930. HPLC Chiralpak AD column, Hex/iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 210 
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nm, 18.1 min (minor isomer), 36.5 min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.14. 
[a]D = -18.1 (c = 5.2, CH2Cl2).  
Methyl (R,3E,5E)-2-((R)-(4- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-hydroxy-
6-phenylhexa-3,5-dienoate (2.2l): The title compound was 
prepared according to the general procedure; the reaction was 
allowed to proceed for 24 h. The diastereomeric ratio was determined by 1H NMR spectroscopic 
analysis of the crude reaction mixture by comparison of the resonances at δ 6.07 (major 
diastereomer) and δ 5.77 (minor diastereomer). White solid (43.1 mg), mp 132-137 °C; 1H NMR 
(600 MHz, CDCl3) δ 7.51 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.36-7.26 (m, 5H), 6.89-
6.80 (m, 2H), 6.65 (d, J = 14.4 Hz, 1H), 6.07 (d, J = 14.3 Hz, 1H), 5.64 (d, J = 9.7 Hz, 1H), 3.78 
(s, 3H), 3.71 (d, J = 11.4 Hz, 3H), 3.49 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.0, 
136.8, 134.6, 134.3 (d, J = 2.3 Hz) 133.2, 131.4, 129.6, 129.5, 128.7, 128.0, 127.1, 126.6, 123.4, 
81.4 (d, J = 5.3 Hz), 80.1 (d, J = 6.6 Hz), 54.8 (d, J = 6.0 Hz), 54.3 (d, J = 6.2 Hz), 53.5; 31P NMR 
(243 MHz, CDCl3) δ 0.87. IR (thin film) ν 2954, 1754, 1289, 1029, 1008, 851, 692 cm-1. HRMS 
(ESI): Calcd. For C22H24BrO7P ([M+H+]): 511.0516, found 511.0530. HPLC Chiralpak OD-H 
column, Hex/iPrOH = 97:3, flow rate = 1.0 mL/min, λ = 210 nm, 35.7 min (major isomer), 45.7 
min (minor isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.27. [a]D = -5.7 (c = 3.9, CH2Cl2). 
 Methyl 4-((1R,2R,E)-1-((dimethoxyphosphoryl)oxy)-2-hydroxy-
2-(methoxycarbonyl)-4-phenylbut-3-en-1-yl)benzoate (2.2m): 
The title compound was prepared according to the general procedure; 
the reaction was allowed to proceed for 24 h. The diastereomeric 
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ratio was determined by 1H NMR spectroscopic analysis of the crude reaction mixture by 
comparison of the resonances at δ 6.46 (major diastereomer) and δ 6.56 (minor diastereomer). 
White solid (36.7 mg), mp 139-140 (decomp) °C; 1H NMR (600 MHz, CDCl3) δ 8.06 (d, J = 8.3 
Hz), 7.53 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 7.4, 2H), 7.37-7.29 (m, 3H), 7.05 (d, J = 15.6 Hz, 1H), 
6.48 (d, J = 16.2 Hz, 1H), 5.80 (d, J = 9.6 Hz, 1H), 3.95 (s, 3H), 3.79 (s, 3H), 3.60 (d, J = 10.8 Hz, 
3H), 3.48 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.0, 166.6, 140.1 (d, J = 2.4 Hz), 
135.8, 132.8, 130.8, 129.4, 128.7, 128.3, 127.9, 126.9, 125.9, 81.7 (d, J = 5.3 Hz), 80.3 (d, J = 6.5 
Hz), 54.6 (d, J = 6.2 Hz), 54.3 (d, J = 6.2 Hz), 53.5, 52.3; 31P NMR (243 MHz, CDCl3) δ 0.96. IR 
(thin film) ν 2955, 1719, 1437, 1283, 1112, 1035, 853 cm-1. HRMS (ESI): Calcd. For C22H25O9P 
([M+H+]): 465.1309, found 465.1316. HPLC Chiralpak AD column, Hex/iPrOH = 90:10, flow 
rate = 1.0 mL/min, λ = 210 nm, 23.4 min (minor isomer), 44.3 min (major isomer). TLC (1:1 
EtOAc/Hexanes): Rf = 0.15. [a]D = -1.0 (c = 6.3, CH2Cl2). 
Methyl (R,E)-2-((R)-((dimethoxyphosphoryl)oxy)(4- 
(trifluoromethyl)phenyl)methyl)-2-hydroxy-4-phenylbut-3-
enoate (2.2n): The title compound was prepared according to the 
general procedure; the reaction was allowed to proceed for 24 h. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.47 (major diastereomer) and δ 6.60 (minor 
diastereomer). White solid (27.7 mg), mp 128-129 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 
7.64 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 7.4 Hz, 2H), 7.38-7.30 (m, 3H), 7.05 
(d, J = 16.2 Hz, 1H), 6.48 (d, J = 15.6 Hz, 1H), 5.81 (d, J = 10.2 Hz, 1H), 3.80 (s, 3H), 3.61 (d, J 
= 10.8 Hz, 3H), 3.51 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.0, 139.2, 135.8, 
132.9, 131.2 (d, J = 32.8 Hz), 128.7, 128.3, 126.9, 125.8, 125.1, 124.8, 123.0, 81.4 (d, J = 5.3 Hz), 
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80.3 (d, J = 6.6 Hz), 54.7 (d, J = 6.0 Hz), 54.3 (d, J = 6.0 Hz), 53.6; 31P NMR (243 MHz, CDCl3) 
δ 0.98; 19F NMR (376 MHz, CDCl3) δ -62.7. IR (thin film) ν 2957, 1743, 1327, 1251, 1126, 1038, 
693 cm-1. HRMS (ESI): Calcd. For C21H22F3O7P ([M+H+]): 475.1128, found 475.1134. HPLC 
Chiralpak IA column, Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 nm, 20.3 min (minor 
isomer), 46.5 min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.29. [a]D = -4.4 (c = 2.8, 
CH2Cl2). 
Methyl (R,E)-2-((R)-((dimethoxyphosphoryl)oxy)(4- 
iodophenyl)methyl)-2-hydroxy-4-phenylbut-3-enoate (2.2o): The 
title compound was prepared according to the general procedure; the 
reaction was allowed to proceed for 24 h. The diastereomeric ratio 
was determined by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison 
of the resonances at δ 5.77 (major diastereomer) and δ 5.03 (minor diastereomer). White solid 
(49.2 mg), mp 137-141 °C; 1H NMR (600 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 
7.4 Hz, 2H), 7.37-7.34 (m, 2H), 7.30-7.28 (m, 1H), 7.19 (d, J = 8.3 Hz, 2H), 7.03 (d, J = 15.7 Hz, 
1H), 6.47 (d, J = 15.6 Hz, 1H), 5.70 (d, J = 10.2 Hz, 1H), 3.78 (s, 3H), 3.59 (d, J = 10.8 Hz, 3H), 
3.49 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.1, 137.3, 136.9, 134.9 (d, J = 2.6 
Hz), 132.7, 129.7, 128.7, 128.3, 126.9, 126.0, 95.3, 81.6 (d, J = 5.6 Hz), 80.3 (d, J = 6.6 Hz), 54.6 
(d, J = 6.0 Hz), 54.3 (d, J = 6.0 Hz), 53.5; 31P NMR (243 MHz, CDCl3) δ 0.98. IR (thin film) ν 
3750, 3649, 2349, 1541, 704, 514 cm-1. HRMS (ESI): Calcd. For C20H22IO7P ([M+H+]): 533.0221, 
found 533.0232. HPLC Chiralpak IA column, Hex/iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 
210 nm, 15.1 min (minor isomer), 33.4 min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.33. 
[a]D = -7.8 (c = 2.0, CH2Cl2). 
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Methyl (R,E)-2-((R)-((dimethoxyphosphoryl)oxy)(4- 
nitrophenyl)methyl)-2-hydroxy-4-phenylbut-3-enoate (2.2p): 
The title compound was prepared according to the general procedure; 
the reaction was allowed to proceed for 24 h. The diastereomeric 
ratio was determined by 1H NMR spectroscopic analysis of the crude reaction mixture by 
comparison of the resonances at δ 6.44 (major diastereomer) and δ 6.22 (minor diastereomer). 
White solid (20.0 mg), mp 141-142 (decomp) °C; 1H NMR (600 MHz, CDCl3) δ 8.25 (d, J = 8.6 
Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 7.4 Hz, 2H), 7.37-7.28 (m, 3H), 7.04 (d, J = 15.6, 
1H), 6.45 (d, J = 15.6 Hz, 1H), 5.83 (d, J = 9.6 Hz, 1H), 3.82 (s, 3H), 3.62 (d, J = 11.4 Hz, 3H), 
3.53 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 171.9, 148.3, 142.4, 135.7, 133.2, 128.9, 
128.8, 128.4, 126.9, 125.4, 123.3, 81.1 80.2, 54.8, 54.4, 53.7; 31P NMR (243 MHz, CDCl3) δ 0.92. 
IR (thin film) 3853, 3735, 3649, 3566, 1749, 1716, 1558, 1541, 1507, 1457 cm-1. HRMS (ESI): 
Calcd. For C20H22NO9P ([M+H+]): 452.1105, found 452.1108. HPLC Chiralpak AD column, 
Hex/iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 210 nm, 24.1 min (minor isomer), 55.4 min 
(major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.18. [a]D = -7.1 (c = 1.3, CH2Cl2). 
Methyl (R,E)-2-((R)-(3- 
bromophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-hydroxy-
4-phenylbut-3-enoate (2.2q): The title compound was prepared 
according to the general procedure; the reaction was allowed to proceed for 24 h. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.46 (major diastereomer) and δ 6.19 (minor 
diastereomer). White solid (35.4 mg), mp 105-110 °C; 1H NMR (600 MHz, CDCl3) δ 7.63 (s, 1H), 
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7.51 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 7.5 Hz, 2H), 7.36-7.24 (m, 5H), 7.04 (d, J = 15.7 Hz, 1H), 
6.48 (d, J = 15.7 Hz, 1H), 5.72 (d, J = 9.8 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 11.2 Hz, 3H), 3.51 
(d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 172.0, 137.4 (d, J = 1.8 Hz), 135.9, 132.8, 
132.2, 131.0, 129.8, 128.7, 128.3, 126.9, 126.5, 126.0, 122.3, 81.3 (d, J = 5.4 Hz), 80.4 (d, J = 6.6 
Hz), 54.6 (d, J = 6.2 Hz), 54.3 (d, J = 6.2 Hz), 53.5; 31P NMR (203 MHz, CDCl3) δ 0.88. IR (thin 
film) ν 1741, 1252, 1036, 698 cm-1. HRMS (ESI): Calcd. For C20H22BrO7P ([M+H+]): 485.0359, 
found 485.0364. HPLC Chiralpak IA column, Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 210 
nm, 25.9 min (minor isomer), 36.3 min (major isomer). TLC (1:4 EtOAc/Hexanes): Rf = 0.19. 
[a]D = -22.8 (c = 3.1, CH2Cl2). 
Methyl (R,E)-2-((R)-(3- 
cyanophenyl)((dimethoxyphosphoryl)oxy)methyl)-2-hydroxy-4-
phenylbut-3-enoate (2.2r): The title compound was prepared 
according to the general procedure; the reaction was allowed to proceed for 24 h. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture by comparison of the resonances at δ 6.44 (major diastereomer) and δ 6.59 (minor 
diastereomer). Some minor diastereomer and trace Pudovik-Brook adduct is present in isolated 
sample. White solid (26.8 mg), mp 116-119 °C; 1H NMR (600 MHz, CDCl3) δ 7.78 (s, 1H), 7.69-
7.66 (m, 2H), 7.50 (t, J = 7.7 Hz, 1H), 7.46 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.7 Hz, 2H), 7.31 (d, J 
= 7.3 Hz, 1H), 7.03 (d, J = 15.7 Hz, 1H), 6.45 (d, J = 15.7 Hz, 1H), 5.77 (d, J = 9.8Hz, 1H), 3.81 
(s, 3H), 3.61 (d, J = 11.3 Hz, 3H), 3.52 (d, J = 11.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 171.9, 
137.0 (d, J = 2.4 Hz) 135.7, 133.1, 132.7, 132.3, 131.6, 129.0, 128.8, 128.4, 126.9, 125.6, 118.4, 
112.5, 80.9 (d, J = 5.3 Hz), 80.2 (d, J = 6.6 Hz), 54.7 (d, J = 6.0 Hz), 54.4 (d, J = 6.0 Hz), 53.7; 
31P NMR (243 MHz, CDCl3) δ 0.89. IR (thin film) ν 2956, 1741, 1255, 1035, 695 cm-1. HRMS 
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(ESI): Calcd. For C21H22NO7P ([M+H+]): 432.1207, found 432.1211. HPLC Chiralpak IA 
column, Hex/iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 210 nm, 22.2 min (minor isomer), 33.4 
min (major isomer). TLC (1:1 EtOAc/Hexanes): Rf = 0.10. [a]D = -7.8 (c = 3.4 CH2Cl2). 
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CHAPTER THREE: 
PHOSPHAZENE-CATALYZED DESYMMETRIZATION OF CYCLOHEXADIENONES BY 
INTRAMOLECULAR DITHIANE ADDITION ‡ 
 
3.1 Introduction 
 The application of desymmetrization methodologies to the expedient synthesis of natural 
products has had a profound impact on the field. Of the scaffolds that have been studied in 
stereoselective organocatalytic desymmetrization reactions, the cyclohexadienone system is a 
noteworthy case and has received increased attention in recent years. The cyclohexene products 
that result from using desymmetrizing addition reactions on cyclohexadienones frequently map 
onto biologically active substructures. By applying the inherent efficiency of desymmetrization 
processes to this important structural unit, a large number of polyfunctionalized synthetic building 
blocks can be accessed in a small number of operations.  
3.2  Background 
3.2.1 Synthetic Value of Cyclohexadienone Desymmetrization Reactions 
 Desymmetrization has become a well-developed strategy for the construction of complex 
molecular frameworks.1-6 Cyclohexadienones are multipurpose synthetic building blocks that have 
found a central role in desymmetrization methodologies. The functional groups present in these 
symmetrical molecules allow for a wide array of downstream transformations and they are all 
																																								 																				
‡ Reprinted in part with permission from Horwitz, M. A.; Massolo, E.; Johnson. J. S. Beilstein J. 
Org. Chem. 2017, 13, 762.	
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formed through a single reaction from cheap and readily available aromatic feedstocks.7-11 These 
substrates have been successfully employed in a number of stereoselective desymmetrization 
reaction manifolds. Recent work by the Corey group has enabled the enantioselective conjugate 
reduction of prochiral cyclohexadienones using copper hydride generated in situ (Scheme 3-1).12 
Using this methodology, the authors were able to access enantioenriched cyclohexenones. 
Scheme 3-1.	Asymmetric Synthesis of Cyclohexenones by Enantioselective Desymmetrization 
	
	 Outside the “simple” context of utilizing asymmetric desymmetrization of 
cyclohexadienones to access enantioenriched products with a single stereocenter, there have been 
numerous examples that provide multiple contiguous stereocenters. Michael additions via enamine 
intermediates have been studied by the Gaunt13 (Scheme 3-2a) and Johnson groups14 (Scheme 3-
2b); in the former case, the cyclohexadienone is formed in situ. The intermolecularity of the latter 
case is particularly noteworthy due to the hindered nature of the para-quinol nucleophile; this fact 
speaks strongly to the electrophilicity of the iminium electrophile. Using these systems, it was 
possible to obtain bicyclic systems with three or four contiguous stereocenters. 
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Scheme 3-2.	Desymmetrization of Cyclohexadienones via Enamine Addition 
 
 
 There are ample additional examples of desymmetrizing additions to achiral 
cyclohexadienones. The You group has disclosed methods for the intramolecular addition of 
amine15 and bisphenylsulfonyl16 nucleophiles using bifunctional cinchona alkaloid catalysts. The 
Sasai and Enders groups used a phosphinosulfonamide organocatalyst to enable a Rauhut-Currier 
reaction to form bicyclic enones (Scheme 3-3).17 These examples provided good precedents for 
organocatalytic ring closure to form hindered bicyclic systems by desymmetrization.  
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Scheme 3-3.	Desymmetrization of Cyclohexadienones by Rauhut-Currier Reaction 
 
	
 Further catalytic modes for cyclohexadienone desymmetrization have been well 
established, including transition-metal catalyzed cyclizations and Brønsted acid catalysis cascades. 
The Tian and Lin group used alkyne-tethered cyclohexadienones in an arylrhodation/conjugate 
addition sequence that enantioselectively delivered oxabicyclo[4.3.0]nonanes (Scheme 3-4).18 In 
that work, the authors surveyed a large number of sophisticated chiral ligands and determined that 
the simple BINAP ligand conveniently offered the highest yields and enantioselectivities. The 
Lautens and Lan groups have also contributed to the further development of this reaction.19,20 The 
Rovis group employed cyclohexadienone hydroperoxides in a chiral phosphoric acid-catalyzed 
[1,2]/[1,4]-addition cascade [21] (Scheme 3-5). The same group also developed an acyl anion 
addition promoted by N-heterocyclic carbenes (NHC) that furnishes bicyclic furanones via Stetter 
addition;22 later, the You group developed an extension of this theme using the same catalytic 
manifold in a new bicyclic substrate class.23  
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Scheme 3-4.	Desymmetrization of Cyclohexadienones by Arylrhodation/Conjugate Addition 
 
	
Scheme 3-5.	Desymmetrization of Cyclohexadienones by Acetalization/Oxy-Michael Cascade 
 
 
 Inspired by these advances, we sought to develop an alternative and complementary 
method invoking the dithiane moiety as an established and easily accessible glyoxylate anion 
surrogate.24-29 This would in principle provide access to highly functionalized products with 
orthogonally protected carbonyl groups in a novel glycolic acid scaffold. 
3.2.2 Reaction Design for Desymmetrization by Intramolecular Dithiane Addition 
 We envisioned utilizing para-quinol derivatives featuring a tethered nucleophile as 
desymmetrization substrates, with the intention of implementing a Brønsted base organocatalyzed 
addition (Scheme 3-6). This reaction would lead to bicyclic systems with the salient attribute of 
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having a convex-concave facial differentiation, allowing subsequent diastereoselective 
transformations. With the aim of using a dithiane nucleophile, we selected 1,3-dithiane-2-
carboxylic acid because of its relatively low pKa (compared with non-carboxylate substituted 
analogs) and the possibility of using an ester linkage as a tether. 
Scheme 3-6.	Desymmetrization of Cyclohexadienone by Tethered Nucleophile 
 
	
3.3  Results and Discussion 
3.3.1  Synthesis of Dithiane-tethered Cyclohexadienones 
 We found that the heretofore unknown dicyclohexylcarbodiimide (DCC) mediated 
coupling between para-quinols and 1,3-dithiane-2-carboxylic acid proceeds in a straightforward 
manner in cases where R is unbranched (though it does work for R = Ph). Using this method, 
diversely functionalized dithiane-linked para-quinols were generated to study the intramolecular 
cyclization. 
3.3.2  Discovery and Scope of Intramolecular Dithiane Addition 
 Based on a prior report31 demonstrating the efficacy of phosphazene bases in deprotonating 
carboxylate dithianes, we selected the commercially available achiral superbase P2-tBu 
phosphazene to initiate the ring closure (Table 3-1).33,34 We found that in the simplest case, with 
the methyl-substituted para-quinol ester (3.1a), the reaction was complete in 30 min at ambient 
temperature with 20 mol % catalyst.35 Extending the length of the alkyl chain, the reaction 
proceeded similarly, even in the presence of a methyl ester or a TBS-protected primary alcohol 
(3.1b-d); a comparable result was observed with a phenyl substituent (3.1e). We considered that 
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if a nucleophilic group were appended to the para-quinol, it would be possible to construct a 5-6-
5 fused ring system. Indeed, when R = CH2CH2NHBoc (3.1f), the desired tricyclic product 3.2f 
was obtained. In all cases only a single diastereomer was observed. In a substrate where a b-methyl 
group is present on the cyclohexadienone (3.1g), the reaction proved to be completely 
regioselective, only allowing conjugate addition to the less substituted position. 
Table 3-1.	Scope of the Intramolecular Dithiane Conjugate Addition Reaction 
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Table 3-1, cont. 
 
3.3.3  Studies on the Asymmetric Intramolecular Dithiane Addition 
 We attempted to render the reaction enantioselective using chiral iminophosphoranes 
(Figure 1) structurally related to P2-tBu phosphazene, which are known to be substantially more 
basic than trialkylamines.36   With C136-40 and C241-57,we observed no product formation, 
presumably due to insufficient basicity. Though C330-32 led to partial conversion of starting 
material, no appreciable enantioselectivity was observed. 
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Figure 3-1.	Chiral Iminophosphorane Catalysts Surveyed for Dithiane Addition 
 
 
3.3.4  Studies on Convex-facial Additions to Cyclized Products 
 To investigate the feasibility of a convex-facial addition, we subjected 3.2a to Luche 
reduction conditions (Scheme 3-7). We found this transformation to be completely 
diastereoselective, and an X-ray diffraction study58 of the product confirmed our hypothesis 
regarding the facial selectivity, as the hydride was delivered to the convex face. An analogous 
reaction occurs when 3.2a is treated with AlMe3, affording the 1,2-addition product (Scheme 3-
3).59-63 
Scheme 3-7.	Convex-facial Additions to Desymmetrized Bicycles 
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3.3.5  Studies on the Attempted Deprotection of Dithiane Conjugate Addition Adducts 
 We next sought to establish the glyoxylate anion equivalency of the dithiane substructure 
in our system. In order to reveal the masked carbonyl functionality, we rigorously applied reported 
dithiane deprotection conditions to 3.2a (Table 3-2). Despite extensive investigations, none of our 
efforts were fruitful, resulting in either no conversion, side reactions,64 or decomposition. We 
rationalize these disappointing results considering: 1) the crowded steric environment surrounding 
the dithiane moiety on the concave face of the bicycle, 2) the sensitive nature of this class of 
compounds, which stems from the highly reactive functional groups present, and 3) the strained 
character of the five-membered a-ketolactone (3.5) that would result from deprotection. In order 
to minimize the observed side reactions, we sought to apply the deprotection conditions to allylic 
alcohol 3.3. However, both the use of NBS and HgCl2/HgO were unsuccessful. 
3.3.6  Attempted Independent Synthesis of Desired a-Ketolactone by Oxidative Deacylation 
 We attempted to synthesize 3.5 via an alternative route using Cu(II)-catalyzed aerobic 
oxidative deacylation76 of the b-keto ester 3.6 (Scheme 3-8).77 The fact that this reaction also leads 
to decomposition of the starting material is cause for general concern about the feasibility of easily 
reaching the target substructure.  
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Table 3-2.	Carbonyl Deprotection Conditions 
	
a 
Different solvent systems, such as acetone/H2O and DMSO were used, stoichiometry was varied 
and the reaction was run also at rt and for longer times (4 and 18 h) but in none of the cases was 
the desired product obtained. b The reaction was also run at rt for 18 h, but the desired product was 
not obtained. c Decomposition products were also observed. d The system MeCN/H2O was also 
used and the reaction was also run at rt and reflux, but in none of the cases was the desired product 
obtained.  
 
Scheme 3-8.	Attempted Oxidative Deacylation 
	
3.3.7  Attempted Desulfurization of Dithiane Conjugate Addition Adducts 
 We further investigated removal of the dithiane moiety via Raney nickel-promoted 
desulfurization (Scheme 3-9). To observe any substrate conversion, it was necessary to use a 
Entry Conditions Result 
165 NBS - MeCN/H2O, 0 °C, 10 mina Side reaction 
266 NBS, AgNO3 - MeCN /H2O, 0 °C, 5 minb Side reaction 
367 PhI(OAc)2 - MeCN /CH2Cl2/H2O, 50 °C, 18 h No reactionc 
468 Hg(ClO4)2 - MeOH/CH2Cl2, rt, 2 h Side reaction 
569 HgCl2,HgO - MeOH/H2O, 55°C, 18 hd No reaction 
670 MeI - MeCN /H2O, reflux, 18 h No reaction 
771 m-CPBA - MeCN, rt, 18 h, then 1M HCl, reflux, 4 h Decomposition 
872 SbCl5 - CH2Cl2, 0 °C, 1 h Decomposition 
973 I2, NaHCO3 - acetone/H2O, 50 °C, 18 h No reaction 
1074 CAN - acetone/H2O, 50 °C , 18 h No reaction 
1175 Chloramine T - MeOH/H2O, 70 °C, 18 h No reaction 
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hydrogen atmosphere. Under those conditions, though the dithiane function was removed, 
degradation occurred. 
Scheme 3-9.	Attempted Desulfurization with Raney Nickel 
 
 
3.4  Conclusion 
In this chapter, we have developed a desymmetrizing intramolecular conjugate addition of a 
tethered dithiane moiety to cresol-derived cyclohexadienones. The substrates are easily accessible 
from cheap starting materials and the reaction provides functionalized bicyclic lactones as a single 
diastereomer.  The products of the reaction were able to undergo diastereoselective convex-facial 
additions. The carbonyl deprotection was unsuccessful and we hope that our efforts can serve as a 
cautionary tale for future synthetic planning involving related structures. 
3.5  Experimental Details 
Methods: Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier transform infrared 
spectrometer. Proton and carbon magnetic resonance spectra (1H NMR, 13C NMR, 19F NMR and 
31P NMR) were recorded on a Bruker model DRX 400 or 600 (1H NMR at 400 MHz or 600 MHz, 
13C NMR at 101 MHz or 151 MHz, or a Bruker AVANCE III-OneBay500 (13C NMR at 235 MHz) 
spectrometer with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 
13C NMR: CDCl3 at 77.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity 
(s = singlet, br-s = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, td = triplet of 
doublets, m = multiplet), coupling constants (Hz), and integration. High resolution mass spectra 
were obtained with a Thermo Fisher Scientific Exactive or FinniganTM LTQ-ICR FTTM (all 
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samples prepared in methanol). Melting points were obtained using a Thomas Hoover UniMelt 
Capillary Melting Point Apparatus. Analytical thin layer chromatography was carried out using 
Whatman 0.25 mm silica gel 60 plates, Sorbent Technologies 0.20 mm Silica Gel TLC plates. 
Visualization was allowed by UV light, phosphomolybdic acid in ethanol, or aqueous ceric 
ammonium nitrate solution. Purification of the reaction products was carried out by using 
Siliaflash-P60 silica gel (40- 63µm) purchased from Silicycle. Yields refer to isolated yields after 
flash column chromatography. Since all results are the averages of two trials, the yields listed in 
the tables may not exactly match those listed below. 
Materials: THF and DCM were purified by passing the solvent through a column of aluminum 
oxide under nitrogen. Dearomatization of phenol derivatives was carried out according to literature 
procedures.7-11 1,3-dithiane-2-carboxylic acid was prepared according to literature procedure.31  
Phosphazene base P2-tBu solution (~2.0 M in THF) and DMAP were purchased from Sigma-
Aldrich and used as received. (Diacetoxyiodo)benzene, [bis(trifluoroacetoxy)iodo]benzene, and 
DCC were purchased from Oakwood Chemical and used as received. 
General procedure for substrate synthesis: 
The substrates were prepared through a two-step synthesis on gram scale. 
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STEP 1 – Dearomatization of phenols7-11 
The phenol (1 equiv) was dissolved in MeCN (3 mL for 1 mmol) and H2O (1 mL for 1 mmol); the 
solution was cooled to 0 °C and PhI(OAc)2 (1.1 equiv) was slowly added as a solid. The reaction 
mixture was allowed stirred at ambient temperature for 18 h. The mixture was diluted with EtOAc 
and washed with water and brine. The combined organic phases were dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude materials thusly obtained were purified 
using flash column chromatography on silica gel. 
STEP 2 – DCC coupling between para-quinols and 1,3-dithiane-2-carboxylic acid 
The desired p-quinols (1 equiv) and 1,3-dithiane-2-carboxylic acid (1.5 equiv) were dissolved in 
CH2Cl2 ([quinol]0 = 1.0 M); 4-(dimethylamino)pyridine (DMAP) (1 equiv) was then added to the 
mixture. The reaction mixture was cooled to 0 °C and N,N'-dicyclohexylcarbodiimide (DCC) (1.1 
equiv) was added. The reaction mixture was allowed to warm to rt and stirred for 18 h. After that 
period, the mixture was filtered through a short plug of silica gel and washed with CH2Cl2.The 
solvent was removed under reduced pressure. The crude materials thusly obtained were purified 
using flash column chromatography on silica gel. 
Characterization of substrates: 
1-Methyl-4-oxocyclohexa-2,5-dien-1-yl 1,3-dithiane-2-carboxylate (3.1a): 
The title compound was obtained in 61% yield. White solid, mp 88-90 °C; 1H 
NMR (600 MHz, CDCl3) δ 6.96 (d, J = 10.2 Hz, 2H), 6.31 (d, J = 10.2 Hz, 2H), 
4.12 (s, 1H), 3.43-3.39 (m, 2H), 2.61-2.57 (m, 2H), 2.19-2.14 (m, 1H), 2.06-1.99 (m, 1H), 1.62 (s, 
3H); 13C NMR (151 MHz, CDCl3) δ 184.8, 168.3, 148.6, 128.5, 75.3, 39.0, 26.4, 25.5, 24.8; IR 
(thin film) n 2931, 1735, 1667, 1631, 1608, 1393, 1285, 1138, 1052, 857 cm-1; HRMS (ESI): 
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Calcd. For C12H14NaO3S2+ ([M+Na+]): 293.0277, found 293.0275; TLC (1:4 EtOAc/hexanes): Rf 
= 0.33. 
1-Ethyl-4-oxocyclohexa-2,5-dien-1-yl 1,3-dithiane-2-carboxylate (3.1b): 
The title compound was obtained in 49% yield. Yellow oil; 1H NMR (600 MHz, 
CDCl3) δ 6.88 (d, J = 10.2 Hz, 2H), 6.36 (d, J = 10.2 Hz, 2H), 4.14 (s, 1H), 3.40 
(ddd, J = 14.3, 12.2, 2.5 Hz, 1H), 2.60-2.57 (m, 1H), 2.18-2.14 (m 1H), 2.06-1.99 (m, 1H), 1.94 
(q, J = 7.5 Hz, 1H), 0.94 (t, J = 7.5 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 185.1, 168.3, 147.6, 
129.6, 78.4, 39.2, 32.2, 25.5, 24.8, 7.7; IR (thin film) n 2935, 1736, 1667, 1631, 1282, 1138, 1063, 
995, 915, 853 cm-1; HRMS (ESI): Calcd. For C13H16NaO3S2+ ([M+Na+]): 307.0433, found 
307.0428; TLC (1:4 EtOAc/hexanes): Rf = 0.38. 
1-(3-methoxy-3-oxopropyl)-4-oxocyclohexa-2,5-dien-1-yl 1,3-
dithiane-2-carboxylate (3.1c): The title compound was obtained in 
49% yield. Light yellow solid, mp 79-80 °C; 1H NMR (600 MHz, 
CDCl3) δ 6.85 (d, J = 10.2 Hz, 2H), 6.34 (d, J = 10.1 Hz, 2H), 4.10 (s, 1H), 3.66 (s, 3H), 3.39-3.34 
(m, 2H), 2.58-2.54 (m, 2H), 2.36-2.33 (m, 2H), 2.26-2.23 (m, 2H), 2.16-2.12 (m, 1H), 2.04-1.97 
(m, 1H). 13C NMR (151 MHz, CDCl3) δ 184.6, 172.5, 168.0, 146.7, 129.9, 52.0, 39.0, 33.8, 28.1, 
25.5, 24.8; IR (thin film) n 2949, 2360, 1734, 1670, 1654, 1521, 1473, 1281, 1136, 990 cm-1; 
HRMS (ESI): Calcd. For C15H18NaO5S2+ ([M+Na+]): 365.0488, found 365.0478; TLC (1:4 
EtOAc/hexanes): Rf = 0.25. 
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1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-oxocyclohexa-2,5-dien-1-
yl 1,3-dithiane-2-carboxylate (3.1d): The title compound was obtained 
in 55% yield. Clear oil; 1H NMR (600 MHz, CDCl3) δ 6.98 (d, J = 10.2 
Hz, 2H), 6.29 (d, J = 10.2 Hz, 2H), 4.11 (s, 1H), 3.75 (t, J = 9.0 Hz, 2H), 3.42-3.35 (m, 2H), 2.59-
2.55 (m, 2H), 2.18-2.16 (m, 1H), 2.08 (t, J = 6.1 Hz, 2H), 2.04-1.95 (m, 1H), 0.87 (s, 9H), 0.03 (s, 
6H). 13C NMR (151 MHz, CDCl3) δ 185.1, 168.1, 147.9, 128.6, 57.7, 42.7, 39.2, 25.8, 25.5, 24.8, 
18.1; IR (thin film) n 2929, 2855, 1739, 1670, 1635, 1508, 1472, 1256, 1097, 838 cm-1; HRMS 
(ESI): Calcd. For C19H30NaO4S2Si+ ([M+Na+]): 437.1247, found 437.1233; TLC (1:4 
EtOAc/hexanes): Rf = 0.32. 
4-Oxo-[1,1'-biphenyl]-1(4H)-yl 1,3-dithiane-2-carboxylate (3.1e): The title 
compound was obtained in 18% yield. Orange solid, mp 113-114 °C; 1H NMR 
(600 MHz, CDCl3) δ 7.41-7.46 (m, 2H), 7.41-7.34 (m, 3H), 7.06 (d, J = 10.1 Hz, 
2H), 6.38 (d, J = 10.1 Hz, 2H), 4.26 (s, 1H), 3.37 (td, J = 12.0, 6.1 Hz, 2H), 2.60-2.57 (m, 2H), 
2.15-2.12 (m, 1H), 2.06-1.99 (m, 1H).13C NMR (151 MHz, CDCl3) δ 185.3, 167.7, 146.8, 136.2, 
129.2, 129.0, 128.5, 125.2, 39.6, 25.6, 24.8; IR (thin film) n 2920, 2360, 1739, 1669, 1277, 1126, 
994, 849, 698 cm-1; HRMS (ESI): Calcd. For C17H16NaO3S2+ ([M+Na+]): 355.0433, found 
355.0425; TLC (1:4 EtOAc/hexanes): Rf = 0.44. 
1-(2-((tert-butoxycarbonyl)amino)ethyl)-4-oxocyclohexa-2,5-dien-1-
yl 1,3-dithiane-2-carboxylate (3.1f): The title compound was obtained 
in 17% yield. White solid, mp 107-109 °C; 1H NMR (600 MHz, CDCl3) 
δ 6.91 (d, J = 10.1 Hz, 2H), 6.32 (d, J = 10.1 Hz, 2H), 4.68 (bs, 1H), 4.10 (s, 1H), 3.22-3.21 (m, 
2H), 3.22-3.21 (m, 2H), 2.58-2.54 (m, 2H), 2.14-2.11 (m, 1H), 2.08-2.05 (m, 2H), 2.03-1.95 (m, 
1H), 1.41 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 184.6, 168.0, 155.6, 147.0, 129.5, 79.7, 39.6, 
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39.3, 35.7, 33.9, 28.4, 25.6, 24.8; IR (thin film) n 3354, 2975, 2929, 1738, 1668, 1517, 1366, 1274, 
1169, 859 cm-1; HRMS (ESI): Calcd. For C18H25NNaO5S2+ ([M+Na+]): 422.1066, found 
422.1054; TLC (1:4 EtOAc/hexanes): Rf = 0.24. 
1,2-Dimethyl-4-oxocyclohexa-2,5-dien-1-yl 1,3-dithiane-2-carboxylate 
(3.1g): The title compound was obtained in 67% yield. White solid, mp 120-
121 °C; 1H NMR (600 MHz, CDCl3) δ 6.91 (d, J = 10.2 Hz, 1H), 6.29 (dd, J 
= 9.9, 2.4 Hz, 1H), 6.16 (s, 1H), 4.13 (s, 1H), 3.48-3.36 (m, 2H), 2.61-2.56 
(m, 2H), 2.20-2.15 (m, 1H), 2.07-1.99 (m, 1H), 2.04 (d, J = 1.2 Hz, 3H), 1.57 (s, 3H); 13C NMR 
(151 MHz, CDCl3) δ 185.3, 168.0, 158.8, 149.4, 128.1, 126.8, 38.4, 26.4, 25.3, 25.3, 24.8, 17.8; ; 
IR (thin film) n 2933, 1734, 1668, 1613, 1433, 1391, 1293, 1134, 1056, 885 cm-1; HRMS (ESI): 
Calcd. For C13H16NaO3S2+ ([M+Na+]): 307.0433, found 307.0431; TLC (1:4 EtOAc/hexanes): Rf 
= 0.25. 
General procedure for intramolecular conjugate addition of dithiane: 
A flame-dried 1 dram vial was charged sequentially with the dithiane-tethered cyclohexadienone 
(0.1 mmol, 1.0 equiv), followed by THF (1.0 mL), and then P2-tBu phosphazene (0.02 mmol, 20 
mol %). The reaction was stirred at room temperature for 30 min. The reaction was quenched with 
saturated ammonium chloride, and the layers were separated. The aqueous layer was extracted 
three times with ethyl acetate, and then the combined organic phases were dried with sodium 
sulfate, and concentrated in vacuo. The crude materials thusly obtained were purified using flash 
column chromatography on silica gel using a hexane/EtOAc system (typically EtOAc/hexanes 
1:9). 
 
87 
	
Characterization of products:  
7a-Methyl-3a,7a-dihydro-2H-spiro[benzofuran-3,2'-[1,3]dithiane]-
2,5(4H)-dione (3.2a): The title compound was prepared by the general 
procedure. White solid, mp 185-187 °C; 1H NMR (600 MHz, CDCl3) δ 6.79 
(dd, J = 10.5 Hz, 1.8 Hz, 1H), 6.10 (d, J = 10.2 Hz, 1H), 3.99-3.94 (m, 1H), 
3.42-3.37 (m, 1H), 2.99 (d, J = 18.6 Hz, 1H), 2.87 (d, J = 7.2 Hz, 1H), 2.69 (dd, J = 18.6 Hz, 7.8 
Hz, 1H), 2.63-2.61 (m, 2H), 2.17-2.13 (m, 1H), 1.87-1.80 (m, 1H), 1.68 (s, 3H); 13C NMR (151 
MHz, CDCl3) δ 193.4, 171.9, 147.7, 130.0, 78.8, 52.5, 49.5, 33.4, 27.4, 26.6, 25.9, 23.6; ; IR (thin 
film) n 2920, 1761, 1681, 1275, 1194, 1104, 1067, 972, 787, 734 cm-1; HRMS (ESI): Calcd. For 
C12H15O3S2+ ([M+H+]): 271.0457, found 271.0457: TLC (2:8 EtOAc/hexanes): Rf = 0.13. 
7a-Ethyl-3a,7a-dihydro-2H-spiro[benzofuran-3,2'-[1,3]dithiane]-2,5(4H)-
dione (3.2b):  The title compound was prepared by the general procedure. White 
solid, mp 109-110 °C; 1H NMR (400 MHz, CDCl3) δ 6.80 (d, J = 10.5 Hz, 1H), 
6.18 (d, J = 10.6 Hz, 1H), 4.02-3.94 (m, 1H), 3.45-3.38 (m, 1H), 3.01 (d, J = 
18.9 Hz, 1H), 2.89 (d, J = 8.0 Hz, 1H), 2.68-2.61 (m, 3H), 2.20-2.13 (m, 1H), 2.04-1.98 (m, 1H), 
1.94-1.89 (m, 1H), 1.87-1.81 (m, 1H), 1.09 (t, J = 5.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 
193.8, 172.0, 147.0, 130.8, 81.2, 50.1, 49.7, 33.8, 32.8, 27.3, 26.0, 23.7, 7.8 IR (thin film) n 3425, 
2970, 1757, 1681, 1388, 1223, 1187, 1116, 978, 9321 cm-1; HRMS (ESI): Calcd. For 
C13H16NaO3S2+ ([M+Na+]): 307.0433, found 307.0433; TLC (2:8 EtOAc/hexanes): Rf = 0.28. 
Methyl 3-(2,5-dioxo-4,5-dihydro-2H-spiro[benzofuran-3,2'-
[1,3]dithian]-7a(3aH)-yl)propanoate (3.2c): The title compound was 
prepared by the general procedure. White solid, mp 114-115 °C; 1H NMR 
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(600 MHz, CDCl3) δ 6.78 (dd, J = 10.5,1.6 Hz, 1H), 6.17 (d, J = 10.6 Hz, 1H), 3.98-3.93 (m, 1H), 
3.72 (s, 3H), 3.42-3.37 (m, 1H), 3.00 (d, J = 18.9 Hz, 1H), 2.89 (d, J = 7.7 Hz, 1H), 2.69 (dd, J = 
18.8, 7.8 Hz, 1H), 2.64-2.61 (m, 2H), 2.59-2.51 (m, 2H), 2.35-2.30 (m, 1H), 2.25-2.20 (m, 1H), 
2.18-2.14 (m, 1H), 1.88-1.81 (m, 1H); 13C NMR (151 MHz, CDCl3) δ 193.3, 172.5, 171.6, 146.0, 
131.1, 79.8, 52.2, 50.5, 49.3, 34.4, 33.4, 28.0, 27.3, 26.0, 23.6; IR (thin film) n 2923, 2852, 1760, 
1735, 1685, 1435, 1166, 1079, 972, 932 cm-1; HRMS (ESI): Calcd. For C15H19O5S2Si+ ([M+H+]): 
343.0668, found 343.0663; TLC (3:7 EtOAc/hexanes): Rf = 0.14. 
7a-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3a,7a-dihydro-2H-
spiro[benzofuran-3,2'-[1,3]dithiane]-2,5(4H)-dione (3.2d):  The title 
compound was prepared by the general procedure. White solid, mp 135-137 
°C; 1H NMR (600 MHz, CDCl3) δ 6.78 (d, J = 10.5 Hz, 1H), 6.15 (d, J = 10.5 Hz, 1H), 3.97 (td, 
J = 13.6, 2.4 Hz, 1H), 3.89-3.86 (m, 1H), 3.80-3.76 (m, 1H), 3.43-3.93 (m, 1H), 3.35 (d, J = 7.8 
Hz, 1H), 2.96 (d, J = 18.8 Hz, 1H), 2.81 (dd, J = 18.8, 7.7 Hz, 1H), 2.63-2.60 (m, 1H), 2.18-2.14 
(m, 1H),2.08-2.04 (m, 1H), 2.88-2.81 (m, 1H), 0.90 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR 
(151 MHz, CDCl3) δ 194.3, 172.2, 147.4, 130.5, 80.7, 57.7, 50.0, 49.5, 41.6, 33.5, 27.3, 26.0, 25.8, 
23.7, 18.1, -5.5, -5.5; IR (thin film) n 23434, 2953, 1761, 1642, 1407, 1248, 1182, 1095, 778 cm-
1; HRMS (ESI): Calcd. For C19H31O4S2Si+ ([M+H+]): 415.1428, found 415.1420; TLC (2:8 
EtOAc/hexanes): Rf = 0.37. 
7a-Phenyl-3a,7a-dihydro-2H-spiro[benzofuran-3,2'-[1,3]dithiane]-2,5(4H)-
dione (3.2e): The title compound was prepared by the general procedure. White 
solid, mp 171-172 °C; 1H NMR (600 MHz, CDCl3) δ 7.46-7.42 (m, 5H), 6.87 
(d, J = 10.2 Hz, 1H), 6.40 (d, J = 10.2 Hz, 1H), 4.02 (t, J = 13.2 Hz, 1H), 3.50 
(t, J = 14.4 Hz, 1H), 3.03 (d, J = 7.2 Hz, 1H), 2.99 (d, J = 18.6 Hz, 1H), 2.72-2.64 (m, 3H), 2.20 
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(m, 1H), 1.87 (q, J = 13.2 Hz, 1H); 13C NMR (151 MHz, CDCl3) δ 193.8, 172.0, 145.3, 138.8, 
131.5, 129.3, 129.2, 124.6, 81.7, 54.6, 49.4, 33.0, 27.4, 26.0, 23.7; IR (thin film) n 2971, 2361, 
1769, 1684, 1540, 1507, 1224, 1170, 997, 799 cm-1; HRMS (ESI): Calcd. For C17H17O3S2+ 
([M+H+]): 333.0614, found 333.0608; TLC (3:7 EtOAc/hexanes): Rf = 0.38. 
Tert-butyl 2,5-dioxohexahydro-2H-spiro[furo[2,3-d]indole-3,2'-
[1,3]dithiane]-7(3aH)-carboxylate (3.2f): The title compound was 
prepared by the general procedure. Two rotamers were observed in a 56:44 
ratio in the 1H NMR spectrum. White solid, mp 196-197 °C; 1H NMR (600 MHz, CDCl3) δ 4.32-
4.04 (m, 1H for the minor rotamer), 4.28-4.25 (m, 1H for the major rotamer) 3.77-3.58 (m, 4H), 
3.19 (dd, J = 17.2, 5.8 Hz, 1H for the minor rotamer), 3.02 (dd, J = 17.1, 5.7 Hz, 1H for the major 
rotamer)., 2.80-2.75 (m, 1H), 2.75-2.73 (m, 4H), 2.63-2.59 (m, 1H), 2.32-2.26 (m, 1H), 2.24-2.19 
(m, 1H), 2.10-1.99 (m, 1H), 1.96-1.89 (m, 1H), 1.48 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 205.0, 
204.7, 171.2, 153.8, 153.5, 88.7, 88.0, 80.7, 60.6, 60.5, 49.3, 48.3, 48.2, 44.4, 44.0, 43.6, 42.9, 
37.3, 37.2, 35.7, 34.8, 28.5, 28.4, 27.6, 27.5, 26.4, 26.3, 23.8; IR (thin film) n 2974, 2927, 1764, 
1721, 1691, 1399, 1249, 1174, 1136 975 cm-1; HRMS (ESI): Calcd. For C18H25NNaO5S2 
([M+Na+]): 422.1067, found 422.1077; TLC (1:1 EtOAc/hexanes): Rf = 0.50. 
7,7a-Dimethyl-3a,7a-dihydro-2H-spiro[benzofuran-3,2'-[1,3]dithiane]-
2,5(4H)-dione (3.2g): The title compound was prepared by the general 
procedure. Impurity present in the δ 2.73-2.67 muliplet makes integral appear 
as 3H. Orange-brown solid, mp 169-179 °C; 1H NMR (600 MHz, CDCl3) δ 
5.96 (s, 1H), 3.96 (t, J = 13.8 Hz, 1H), 3.35 (t, J = 13.8 Hz, 1H), 2.98 (d, J = 19.2 Hz, 1H), 2.87 
(d, J = 9.0 Hz, 1H), 2.73-2.67 (m, 1H), 2.63-2.60 (m, 2H), 2.17-2.14 (m, 1H), 2.09 (s, 3H), 1.83 
(q, J = 13.2 Hz, 1H), 1.69 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 193.2, 171.9, 159.3, 128.5, 81.0, 
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53.2, 49.5, 33.1, 27.1, 26.1, 25.7, 23.7, 18.4; IR (thin film) n 2920, 1266, 1760, 1671, 1425, 1228, 
1190, 1098, 970, 935 cm-1; HRMS (ESI): Calcd. For C13H17O3S2 ([M+Na+]): 285.0614, found 
285.0611; TLC (2:8 EtOAc/hexanes): Rf = 0.13. 
Procedure for the preparation of 5-hydroxy-7a-methyl-3a,4,5,7a-tetrahydro-2H-
spiro[benzofuran-3,2'-[1,3]dithian]-2-one (3.3) via Luche reduction of enone 3.2a: 
CeCl3•7H2O (1.2 equiv) and NaBH4 (5.3 equiv) were added to a solution of the substrate (3.2a; 
0.80 mmol) in MeOH (0.2 M) at -10 °C. The reaction mixture was stirred at the same temperature 
for 40 min. After this period, it was quenched with 1 M HCl and extracted with EtOAc three times. 
The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography on silica gel using 
EtOAc/hexanes 3:7 as the eluent. 
White solid, mp 97-99 °C; 1H NMR (600 MHz, CDCl3) δ 5.95 (d, J = 10.2 Hz, 
1H), 5.79 (d, J = 10.2 Hz, 1H), 4.20-4.16 (br, 1H), 4.00 (t, J = 13.8 Hz, 1H), 
3.62 (t, J = 18.3 Hz, 1H), 2.68-2.64 (m, 2H), 2.46-2.43 (d, J = 12.0, 5.4 Hz, 1H), 
2.41-2.37 (m, 1H), 2.22-2.18 (m, 1H), 1.98-1.90 (m, 1H), 1.86 (d, J = 7.2 Hz, 
1H), 1.77-1.70 (m, 1H), 1.67 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.6, 134.7, 129.6, 65.4, 
49.9, 49.8, 49.8, 31.3, 29.0, 28.2, 26.5, 24.3; IR (thin film) n 3035, 2926, 1752, 1423, 1276 1189, 
1148, 1061, 956, 732 cm-1; HRMS (ESI): Calcd. For C12H17O3S2 ([M+Na+]): 273.0614, found 
273.0610; TLC (6:4 EtOAc/hexanes): Rf = 0.34. 
Procedure for the preparation of 5-hydroxy-5,7a-dimethyl-3a,4,5,7a-tetrahydro-2H-
spiro[benzofuran-3,2'-[1,3]dithian]-2-one (3.4) via 1,2-addition of AlMe3: A solution of the 
substrate (3.2a; 0.09 mmol) in dry CH2Cl2 (1.0 mL) was added to a solution of AlMe3 (2.0 M in 
toluene, 4 equiv) in dry CH2Cl2 (1.0 mL) at 0 °C. The reaction mixture was allowed to rt and kept 
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under stirring for 3 h. After this period, it was quenched with MeOH and extracted with CH2Cl2 
and EtOAc. The combined organic phases were dried over anhydrous Na2SO4 and the solvent was 
removed under reduced pressure.  
Light yellow solid, mp 179-180 °C; 1H NMR (600 MHz, CDCl3) δ 5.91 (dd, J = 
10.1, 1.4 Hz, 1H), 5.67 (d, J = 10.1 Hz, 1H), 4.06-4.01 (m, 1H), 3.62-3.57 (m, 
1H), 2.71-2.65 (m, 3H), 2.50 (dd, J = 12.7, 5.6 Hz, 1H), 2.23-2.16 (m, 2H), 1.95-
1.91 (m, 2H), 1.70 (s, 3H), 1.28 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 172.7, 
137.9, 128.0, 79.1, 68.9, 50.0, 36.7, 29.3, 28.3, 26.5, 26.4, 24.4; IR (thin film) n 3433, 2960, 2088, 
1752, 1643, 1373, 1280, 1193, 1151, 1055 cm-1; HRMS (ESI): Calcd. For C13H18NaO3S2 
([M+Na+]): 309.0590, found 309.0593; TLC (4:6 EtOAc/hexanes): Rf = 0.43. 
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CHAPTER FOUR: 
DIASTEREOSELECTIVE ORGANOCATALYTIC ADDITION OF a-ANGELICA LACTONE 
TO b-HALO-a-KETOESTERS§ 
	
4.1 Introduction 
 The glycolic acid structural unit presents diverse possibilities as a synthetic intermediate 
and appears in many natural product frameworks. The proximity of functional groups in this 
moiety allows for a large number of potential chemical elaborations. Thus, methods for the direct 
construction of this motif have intrinsic value and are desirable from a complexity-building 
standpoint. One of the most straightforward approaches to forming a glycolic acid subunit is to 
carry out a nucleophilic addition into an a-ketoester. With the goal of increasing the number of 
contiguous stereocenters that can be set during this process, we selected a more complex 
nucleophile than has previously been used for this type of process. In this chapter, we develop a 
diastereoselective addition of a-angelica lactone into b-halo-a-ketoesters using commercial 
quinidine as the organocatalyst. 
 
 
 
																																								 																				
§	Reprinted in part with permission from Griswold, J. A.; Horwitz, M. A.; Leiva, L. V.; Johnson, 
J. S. J. Org. Chem. 2017, 82, 2276. Copyright 2017 American Chemical Society.	
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4.2 Background 
4.2.1 Construction of Glycolic Acid Scaffolds 
 The construction of contiguous stereogenic polyads is an ongoing challenge in organic 
synthesis. In this context, b-stereogenic a-ketoesters (4.1) are molecules of interest due to their 
appreciable electrophilicity and their available functional handles for downstream 
transformations.1 Previously, our group has developed a number of methods for their synthesis,2 
as well as their application in complexity-building transformations encompassing a variety of 
reaction manifolds (i.e., transfer hydrogenation, Henry reaction, acetone aldol, benzoin addition, 
and homoenolate addition; Scheme 4-1a).3b-3i While these methods have provided access to a wide 
array of fully substituted glycolic acid scaffolds, there are few examples of the addition of prochiral 
nucleophiles.3a,3f, 3g The application of a-angelica lactone (4.2) as a nucleophile presents an 
interesting opportunity to build more stereochemically complex products. 
4.2.2 Established Reactivity Pattern of a-Angelica Lactone 
Unlike previously deployed pro-nucleophiles, a-angelica lactone (4.2) poses additional 
challenges with respect to (1) reactivity due to the imposition of increased steric bulk; (2) 
regioselectivity (a- vs g-nucleophilicity of the dienolate); and (3) stereoselectivity (eight 
stereoisomers are possible in the a-addition mode). This class of nucleophile has been studied in 
the stereoselective addition to nitrostyrenes and other prochiral electrophiles using cinchona 
alkaloid-derived thiourea organocatalysts (Scheme 4-1b).4a Herein, we describe initial studies 
toward the creation of complex stereotriads in the form of a quinidine-catalyzed diastereoselective 
aldol addition of a-angelica lactone (4.2) to b-halo-a-ketoesters (4.1) (Scheme 4-1c). 
 
98 
	
Scheme 4-1.	Proposed Addition of a-Angelica Lactone to Stereogenic a-Ketoester 
 
 
Other additions to nitrostyrenes,4 aldimines,5 enones,6 enals,7 and vinyl sulfones8 have also 
been studied (examples in Scheme 4-2). In all of these cases, the a-angelica lactone exhibited 
electrophilic trapping at the g-carbon. A rare example from Boukouvalas achieved a-trapping with 
a-angelica lactones via in situ generation of tin or boron dienolates for addition into aldehydes.9  
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Scheme 4-2.	Extant Aysmmetric Additions with a-Angelica Lactone 
 
 
4.3 Results and Discussion 
4.3.1 Reaction Optimization and Studies Toward Rendering the Reaction Asymmetric 
Based on the high levels of Felkin-Ahn diastereoselectivity observed with b-halo-a-
ketoesters (4.1) previously,3b, 3d-3f we selected this substrate class for our investigation. Initially, a 
screen of bases in THF (Table 4-1, entries 1-5) demonstrated that quinidine was the best base for 
the reaction. Then, by studying the reaction in different solvents (Table 4-1, entries 5-10), we found 
2-MeTHF to be optimal. We observed that there was no improvement when the reaction time was 
extended to 24 h, either at -20 ºC (Table 4-1, entry 11) or room temperature (Table 4-1, entry 12). 
Although a low level of enantioselectivity (16% ee) was observed with QN-1 (Table 4-2, entry 1), 
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no enantioselectivity (0% ee) was observed with quinidine (Table 4-2, entry 6). In cases where the 
reactions worked, no minor diastereomers were observed. 
Table 4-1.	Reaction Optimization for a-Angelica Lactone Addition: Base and Solvent Screena 
Entry Conditions % Yield (1H NMR) drb 
1 10 mol % KOtBu, THF, 6 h, rt 0 - 
2 10 mol % DBU, THF, 6 h, rt 0 - 
3 10 mol % TEA, THF, 6 h, rt Trace product - 
4 10 mol % TMG, THF, 6 h, rt Trace product - 
5 10 mol % quinidine, THF, 6 h, rt 61 >20:1 
6 10 mol % quinidine, EtOAc, 6 h, rt 66 >20:1 
7 10 mol % quinidine, DMSO, 6 h, rt 23 n.d. 
8 10 mol % quinidine, TBME, 6 h, rt 45 >20:1 
9 10 mol % quinidine, Et2O, 6 h, rt 46 >20:1 
10 10 mol % quinidine, 2-MeTHF, 6 h, rt 91 >20:1 
11 10 mol % quinidine, 2-MeTHF, 24 h, -20 ºC 43 >20:1 
12 10 mol % quinidine, 2-MeTHF, 24 h, rt 53 >20:1 
a Optimized conditions are italicized. b In general, we started by looking in the crude NMR 
spectra to see if anything that could be a diastereomer could be identified. Some cases were more 
clear than others. The most definitive method that we found to identify diastereomers or g-
addition products was to flash the crude material and then flush the column with x+10% more 
polar solvent system (where x was the gradient that allowed the product to elute cleanly) in an 
EA/hexanes gradient for >10 fractions. We then concentrated all fractions on each side of the 
desired product (more polar and less polar) and if we found anything (1H NMR analysis), we 
went back to the crude spectra and calculated the dr. It is possible that a minor diastereomer or g-
addition product for some cases might be not isolable due to instability, but this procedure was 
the best readout feasible with the available data. 
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Table 4-2.	Enantioselectivity Data for Chiral Catalysts 
 
	
Entry Conditions er 
1 10 mol % QN-1, THF, 21 h, rt 58.0:42.0 
2 10 mol % QN-2, THF, 6 h, rt 53.5:46.5 
3 10 mol % QD-1, 2-MeTHF, 6 h, rt 54.0:42.0 
4 10 mol % Ph-Dixon, THF, 19 h, rt 52.5:47.5 
5 10 mol % Ph-Dixon, THF, 16 h, -40 ºC 55.5:44.5 
6 10 mol % quinidine, THF, 6 h, rt 50.5:49.5 
 
After performing the above aldol reactions and studying varations of base (whether chiral 
or achiral) and solvent, our results indicated that quinidine was an optimal catalyst for the 
diastereoselective addition. Quinidine provides a racemic product and to date the maximum 
enantioselectivity observed for the title reaction with any catalyst is 58:42 er. 
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4.3.2 Scope of Reaction 
Intriguingly, in all cases we studied, capture of the electrophile at the a-position of the 
lactone was the dominant mode of reactivity. We speculate that this divergence may arise from the 
more demanding steric environment imposed by the a-ketoester, as compared with those used in 
previous reports.4-8 Additionally, for the most part, substitution at the b-position of the a-ketoesters 
does not affect the intrinsically high diastereoselectivity of the reaction. Using b-halo-b-benzyl a-
ketoesters, catalyzed addition of a-angelica lactone provided the aldol products 4.3a-4.3c in 
modest yields in >20:1 dr (Table 4-3). By comparing b-bromo-substituted 4.3a with b-chloro-
substituted 4.3b, we found that the identity of the halogen has no impact on diastereoselectivity. 
Benzyl-substituted substrates 4.3d and 4.3e gave >20:1 dr; however, para-chlorophenyl-
substituted 4.3d gave an elevated 73% yield while ortho-fluoro-substituted 4.3c gave 55% yield. 
Changing the ortho-tolyl group (4.3e) to a meta-tolyl group (4.3f) resulted in a dramatic loss of 
diastereoselectivity; the reason for this decrease in stereoselectivity is unclear. Aliphatic products 
4.3g and 4.3h were formed diastereoselectively in 41% and 48% yield, respectively. While the 
branched product 4.3j was formed in higher yield relative to other aliphatic substrates, a 
significantly lower diastereoselectivity was observed (4.0:1 dr). We found that the reaction to give 
4.3i was also diastereoselective, though low yielding (primarily due to product instability on 
column purification). 
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Table 4-3.	Scope of the Diastereoselective Addition of a-Angelica Lactone to b-Halo-a-ketoesters 
	
a Reaction was conducted on 0.1 mmol scale, using 2.0 equiv of a-angelica lactone. b Yield was 
determined by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene as an internal standard.   
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4.3.3 Determination of Relative Configuration and Stereochemical Model for Observed 
Relative Stereochemistry 
The relative stereochemistry afforded by the reaction was determined by an X-ray 
diffraction study performed on the lactone product 4.3a (Table 4-3).10 In order to rationalize the 
observed stereochemical outcome of the reaction, the Felkin-Anh (or Cornforth) model11 for the 
approach of the nucleophile to the b-halo-a-ketoester can be used, whereby the nucleophile 
approaches anti to the large b-halo substituent (Scheme 4-3a). In this model, the angelica lactone 
attacks at the Bürgi-Dunitz angle over the smallest b-substituent while the carbonyl is orthogonal 
to the b-halo group, thereby controlling the relationship between secondary halogen-bearing 
stereocenter and the tertiary alcohol. Governance of the lactone stereocenter could arise from the 
trajectory of the a-angelica lactone that minimizes repulsion between the lone pairs on the furanyl 
oxygen and the carbonyl oxygen (Scheme 4-3b). We propose that hydrogen-bonding with the 
catalyst facilitates this step, although stereochemical transmission from the chiral catalyst is poor 
at our current level of optimization. 
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Scheme 4-3.	Stereochemical Model for Addition of a-Angelica Lactone to b-Halo-a-ketoesters 
 
 
 
 
106 
	
4.3.4 Hydrogenation of Alkene in Aldol Adduct 
Having developed conditions for the diastereoselective generation of 4.3, we sought to extend our 
stereochemical arrays using downstream reduction of the dihydrofuranone. In the event, the 
resultant stereocenter was provided in >20:1 dr through catalytic hydrogenation (Scheme 4-4). A 
syn relationship between the lactone methine protons was determined through NOESY analysis, 
which is consistent with hydrogenation from the less hindered face of the lactone. 
Scheme 4-4.	Hydrogenation of a-Angelica Lactone Addition Product 
 
4.4 Conclusion 
Drawing inspiration from prior work on a-angelica lactones and a-ketoesters, this work 
presents new opportunities for accessing glycolic acid scaffolds. This reaction proceeded 
diastereoselectively for a variety of a-ketoester derivatives. This method represents a convenient 
way to diastereoselectively produce three contiguous stereocenters using a commercial 
organocatalyst. Additionally, this method represents a rare case where a-angelica lactone behaves 
as a regioselective a-nucleophile. Future directions for this work include investigations into the 
regioselectivty phenomenon and an expanded study of more complex a-angelica lactone 
nucleophiles.12 
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4.5 Experimental Details 
Methods: Nuclear magnetic resonance spectra (1H NMR, 13C NMR, 19F NMR and 31P NMR) were 
recorded at the following frequencies: 1H NMR at 400 MHz or 600 MHz, 13C NMR at 101 MHz 
or 151 MHz, 19F NMR at 376 MHz and 31P NMR at 162 MHz or 243 MHz with solvent resonance 
as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 13C NMR: CDCl3 at 77.0 ppm). 1H 
NMR data are reported as follows: chemical shift, multiplicity (s = singlet, br-s = broad singlet, d 
= doublet, dd = doublet of doublets, t = triplet, m = multiplet), coupling constants (Hz), and 
integration. Mass spectra were obtained using a Finnigan linear trap quadrapol Fourier transform 
(LTQ-FT) spectrometer. TLC visualization was accomplished with UV light, phosphomolybdic 
acid in ethanol, or aqueous ceric ammonium nitrate solution. Yields refer to isolated yields after 
flash column chromatography; some samples contain residual minor diastereomers. Since all 
results are the averages of two trials, the stereoisomer ratios listed in the tables may not exactly 
match those represented in the NMR data below.  
Materials: 2-MeTHF and a-angelica lactone were purchased and used as received. b-halo-a-
ketoesters were prepared according to literature procedures.3b-3e Commercially available quinidine 
was used as received. Since dr and % yield values reported in the tables reflect an average of two 
trials, they may not exactly match the isolated yields reported below. 
General procedure for addition of a-angelica lactone to b-halo-a-ketoester: 
A 1 dram vial was charged sequentially with b-halo-a-ketoester (0.1 mmol, 1.0 equiv), followed 
by 2-MeTHF (1.0 mL), and finally the a-angelica lactone (0.2 mmol, 2.0 equiv). The reaction was 
stirred at room temperature for one min. Quinidine (0.01 mmol, 10 mol %) was added in one 
portion. The reaction was stirred at room temperature for 6 h, then concentrated in vacuo. The 
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crude materials thusly obtained were purified using flash column chromatography, with a gradient 
from 95:5 hexanes/EtOAc to 80:20 hexanes/EtOAc. 
(±)-Ethyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-
3-yl)-4-phenylbutanoate (4.3a): The title compound was prepared 
according to the general procedure; 18.1 mg (47%) was isolated. No 
minor diastereomer was observed. Light yellow solid, mp 114-116 °C; 1H NMR (600 MHz, 
CDCl3) δ 7.43 (d, J = 7.2 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 7.30 (t, J = 7.2 Hz, 1H) 5.29 (s, 1H), 
5.05 (dd, J = 11.4, 2.4 Hz, 1H), 4.35-4.30 (m, 1H), 4.26-4.21 (m, 1H), 3.98 (s, 1H), 3.91 (br, 1H), 
3.61 (dd, J = 14.4, 2.4 Hz, 1H), 3.03 (dd, J = 14.4, 11.4 Hz, 1H), 2.03 (s, 3H), 1.30 (t, J = 7.2 Hz, 
3H); 13C NMR (151 MHz, CDCl3) δ 174.0, 171.2, 154.4, 137.9, 129.6, 128.4, 126.9, 100.7, 80.5, 
63.4, 58.5, 50.3, 38.2, 14.1, 13.9; IR (thin film) n 3433, 2359, 1794, 1747, 1647, 1541, 1456, 1237, 
1122, 944, 777 cm-1; HRMS (ESI): Calcd. For C17H19BrNaO5+ ([M+Na+]): 405.0308, found 
405.0296; TLC (1:5 EtOAc/hexanes): Rf = 0.51. 
(±)-Methyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)-4-phenylbutanoate (4.3b): The title compound 
was prepared according to the general procedure; some impurities 
remained after repeated silica gel column chromatography; NMR yields were calculating using 
1,3,5-trimethoxybenzene as an internal standard and using the signal of the desired product at δ 
5.27 in the crude 1H NMR spectrum. The product was obtained in 49% 1H NMR yield. No minor 
diastereomer was observed. White solid, mp 70-72 °C; 1H NMR (600 MHz, CDCl3) δ 7.41 (d, J 
= 7.8 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 7.29 (t, J = 7.2 Hz, 1H), 5.27 (s, 1H), 4.88 (dd, J = 11.4, 
2.4 Hz, 1H), 3.92 (s, 1H), 3.90 (t, J = 2.4 Hz, 1H), 3.83 (s, 3H), 3.50 (dd, J = 13.8, 2.4 Hz), 3.89 
(dd, J = 13.8, 2.4 Hz), 2.04 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 174.1, 171.7, 154.7, 137.2, 
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129.7, 128.4, 127.0, 100.2, 80.9, 64.5, 53.6, 50.5, 37.7, 14.0; IR (thin film) n 3461, 1752, 1636, 
1455, 1254, 1140, 1084, 703, 641, 523 cm-1; HRMS (ESI): Calcd. For C16H17ClNaO5+ ([M+Na+]): 
347.0675, found 347.0648; TLC (1:5 EtOAc/hexanes): Rf = 0.10. 
(±)-Isopropyl 3-bromo-4-(2-fluorophenyl)-2-hydroxy-2-(5-methyl-
2-oxo-2,3-dihydrofuran-3-yl)butanoate (4.3c): The title compound 
was prepared according to the general procedure; some impurities 
remained after repeated silica gel column chromatography; NMR yields were calculating using 
1,3,5-trimethoxybenzene as an internal standard and using the signal of the desired product at δ 
5.29 in the crude 1H NMR spectrum. The product was obtained in 57% 1H NMR yield.  No minor 
diastereomer was observed. White solid, mp 92-94 °C, 1H NMR (600 MHz, CDCl3) δ  7.50 (t, J 
= 7.8 Hz, 1H), 7.30-7.26 (m, 1H), 7.17-1.15 (m, 1H), 7.09-7.06 (m, 1H), 5.29 (s, 1H), 5.12-5.08 
(m, 2H), 4.00 (s, 1H), 3.88 (s, 1H), 3.46 (d, J = 14.4 Hz, 1H), 3.34 (dd, J = 14.4, 11.4 Hz, 1H), 
2.02 (s, 3H), 1.30 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.6 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 
173.9, 170.6, 162.1, 154.3, 131.5 (d, J = 4.1 Hz), 128.7 (d, J = 8.0 Hz), 125.0 (d, J = 15.3 Hz), 
124.1 (d, J = 3.8 Hz), 115.4 (d, J = 22.2 Hz), 100.7, 79.9, 72.1, 56.5, 50.3, 31.0 (d, J = 2.1 Hz), 
21.4, 21.3,14.1; 19F NMR (376 MHz, CDCl3) δ -117.1; IR (thin film) n 3853, 3750, 3649, 3437, 
2349, 1653, 1558, 1507, 1457, 716, 578 cm-1; HRMS (ESI): Calcd. For C18H20BrFNaO5+ 
([M+Na+]): 437.0370, found 437.0356; TLC (1:5 EtOAc/hexanes): Rf = 0.57. 
(±)-Isopropyl 3-bromo-4-(4-chlorophenyl)-2-hydroxy-2-(5-
methyl-2-oxo-2,3-dihydrofuran-3-yl)butanoate (4.3d): The title 
compound was prepared according to the general procedure; the 
crude reaction mixture was purified using flash column chromatography; 30.0 mg (70%) was 
isolated. No minor diastereomer was observed. Yellow solid, 117-120 °C, 1H NMR (600 MHz, 
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CDCl3) δ 7.38 (d, J = 8.4 Hz, 2 H), 7.33 (d, J = 8.4 Hz, 2 H), 5.28 (s, 1H), 5.09 (m, 1H), 4.97 (s, 
1H), 5.00 (dd, J = 11.4, 2.4 Hz, 1H), 3.98 (s, 1H), 3.86 (t, J = 2.4 Hz, 1H), 3.55 (dd, J = 14.4, 1.8 
Hz, 1H), 3.02 (dd, J = 14.4, 2.4 Hz, 1H), 2.03 (s, 3H), 1.27 (dd, 12.6, 6.6 Hz, 6H); 13C NMR (151 
MHz, CDCl3) δ 174.1, 170.6, 154.4, 136.4, 132.8, 131.1, 128.5, 100.7, 80.0, 72.1, 58.2, 50.2, 37.6, 
21.4 (d, J = 8.9 Hz), 14.1; IR (thin film) n 3421, 2359, 1794, 1741, 1635, 1495, 1102, 944, 813, 
536 cm-1; HRMS (ESI): Calcd. For C18H20BrClNaO5+ ([M+Na+]): 453.0075, found 453.0068; 
TLC (1:5 EtOAc/hexanes): Rf = 0.30. 
(±)-Tert-butyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)-3-(o-tolyl)propanoate (4.3e): The title compound 
was prepared according to the general procedure; the crude reaction 
mixture was purified using flash column chromatography;  15.8 mg (43%) was isolated. No minor 
diastereomer was observed. White solid, mp 143-144 °C, 1H NMR (600 MHz, CDCl3) δ 7.86 (br, 
1H), 7.21-7.20 (m, 2H), 7.14 (m, 1H), 6.40 (s, 1H), 5.30 (s, 1H), 4.14 (s, 1H), 4.12 (t, J = 3.6 Hz, 
1H), 2.49 (s, 3H), 2.02 (s, 3H), 1.16 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 174.4, 169.5, 153.8, 
136.1, 135.5, 103.2, 129.0, 128.9, 126.7, 100.4, 85.7, 80.3, 55.7, 51.3, 27.2, 19.6, 14.1; IR (thin 
film) n 3853, 3839, 3734, 3649, 3446, 2390, 1653, 1558, 1540, 1507, 578, 508 cm-1; HRMS (ESI): 
Calcd. For C19H23ClNaO5+ ([M+Na+]): 389.1126, found 389.1114; TLC (1:5 EtOAc/hexanes): Rf 
= 0.57. 
 (±)-Tert-butyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)-3-(m-tolyl)propanoate (4.3f): The title compound 
was prepared according to the general procedure; the crude reaction 
mixture was purified using flash column chromatography; 16.0 mg (44%) was isolated. The 
diastereoselectivity was determined by comparing the signals at δ 5.86 (major) and δ 5.81 (minor). 
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Trace amounts of both diastereomers of the g–addition product were also observed in the crude 1H 
NMR spectrum, and were identified after separation by column chromatography. White solid, mp 
133-135 °C; 1H NMR (600 MHz, CDCl3) δ 7.32 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 7.22 (t, J = 7.8 
Hz, 1H), 7.14 (d, J = J = 7.8 Hz, 1H), 5.87 (s, 1H), 5.28 (s, 1H), 4.16 (t, J = 2.4 Hz, 1H), 3.82 (s, 
1H), 2.35 (s, 3H), 2.02 (s, 3H), 1.32 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 174.2, 169.4, 153.6, 
137.7, 135.9, 129.9, 129.7, 128.1, 126.2, 100.5, 85.8, 80.2, 62.1, 50.9, 27.5, 21.4, 14.1; IR (thin 
film) n 3853, 3837, 3801, 3734, 3627, 2360, 2341, 1683, 1539, 1244, 791, 668 cm-1; HRMS (ESI): 
Calcd. For C19H23ClNaO5+ ([M+Na+]): 389.1126, found 389.1114; TLC (1:5 EtOAc/hexanes): Rf 
= 0.62. 
(±)-Isopropyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-
3-yl)butanoate (4.3g): The title compound was prepared according to the 
general procedure; the crude reaction mixture was purified using flash column 
chromatography; 14.0 mg (44%) was isolated. No minor diastereomer was observed. White solid, 
mp 84-85 °C, 1H NMR (600 MHz, CDCl3) δ 5.25 (s, 1H), 5.10 (m, 1H), 4.98 (q, 1H), 3.81 (s, 1H), 
3.64 (t, 1H), 2.00 (s, 3H), 1.87 (d, J = 6.6 Hz, 1H), 1.28 (dd, J = 33.6, 6.0 Hz, 6H); 13C NMR (151 
MHz, CDCl3) δ 173.9, 170.9, 154.1, 100.7, 79.9, 71.8, 50.7, 50.1, 21.5, 21.3,19.7, 14.0; IR (thin 
film) n 3446, 2393, 1740, 1653, 1287, 1102, 782, 579, 519, 503 cm-1; HRMS (ESI): Calcd. For 
C12H17BrNaO5+ ([M+Na+]): 343.0152, found 343.0146; TLC (1:5 EtOAc/hexanes): Rf = 0.39. 
(±)-Isopropyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)hex-5-enoate (4.3h): The title compound was 
prepared according to the general procedure; the crude reaction mixture 
was purified using flash column chromatography; 18.0 mg (54%) was isolated. No minor 
diastereomer was observed. Clear oil, 1H NMR (600 MHz, CDCl3) δ 5.60-5.93 (m, 1H), 5.27-5.21 
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(m, 3H), 5.10 (quintet, J = 6.0 Hz, 1H), 4.83 (dd, J = 10.8, 3.0 Hz, 1H), 3.89 (s, 1H), 3.79 (br, 1H), 
2.95-2.91 (m, 1H), 2.69-2.64 (m, 1H), 2.00 (s, 3H), 1.31 (d, J = 6.6 Hz, 3H), 1.26 (d, J = 6.6 Hz, 
3H); 13C NMR (151 MHz, CDCl3) δ 173.9, 170.6, 154.2, 134.6, 118.3, 100.6, 79.9, 72.0, 56.3, 
50.2, 36.5, 21.5, 21.3, 14.1; IR (thin film) n 3448, 1797, 1739, 1646, 1249, 1182, 1102, 945, 607, 
505 cm-1; HRMS (ESI): Calcd. For C14H19BrNaO5+ ([M+Na+]): 369.0308, found 369.0297; TLC 
(1:5 EtOAc/hexanes): Rf = 0.35. 
(±)-Isopropyl 5-(benzyloxy)-3-bromo-2-hydroxy-2-(5-methyl-2-
oxo-2,3-dihydrofuran-3-yl)pentanoate (4.3i): The title compound 
was prepared according to the general procedure; the crude reaction 
mixture was purified using flash column chromatography; 13.3 mg (30%) was isolated. No minor 
diastereomer was observed. Clear oil, 1H NMR (600 MHz, CDCl3) δ 7.41-7.28 (m, 5H), 5.25 (s, 
1H), 5.14-5.09 (m, 1H), 4.98 (dd, J = 11.1, 2.4 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 
11.1 Hz, 1H), 4.00 (s, 1H), 3.80-3.79 (m, 2H), 2.48-2.43 (m, 1H), 2.19-2.13 (m, 1H), 2.00 (s, 3H), 
1.39-1.35 (m, 1H), 1.32 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) 
δ 173.8, 170.7, 154.2, 138.3, 128.4, 127.7, 127.6, 100.6, 80.0, 72.9, 71.9, 68.0, 54.1, 50.4, 32.0, 
21.5, 21.4, 14.1; IR (thin film) n 3464, 2389, 1738, 1640, 1102, 788, 699, 607, 526-1; HRMS 
(ESI): Calcd. For C20H25BrNaO6+ ([M+Na+]): 463.0727, found 463.0708; TLC (1:5 
EtOAc/hexanes): Rf = 0.27. 
(±)-Isopropyl 3-bromo-2-hydroxy-4-methyl-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)pentanoate (4.3j): The title compound was prepared 
according to the general procedure; the crude reaction mixture was purified 
using flash column chromatography; 20.0 mg (57%) was isolated. The diastereoselectivity was 
determined by comparing the signals at δ 4.82 (major) and δ 5.04 (minor).  White solid, mp 150-
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152 °C, 1H NMR (600 MHz, CDCl3) δ 5.25 (s, 1H), 5.08 (m, 1H), 4.82 (d, J = 1.8 Hz, 1H), 3.87 
(s, 1H), 3.81 (t, J = 2.4 Hz, 1H), 2.37 (m, 1H), 2.0 (s, 3H), 1.28 (dd, J = 37.2, 6.0 Hz, 6H), 1.15 
(dd, J = 26.4, 6.6 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 173.9, 171.2,154.0, 100.9, 80.9, 71.9, 
65.3, 50.7, 29.8, 23.2, 21.4, 21.3, 18.0, 14.0; IR (thin film) n 3459, 2968, 1796, 1736, 1647, 1388, 
1271, 1104, 942, 780 cm-1; HRMS (ESI): Calcd. For C14H21BrNaO5+ ([M+Na+]): 371.0465, found 
371.0453; TLC (1:5 EtOAc/hexanes): Rf = 0.52. 
(±)-Ethyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxotetrahydrofuran-
3-yl)-4-phenylbutanoate (4.4a): A 1 dram vial was charged with 10% 
Pd/C (40 w/w %) and flushed with nitrogen. A solution of ethyl 3-
bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-yl)-4-phenylbutanoate (3a) (0.1 mmol, 
1.0 equiv) dissolved in EtOAc (1 mL) was added. The solution was sparged with H2 for 5 min. 
The reaction was then allowed to stir for 72 h in a high-pressure reactor under 120 psi H2. The 
reaction mixture then was filtered through a Celite® plug, rinsing with ethyl acetate, and 
concentrated in vacuo. The crude materials thusly obtained were purified using flash column 
chromatography, with a gradient from 95:5 hexanes/EtOAc to 80:20 hexanes/EtOAc to yield 
25.0mg (64%) desired product in >20:1 dr.  Clear oil, 1H NMR (600 MHz, CDCl3) δ 7.36-7.28 
(m, 5H), 4.59-4.55 (m, 1H), 4.46-4.42 (m, 3H), 4.04 (br, 1H), 3.77 (dd, J = 12.0, 9.0 Hz, 1H), 3.55 
(d, J = 14.4 Hz, 1H), 2.70 (dd, J = 14.1, 12.0 Hz, 1H), 2.63-2.58 (m, 1H), 1.88-1.83 (m, 1H), 1.46 
(d, J = 6.0 Hz, 3H), 1.41 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.5, 171.9, 138.0, 
129.3, 128.4, 127.0, 78.4, 75.0, 63.4, 58.0, 48.1, 38.6, 32.2, 20.9, 14.2; IR (thin film) n 3776, 3453, 
2391, 2349, 1767, 1642, 1260, 749, 543 cm-1; HRMS (ESI): Calcd. For C17H21BrNaO5+ 
([M+Na+]): 407.0465, found 407.0454; TLC (1:5 EtOAc/hexanes): Rf = 0.24. 
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CHAPTER FIVE: 
PROGRESS TOWARD THE TOTAL SYNTHESIS OF THE VERATRUM ALALOIDS 
JERVINE, CYCLOPAMINE, AND VERATRAMINE 
 
5.1 Introduction 
 The utility of studying natural product synthesis can be viewed from several distinct 
vantage points. The most common reason for this challenging pursuit is to access druglike 
molecules in the smallest number of steps possible. While this is a noble and worthy reason in and 
of itself, the counterargument is that a large number of total syntheses that are published result in 
milligram or sub-milligram quanities of material and contain steps that would be unattractive on 
larger scale, or simply contain too many steps to result in a translational breakthrough. Taking 
these practical considerations to heart, recent efforts in natural product synthesis groups have 
sought to oppose the lengthy, “finish at all costs” style total synthesis and have placed emphasis 
on efficiency and ideality; an optimist may look to this trend and see the possibility for rejuvenation 
and advancement for this field. 
 From another standpoint, natural product synthesis represents one of the most robust ways 
to train chemists to solve hard problems. In this vein, we can see there is great didactic value 
provided by challenges that often are much harder and less predictable than even a research adviser 
could intentionally devise. While methodology projects focus on optimization of a reaction by 
changing any variables of our choosing (making structural or electronic modifications to our 
substrates, changing the catalyst or ligand, studying the effect solvent and temperature and time), 
117 
	
we generally do not have that luxury in natural product synthesis. The structural and 
stereochemical constraints imposed by synthetic targets from nature are uncompromising. These 
challenges make the total synthesis of natural products an invaluable tool for chemists to test the 
limits of methodogies and synthetic tactics in practice.  
 In this chapter, we describe progress toward the total synthesis of three alkaloids from the 
Veratrum genus: jervine, cyclopamine, and veratramine. These targets possess desirable biological 
activities and have numerous structural features that have necessitated creative synthetic strategies. 
The work presented in this chapter will serve as a blueprint for the completion of the final targets 
using the dearomatization-desymmetrization approach that we will propose in this chapter. 
5.2 Background 
5.2.1 Biological Activity of the Veratrum Alkaloids 
 The abundance of natural products with unique and desirable biological properties provides 
chemists with a diverse array of challenges and inspiration for the development of new synthetic 
strategies and tactics. Jervine (5.6), cyclopamine (5.21), and veratramine (5.11) are representative 
members of the Veratrum steroidal alkaloids,1 which are most conspicuously known as antagonists 
of Smoothened (Smo), a Hedgehog (Hh) signaling protein; dysregulation of this cell signaling 
pathway is often implicated in rhabdomyosarcoma, medulloblastoma, basal cell carcinoma, and 
pancreatic, breast, and prostate cancers.2 Hedgehog signaling inhibition allows improved delivery 
of chemotherapeutics for pancreatic cancer in a mouse model.3 A semisynthetic analogue of 
cyclopamine called IPI-926 (saridegib) is a drug candidate that has been evaluated in clinical 
trials.4 By utilizing a late-stage functionalization of cyclopamine, a kilogram-scale approach to the 
synthesis of saridegib has been developed.4d In addition to these exciting developments, it has been 
shown that introducing structural modifications to the parent structure of cyclopamine can allow 
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increased stability as well as improved Hh signal inhibition.5 With these possibilities in mind, a de 
novo synthesis is attractive as it might allow modifications in different regions of the parent 
structure and potentially provide a more diverse array of analogues. Others6,7 have taken this 
approach, although de novo routes have not yet been completed to date and reliance on the chiral 
pool has left room for exploration of other tactics. 
5.2.2 Overview of Extant Synthetic Work on Veratrum Alkaloids 
 Early synthetic efforts to access this family of compounds were successful in providing a 
conceptual framework to obtain these molecules, though the routes began from steroidal starting 
materials and suffered from high step counts; a synopsis of these efforts is outlined below.8 
Subsequent studies expanded on that work and led to completed syntheses of verarine, 
veratramine, jervine, and veratrobasine.9 More recent work established a novel skeletal 
rearrangement for the transformation of 12b-hydroxy steroids (containing a 6-6-6-5 ABCD ring 
system) into C-nor-D-homo-steroids (containing a 6-6-5-6 ABCD ring system), allowing a new 
path to the Veratrum alkaloids.10 After construction of the steroidal portion, installation of a 
spirocyclic lactone facilitated elaboration to the fused tetrahydrofuran and piperidine rings.  
 A model study directed toward a de novo synthesis of the DEF ring system achieved a high 
level of efficiency,11 but several key issues remained: the methyl group of the piperidine was not 
incorporated, the tetrahydrofuran contained a methyl group in the wrong oxidation state (and with 
incorrect relative stereochemistry), and the synthesis was racemic. Recently, our group has 
developed a research focus on developing efficient synthetic routes toward steroidal alkaloids 
using local desymmetrization (diastereotopic group selection).12 In this chapter, we present a de 
novo route that attempts to address challenges associated with the spirocylic tetrahydrofuran 
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subunit of the Veratrum alkaloids using a merged oxidative dearomatization-local 
desymmetrization approach. 
5.2.3 Masamune Synthesis of Jervine 
 In 1967, Masamune and coworkers reported a synthesis of jervine (Scheme 5-1).8a Their 
approach began with 17-acetyl-5a-etiojerva-12,14-16-trien-3b-ol (5.1), which was accessible by 
synthetic means from Hagemann’s ester13 or via degradation of hecogenin14. The early steps of the 
synthesis converted the methyl ketone into a mixture of diastereomeric benzylic bromides 5.2, 
which were alkylated with a pyrrolidine enamine nucleophile. Unfortunately, this key fragment 
coupling reaction only afforded a 5% yield of the steroidal alkaloid product 5.3. A Birch reduction 
and epoxidation furnished intermediate 5.4, which was further elaborated to the hexacyclic 
alkaloid 5.5 through an epoxide-opening/dehydration sequence. Late-stage oxidation in the C ring 
and installation of the unsaturation in the B ring led to completion of the synthesis of jervine. 
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Scheme 5-1.	Overview of Masamune Synthesis of Jervine 
 
 The Masamune synthesis was a foundational effort which, while not practical in many 
respects, represents a fundamental analytical mindset that has persevered for several decades. In 
this route, we see a convergent approach to coupling a “steroid” and an “alkaloid” while expending 
much time and energy constructing the unique features present the tetrahydrofuran core of this 
complex target. 
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5.2.4 Johnson Synthesis of Veratramine 
 In the same year that Manamune and coworkers disclosed their synthesis of jervine (5.6), 
W. S. Johnson disclosed a synthesis of veratramine (5.11) which began from the same 
intermediate.8b They began by homologating the methyl ketone present in 5.1 into an aldehyde by 
performing a Corey-Chaykovsky epoxidation, followed by Lewis acid-mediated epoxide opening. 
The aldehyde 5.7 was obtained as an epimeric mixture, which was carried through a Strecker 
reaction to obtain 5.8 as a mixture of stereoisomers. Cyclization under basic conditions provided 
enamine 5.9, which was hydrolyzed under acid conditions to ketone 5.10. Subsequent reduction 
of the ketone, installation of the alkene in the A ring, and global deprotection yielded veratramine 
(5.11). 
 By its nature, this synthesis has many similarities to the Masamune approach to jervine. In 
both routes, we see a strong focus on taking an established steroidal building block and utilizing it 
to construct the alkaloid portion of the molecule. The amount of work these routes represent 
reinforces the idea that these targets are particularly difficult to attack from the standpoint of 
convergency. Moreover, they underscore the importance of designing reactions that exhibit high 
levels of stereocontrol in order to preserve valuable late-stage material. 
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Scheme 5-2.	Overview of Johnson Synthesis of Veratramine 
 
5.2.5 Giannis Synthesis of Cyclopamine 
	 The Giannis group has reported a creative rearrangement of 6-6-6-5 ring systems into the 
6-6-5-6 ring system of C-nor-D-homo-steroids.10b Using Comins’ reagent as a triflate source 
allowed the authors to convert the secondary alcohol present in 12b-hydroxy steroids into a 
nucleofuge, which enabled the Wagner-Meerwein rearrangement to occur in a number of complex 
contexts (Scheme 5-3). With this methodology, the authors were able to convert 5.12 into 5.13 in 
32% yield, and 5.14 into a mixture of endocyclic and exocyclic alkenes favoring the former. 
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Scheme 5-3.	Approach to C-nor-D-homo-Steroids Developed by the Giannis Group 
	 This rearrangement tactic was applied in the synthesis of cyclopamine from 
dehydroepiandrosterone.10a From the intial 6-6-6-5 steroid, a C-H functionalization protocol 
enabled installiation of the 12b-hydroxyl group in 5.17. A sequence of diastereoselective 
organometallic additions allowed subsequent elaboration of the ketone into the key spirocyclic 
lactone 5.18. The key rearrangement of 5.18 into 5.19 proceeded through deprotection with 
hydrogen fluoride and treatment with triflic anhydride to give a 7:3 mixture of alkenes 
(endocyclic:exocyclic). The authors were only able to carry out the downstream piperidine closure 
using the exocyclic alkene. The nitrogen was installed by reacting the lactone enolate with trisyl 
azide. Subequent Horner-Wadsworth-Emmons olefination set the stage for an annulative 
Mitsunobu reaction to provide the piperidine F ring. The location of the alkene in the D ring was 
corrected using an Alder-ene reaction with N-sulfinylbenzenesulfonamide followed by treatment 
with Raney nickel. The synthesis of cyclopamine was completed shortly thereafter. 
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Scheme 5-4.	Overview of Giannis Synthesis of Cyclopamine 
 
 The Giannis approach to cylcopamine is primarily noteworthy because it makes a 
significant advance towards realistic accessibility of this difficult family of natural products. 
Additionally, there are many system-specific lessons from this work that will inform future efforts. 
However, while this route possesses the conceptual novelty of starting from a 6-6-6-5 system, it 
ultimately rests on the availability of a steroidal starting material. This weakness, combined with 
the overall length of the route, leave room for improvement. 
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5.2.6 Wright Approach to the Veratrum Alkaloid Core 
 In 2011, the Wright group described a domino olefin methathesis approach to the synthesis 
of the DEF ring system of jervine and cyclopamine.11 In their retrosynthetic analysis of 
cyclopamine, they envisioned using a key domino olefin metathesis reaction on a bicyclic furan 
with tethered terminal alkenes to simultaneously close the D and F rings of the target (Scheme 5-
5). The authors began their endeavor using the monosubstituted furan 5.22 in a Diels-Alder 
reaction to from 5.23 in 77% yield (Scheme 5-6). Subsequent dehalogenation and aza-Michael 
addition with allylamine gave 5.25, formed as a single diastereomer. Finally a domino metathesis 
reaction with Grubbs second generation catalyst provided 5.26 in 96% yield. 
Scheme 5-5.	Retrosynthetic Analysis in Wright Approach 
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Scheme 5-6.	Wright’s Domino Metathesis Approach 
 
 Though this approach to the DEF ring system is incredibly efficient at constructing a model 
scaffold, there are several shortcomings that prevent it from being applied to a full route to the 
target molecule. At present, the route is racemic and would require a mechanism for enantiocontrol 
in the Diels-Alder reaction. The methyl ester in 5.26 would need to be transformed into a methyl 
group; it also has the wrong relative stereochemistry for the target molecule. Additionally, it is not 
immediately obvious how the alkene moieties can be elaborated into useful functional handles for 
a full route. These drawbacks collectively informed our decision to avoid this type of domino 
metathesis approach in our own investigations. 
5.2.7 Other De Novo Approaches to the Synthesis of the Veratrum Alkaloid Core 
 Giannis developed a synthetic approach that enabled access to all diastereomers of the 
cyclopamine alkaloid substructure in 2009 (Scheme 5-7).6 In this work, the authors used the 
stereochemistry present in (-)-citronellal (5.27) to construct the core EF ring system of jervine and 
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cyclopamine. After oxidizing 5.27 to carboxylic acid 5.28 with silver oxide, DPPA was used to 
promote a Curtius rearrangement to form 5.29 in 91% yield. Oxidative cleavage and cyclization 
provided 5.30, which was used to form an enolate and react with chiral oxaziridine (-)-DCCSO to 
obtain 5.31 in >20:1 dr. Subsequent elaboration into 5.32 was possible by adding an enol silane 
into a derivative of 5.31. Retro-Claisen reaction with LiOH and esterification provided the chiral 
building block 5.34. This chiral pool approach only suffers from a few oxidation/reduction steps. 
The principal drawbacks to this route are that it does not incorporate a methyl group in the lactone 
(E ring) and it fails to demonstrate that a lactone is an appropriate surrogate for a spirocyclic 
stereocenter. 
 Later work on a de novo approach was reported by DeMatteo and Taber in a 2012 paper,7a 
where the authors focused on the same region of the target molecules. Using chemistry similar to 
the work by Giannis (Scheme 5-7) to convert (-)-citronellal to a piperidine, they arrived at 5.35. 
Subsequent halohydration allowed epoxide formation to give 5.37, which was found to react with 
a 2-butenyl Grignard reagent to give a 1:1 diastereomeric mixture of 5.38. Benzyl protection of 
the alcohol and conversion of the alkene to an alkyne by a three-step sequence furnished 5.40. As 
compared to the Giannis chiral pool approach, this route has the advantage of incorporating the 
methyl group in the E ring, though it has not been demonstrated that the ring can be closed. In a 
separate route where Taber merged his approach with that of Giannis, the authors reported an 
unoptimized alkylation of 5.34 to give 5.35 with the stereochemistry required for the targets 
(Scheme 5-9). 
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Scheme 5-7.	De Novo Approach of Giannis 
 Both of these de novo approaches are significant developments toward a more ideal route 
to the Veratrum alkaloids. In spite of this, it deserves note that (a) they both rely on the chiral pool 
for starting materials, (b) they are, arguably, not concise routes, and (c) they would require 
converting a lactone into a spirocyclic stereocenter. With these considerations in mind, we 
envisioned the following retrosynthetic analysis of the target molecules. 
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Scheme 5-8.	De Novo Approach of Taber 
	
Scheme 5-9.	Taber’s Alkylation of the Alkaloid Core 
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5.2.8 Retrosynthetic Analysis for Dearomatization/Local Desymmetrization Approach 
 Our retrosynthetic analysis of the target molecules placed an emphasis on the construction 
of the alkaloid core, which possesses several challenging structural features, including a unique 
fused tetrahydrofuran/piperidine ring system (Scheme 5-10). We envisioned that all three alkaloids 
might arise from a common synthetic intermediate type resembling piperidine 5.36. We considered 
that by having a synthetic strategy that furnishes a functionalized aromatic D ring, we might be 
able to access veratramine using a substitution pattern that is well suited for steroid-alkaloid 
coupling. Alternatively, for jervine and cyclopamine, we imagined using a phenol (5.38) in an 
oxidative dearomatization15 to provide a cyclohexadienone; such a cyclohexadienone intermediate 
(5.39) would allow a local desymmetrization via diastereotopic group discrimination to define the 
spirocyclic stereocenter (as in 5.40). With these considerations in mind, we made it our goal to 
synthesize the stereochemical array of the common intermediate 5.36. 
5.3 Results and Discussion 
5.3.1 Synthesis of Stereotriad from b-Methyltyrosine Derivative 
 As a first investigation into the feasibility of this synthetic plan, we aimed to study a 
simplified model system for the intramolecular oxidative dearomatization. We began by 
synthesizing the known racemic b-methyltyrosine derivative 5.41,16 which was obtained in three 
steps from 4-methoxyacetophenone and hippuric acid (and can be produced on decagram scale in 
a single batch) (Scheme 5-11). Weinreb amide formation proceeded smoothly in 70% yield, 
providing amide 5.42 in >20:1 dr after recrystallization. 
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Scheme 5-10.	Retrosynthetic Analysis and Overall Synthetic Plan 
	
 
Grignard addition of 5.43 furnished ketone 5.44, which could be diastereoselectively reduced to 
afford triad 5.45 in 57% yield over two steps. The ability of the nitrogen-bearing stereocenter to 
control the stereochemical outcome at the adjacent carbon is an attractive aspect of this synthetic 
route.17  
5.3.2 Synthesis of Dearomatization Substrate from Stereotriad 
 Aiming to study the dearomatization in a model system, we minimized the number of 
reactive functional groups present by hydrogenating the terminal alkene to obtain 5.46 in 51% 
yield. Attempts to carry out hydroboration on the 1,1-disubstituted alkene (with substrate-
controlled or reagent-controlled diastereoselectivity) in 5.45 were unsuccessful. Other efforts to 
utilize the terminal alkene in 5.45 for epoxide formation and epoxide-opening ring closure 
132 
	
sequences were similarly fruitless. Demethylation of ether 5.46 using BBr3 resulted in the target 
oxidative dearomatization substrate, phenol 5.47. 
5.3.3 Dearomatization of Phenol to Cyclohexadienone 
 Guided by prior studies utilizing PhI(OAc)2 in TFA,15e dearomatization of the phenol 5.47 
under these conditions led to the expected spiro-tetrahydrofuran 5.48 and the undesired 
dihydrooxazine 5.4918 in a combined yield of 52% over two steps. Unfortunately, the two 
dearomatization products were inseparable; however, this model system provided a useful lesson 
that it is important to transform the benzamide into a non-reactive functionality prior to 
dearomatization. 
5.3.4 Discussion of Competitive Cyclization and Proposed Revisions to Route 
 In view of the competitive cyclization pathways that are observed during the oxidative 
dearomatization of 5.47, it appears that the options available are (a) close the piperidine first, with 
the idea of preventing participation of the benzoyl group, or (b) use a different protecting group 
on the nitrogen. Because the benzoyl protecting group is necessary for isolating a single alkene 
isomer in the synthesis of b-methyltyrosine derivative 5.41, pursuing option (b) would necessarily 
involve removal of the protecting group from 5.41 (or a downstream intermediate) and attaching 
a different protecting group which cannot participate in the competitive cyclization. Seeking to 
avoid protecting group manipulations, we first investigated option (a). However, in a number of 
studies that ended only in synthetic dead ends, we learned that it is difficult to close the piperidine 
prior to tetrahydrofuran formation due to another competitive cyclization process (Scheme 5-12). 
We observed that tetrahydrofuran formation can outcompete piperidine formation in several 
contexts, even when the nitrogen protected group is benzyl. 
133 
	
Scheme 5-11.	Synthesis of Spirocyclic Tetrahydrofuran Core 
 
 
(a) CH3NHOCH3•HCl, AlMe3, CH2Cl2, rt; (b) 5.43, THF, 0 ºC to rt; (c) NaBH4, MeOH, 0 ºC to 
rt; (d) H2 (1 atm), Pd/C, MeOH, rt; (e) BBr3, DCM, -78 ºC to 0 ºC; (f) PhI(OAc)2, TFA, DCM, 0 
ºC to rt. 
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Scheme 5-12.	Common Competive Tetrahydrofuran Formation 
 
 
 With this added challenge in mind, we have elected to pursue option (b). We intend to 
implement a protecting group manipulation on stereotriad 5.52 to create a scenario where the 
nitrogen protecting groups cannot participate in the type of dearomative cyclization that led to 
5.49. We anticipate that using this strategy, as well as a more functionalized methallyl group, will 
allow us to close both the spirocyclic tetrahydrofuran and the piperidine. We are optimistic that 
our proposed revisions to the existing route will allow us to arrive at an intermediate resembling 
5.54, which will serve as a crucial building block for the completion of the synthesis of jervine and 
cyclopamine.  
Scheme 5-13.	Plan for Future Work 
 
 
135 
	
5.4 Conclusion 
 A key building block for the alkaloid core of jervine, cyclopamine, and veratramine has 
been synthesized in a short sequence that utilizes high yielding transformations. The unresolved 
issues for this synthetic approach, going forward, will be (1) finding a nitrogen protecting group 
that does not participate in the competitive dearomative cyclization, (2) executing a local 
desymmetrization of the D ring after dearomatization, and (3) rendering the synthesis asymmetric 
by employing an enantioselective hydrogenation in the synthesis of 5.41. We are optimistic that 
these issues are resolvable and will present exciting opportunities for reaction development and 
synthetic planning. Studies toward these ends are ongoing in our laboratory. 
5.5 Experimental Details 
General Comments. Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier transform 
infrared spectrometer. Proton and carbon magnetic resonance spectra (1H NMR and 13C NMR) 
were recorded with solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 
13C NMR: CDCl3 at 77.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity 
(s = singlet, br s = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = 
multiplet), coupling constants (Hz), and integration. High resolution mass spectra were obtained 
via Fourier transform mass spectrometry (FTMS) with electrospray ionization (ESI) and external 
calibration in positive ion mode (all samples prepared in methanol). Melting points were obtained 
using a capillary melting point apparatus. Visualization for thin layer chromatography (TLC) was 
allowed by UV light, phosphomolybdic acid in ethanol, or aqueous ceric ammonium nitrate 
solution. Purification of the reaction products was carried out by using silica gel (40- 63µm). 
Reagents, catalysts, and ligands were purchased and used as received. Solvents were purified by 
136 
	
passage through an aluminum oxide column using nitrogen. Methyl ester 5.4116 was made 
according to literature procedure. 
(±)-N-(1-(methoxy(methyl)amino)-3-(4-methoxyphenyl)-1-
oxobutan-2-yl)benzamide (5.42): A 2 L round-bottomed flask with 
a stir bar was charged with N,O-dimethylhydroxylamine 
hydrochloride (16.68 g, 171.0 mmol, 3.0 equiv) and  DCM (340 mL). The flask was cooled in an 
ice bath and placed under an atmosphere of N2. Trimethylaluminum (2.0 M solution in heptane, 
85.5 mL, 171.0 mmol, 3.0 equiv) was added in a dropwise fashion. The ice bath was removed and 
the reaction was stirred for 30 min at room temperature. A solution of methyl ester 5.41 (18.66 g, 
57.0 mmol, 1.0 equiv) in DCM (170 mL) was added dropwise. The reaction was allowed to stir 
for 24 h. Once complete, the reaction was cooled in an ice bath and, while stirring, quenched with 
saturated sodium potassium tartrate in a dropwise fashion until the reaction stopped bubbling. The 
quenched reaction was allowed to continue stirring for 1 h. The reaction mixture was filtered 
through a Celite® pad using DCM and the filtrate was concentrated in vacuo. The crude material 
was purified by silica gel chromatography (30:70 to 60:40 ethyl acetate/hexanes) and subsequently 
recrystallized from EtOAc/hexanes to obtain the desired product as a white solid (14.26 g, 70%). 
The product was obtained in >20:1 dr, which was determined by comparing the signals at δ 5.51 
(minor) and δ 5.46 (major) in the 1H NMR spectrum. Analytical data: mp 128-130 ºC; 1H NMR 
(600 MHz, CDCl3): δ 7.65 (d, J = 8.4 Hz, 2H), 7.48-7.46 (m, 1H), 7.40-7.37 (m, 2H), 7.17 (d, J = 
7.8 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 1H), 5.47-5.45 (m, 1H), 3.92 (s, 3H), 
3.79 (s, 3H), 3.33-3.30 (m, 1H), 3.28 (s, 3H), 1.38 (d, J = 7.1 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 172.0, 167.1, 158.6, 134.1, 133.6, 131.6, 128.8, 128.5, 127.0, 113.9, 61.8, 55.2, 53.7, 
42.0, 32.1, 18.7; IR (thin film) n 3310, 2935, 1636, 1509, 1249, 1179, 1036, 987, 912, 834 cm-1; 
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HRMS (ESI): Calcd. for C20H24N2NaO4+ ([M+Na+]): 379.1628, found 379.1623; TLC (60:40 
EtOAc/hexanes): Rf = 0.42. 
(±)-N-(4-hydroxy-2-(4-methoxyphenyl)-6-methylhept-6-en-3-
yl)benzamide (5.45): A flame dried 1 L round-bottomed flask was 
charged with Weinreb amide 5.42 (534.6 mg, 1.5 mmol, 1.0 equiv) 
and THF (6.0 mL). The reaction was placed under N2 and stirred in an ice bath. A commercial 
solution of methallylmagnesium chloride (0.5 M, 9.0 mL, 4.5 mmol, 3.0 equiv) was added slowly 
as a steady stream. The reaction was stirred at room temperature for 14 h, at which point the 
reaction was quenched by addition of saturated aqueous ammonium chloride solution with cooling 
in an ice bath. The solution was transferred to a separatory funnel and extracted three times with 
diethyl ether. The combined organic phases were dried with sodium sulfate and concentrated in 
vacuo to afford the crude product, which was recrystallized from ethyl acetate and hexanes to 
obtain the desired product (the conjugated enone formed by isomerization was also present as an 
impurity). The material was carried on without further purification (when silica gel 
chromatography was attempted in other trials, the alkene was found to isomerize during the 
purification, which prevented clean isolation). Methallyl ketone 5.44 was dissolved in MeOH (7.5 
mL) and cooled in an ice bath. NaBH4 (192.9 mg, 5.1 mmol, 3.4 equiv with respect to 5.42) was 
added carefully. The reaction was stirred for 2 h under N2 and slowly allowed to warm to room 
temperature. The reaction was then quenched with 1 M HCl (aqueous) and concentrated in vacuo 
to remove MeOH. The crude residue was partitioned between ethyl acetate and 1 M HCl and the 
layers were separated. The aqueous layer was extracted three times with ethyl acetate. The 
combined organic layers were dried with sodium sulfate and concentrated in vacuo to afford the 
crude product, which was purified by silica gel chromatography (20:80 to 40:60 ethyl 
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acetate/hexanes) to obtain the desired product as a white solid (300.8 mg, 57% over the two steps 
from 10 to 13). The product was obtained in >20:1 dr, which was determined by comparing the 
signals at δ 4.85 (major) and δ 4.77 (C5 epimer) in the 1H NMR spectrum. No C4 epimer was 
observed. Analytical data: mp 89-90 ºC, 1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 8.0 Hz, 2H), 
7.54-7.51 (m, 1H), 7.45-7.42 (m, 2H), 7.30 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 8.7 Hz, 2H), 5.81 (d, 
J = 9.3 Hz, 1H), 4.92 (s, 1H), 4.85 (s, 1H), 4.32-4.28 (m, 1H), 3.85 (s, 3H), 3.58-3.51 (m, 2H), 
2.68 (br s, 1H), 2.29-2.20 (m, 2H), 1.71 (s, 3H), 1.39 (d, J = 7.2 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 167.7, 158.6, 142.6, 134.1, 133.5, 131.7, 129.3, 128.7, 126.8, 114.1, 114.1, 69.1, 58.8, 
55.3, 42.6, 38.0, 22.4, 18.9; IR (thin film) n 3423, 2965, 1646, 1513, 1249, 1179, 1035, 835, 712, 
559 cm-1; HRMS (ESI): Calcd. for C22H28NO3+ ([M+H+]): 354.2064, found 354.2060; TLC (20:80 
EtOAc/hexanes): Rf = 0.07. 
(±)-N-(4-hydroxy-2-(4-methoxyphenyl)-6-methylheptan-3-
yl)benzamide (5.46): Alcohol 5.45 (277.0 mg, 0.79 mmol, 1.00 
equiv) was added to a scintillation vial, followed by 10% Pd/C (55.4 mg, 20 w/w %). The flask 
was placed under an atmosphere of N2, and then MeOH (7.9 mL) was added slowly. The solution 
was sparged with H2 for 15 min, then the exit line was removed and the reaction was allowed to 
stir for 2 h at room temperature under a balloon of H2. Once complete, the reaction was flowed 
through a pad of Celite® with additional methanol, and the filtrate was concentrated in vacuo. The 
crude product was purified by silica gel chromatography (20:80 to 40:60 ethyl acetate/hexanes) to 
obtain the desired product as a white solid (140.7 mg, 51%). Analytical data: mp 70-72 ºC, 1H 
NMR (600 MHz, CDCl3): δ 7.50-7.48 (m, 3H), 7.40-7.38 (m, 2H), 7.24 (d, J = 8.6 Hz, 2H), 6.94 
(d, J = 8.7 Hz, 2H), 5.86 (d, J = 7.7 Hz, 1H), 4.31-4.28 (m, 1H), 3.83 (s, 3H), 3.81-3.79 (m, 1H), 
3.33 (d, J = 7.4 Hz, 1H), 3.19-3.14 (m, 1H), 1.94-1.88 (m, 1H), 1.49-1.44 (m, 1H), 1.40 (d, J = 7.0 
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Hz, 3H), 1.24-1.20 (m, 1H), 0.95 (d, J = 6.7 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 168.4, 158.6, 134.6, 134.0, 131.7, 128.8, 128.6, 126.9, 114.4, 70.8, 60.6, 55.3, 
41.9, 39.4, 24.4, 24.1, 21.6, 20.0; IR (thin film) n 3426, 2956, 1644, 1514, 1304, 1285, 1250, 1179, 
1038, 733 cm-1; HRMS (ESI): Calcd. for C22H30NO3+ ([M+H+]): 356.2220, found 356.2213; TLC 
(40:60 EtOAc/hexanes): Rf = 0.35. 
 (±)-N-(2-isobutyl-4-methyl-8-oxo-1-
oxaspiro[4.5]deca-6,9-dien-3-
yl)benzamide (5.48) and (±)-4-(1-
hydroxy-3-methylbutyl)-5-methyl-2-
phenyl-1-oxa-3-azaspiro[5.5]undeca-2,7,10-trien-9-one (5.49): Alcohol 5.46 (287 mg, 0.81 
mmol, 1.0 equiv) was added to a flame dried 100 mL round-bottomed flask, followed by DCM 
(8.0 mL). The reaction was cooled to -78 ºC in a dry ice/acetone bath and placed under nitrogen 
before adding BBr3 (0.23 mL, 2.42 mmol, 3.0 equiv) dropwise. Then the reaction was placed in 
an ice water bath and allowed to stir for 1 h. Once complete, the reaction was quenched by adding 
MeOH dropwise. Then water was added and the layers were separated. The aqueous layer was 
extracted three times with DCM. The combined organic layers were dried with sodium sulfate and 
concentrated in vacuo to afford the crude phenol 5.47, which was carried on without further 
purification. PhI(OAc)2 (390 mg, 1.21 mmol, 1.5 equiv with respect to 5.46) was dissolved in 
DCM (28.8 mL), cooled to 0 ºC in an ice bath, and then TFA (0.14 mL, 1.9 mmol, 2.3 equiv) was 
added dropwise. After stirring for 15 min at room temperature, the solution was added dropwise 
to a solution of the crude phenol 5.47 in DCM (28.8 mL) at 0 °C. The reaction was then allowed 
to warm to room temperature slowly and stir for 3 h. NaHCO3 (339 mg, 4.0 mmol, 5.0 equiv) was 
added and the reaction was allowed to continue stirring for 10 min before concentration in vacuo. 
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The crude residue was purified by silica gel chromatography (10:90 to 30:70 ethyl acetate/hexanes) 
to obtain an inseparable mixture of the two products as a red-brown foam (142.7 mg, 52% over 
two steps); the composition (by 1H NMR analysis) was found to be 5.48:5.49 = 1.2:1. 1H NMR 
signals were assigned to 5.48 and 5.49, though assignments were not made for 13C NMR. 
Analytical data: 1H NMR (600 MHz, CDCl3) 5.48: δ 7.80 (d, J = 7.6 Hz, 2H), 7.60-7.57 (m, 1H), 
7.52-7.49 (m, 2H, overlaps with 5.49), 6.88-6.85 (m, 1H, overlaps with 5.49), 6.78-6.76 (m, 1H, 
overlaps with 5.49), 6.28-6.26 (m, 1H), 6.24-6.22 (m, 1H), 6.20 (d, J = 7.7 Hz, 1H), 4.71-4.68 (m, 
1H), 4.22-4.19 (m, 1H), 2.76-2.71 (m, 1H), 1.90-1.85 (m, 1H, overlaps with 5.49), 1.72-1.67 (m, 
1H), 1.62-1.58 (m, 1H), 1.00-0.96 (m, 6H, overlaps with 5.49), 0.92-0.89 (m, 3H, overlaps with 
5.49); 5.49: δ 7.97 (d, J = 7.6 Hz, 2H), 7.52-7.49 (m, 1H, overlaps with 5.48), 7.44-7.41 (m, 2H), 
6.88-6.85 (m, 1H, overlaps with 5.48), 6.78-6.76 (m, 1H, overlaps with 5.48), 6.45-6.43 (m, 1H), 
6.42-6.40 (m, 1H), 3.99-3.97 (m, 1H), 3.56 (dd, J = 11.3, 4.0 Hz, 1H), 2.02-1.98 (m, 1H), 1.90-
1.85 (m, 1H, overlaps with 5.48), 1.35-1.31 (m, 1H), 1.00-0.96 (m, 6H, overlaps with 5.48), 0.92-
0.89 (m, 3H, overlaps with 5.48); 13C NMR (151 MHz, CDCl3) δ 185.4, 185.0, 167.5, 154.3, 
150.8, 147.1, 146.4, 142.8, 133.9, 132.4, 132.1, 131.2, 131.1, 130.9, 129.2, 128.9, 128.4, 128.2, 
127.3, 126.9, 83.1, 81.3, 75.6, 68.7, 59.9, 58.5, 45.8, 44.6, 39.7, 34.4, 25.1, 24.2, 24.1, 23.3, 22.1, 
21.4, 11.4, 9.5; IR (thin film) n 3317, 2956, 1669, 1532, 1490, 1385, 1291, 1178, 862, 732 cm-1; 
HRMS (ESI): Calcd. for C21H26NO3+ ([M+H+]): 340.1907, found 340.1904; TLC (30:70 
EtOAc/hexanes): Rf = 0.35 (5.48), 0.46 (5.49). 
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CHAPTER SIX: 
ENANTIO- AND DIASTEREOSELECTIVE ORGANOCATALYTIC CONJUGATE 
ADDITION OF NITROALKANES TO ENONE DIESTERS 
 
6.1 Introduction 
 The advent of organocatalysis has led to the development of catalysts which operate via a 
number of distinct activation modes. Hydrogen-bonding catalysis in particular has experienced a 
surge in popularity in the last two decades, largely as a result of the incorporation of thioureas and 
related hydrogen-bond donor motifs into complex catalyst architectures. In the last five years, a 
family of bifunctional thiourea-iminophosphorane organocatalysts has been demonstrated to have 
promising possibilities for enabling new reactivity in a stereoselective manner, such as the 
asymmetric reductive coupling reaction discussed in Chapter Two. In this chapter, we discuss a 
stereoselective conjugate addition of nitroalkanes to enone diester electrophiles. Using the 
conjugate addition reaction as a means of incorporating nitrogen stereoselectively into small 
molecules, we are able to generate small polyads via this synthetic framework. 
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6.2 Background 
6.2.1 Organocatalytic Conjugate Additions of Nitroalkanes 
 The prevalence of nitrogen-containing acyclic and heterocyclic scaffolds in bioactive 
molecules provides opportunities for the development of methodologies for their efficient 
construction. Asymmetric organocatalytic conjugate additions of nitroalkanes have enabled the 
rapid construction of small polyads possessing numerous functional handles for downstream 
transformations. Previous approaches utilizing Brønsted base organocatalysis have accomplished 
this transformation in a stereoselective manner.1 
6.2.2 The Challenge of Diastereoselectivity in Nitroalkane Conjugate Additions 
 Although methods have been developed for the enantioselective addition of nitromethane 
(Scheme 6-1a), diastereocontrol with homologs has proven challenging in many contexts because 
of prochirality in both reaction partners.22 For example, in nitroethane conjugate addition reactions 
developed by Wang (Scheme 6-2a) and Wulff (Scheme 6-2b) using a nitrostyrene electrophile, 
diastereoselectivity was universally poor. In a case where Pedrosa used chalcones as electrophiles 
(Scheme 6-2c), the same problem resulted. These studies indicate that, even when the chiral 
catalyst contains functional groups necessary to interact with both the nucleophile and the 
electrophile, it is difficult to create a situation where only a single prochiral face of each component 
is displayed to the other. 
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Scheme 6-1.	Asymmetric Conjugate Additions of Nitroalkanes 
 
 We sought to meet this challenge by using a bifunctional organocatalyst to 
stereoselectively orient and unite extended nitroalkanes with functionalized Michael acceptors, 
starting from simple building blocks. In this chapter, we report the enantio- and diastereoselective 
conjugate addition of nitroethane and nitropropane to enone diester electrophiles (Scheme 6-1b). 
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Scheme 6-2.	The Challenge of Diastereoselectivity in Nitroalkane Conjugate Additions 
 
 
 
148 
	
6.3 Results and Discussion 
6.3.1 Synthesis of Starting Materials by One-pot Sequence 
 With the aim of exploiting these highly activated substrates and delivering useful 
functionality in the derived products, we initiated conjugate addition reaction studies with enone 
diester 6.1a. The preparation of this electrophile was achieved by a one-pot reaction wherein di-
tert-butyl 2-diazomalonate was subjected to oxo transfer under the action of Rh(II)/propylene 
oxide, and the resulting ketone underwent Wittig olefination with a stabilized ylide (Scheme 6-
3).3-4 The telescoped sequence avoided the problematic hydration issues associated with isolating 
ketomalonates.5 Using this reaction sequence, we synthesized a variety of enone diesters in 
moderate to good yields. 
Scheme 6-3.	One-pot Synthesis of Enone Diesters 
	
6.3.2 Optimization of Conjugate Addition Reaction 
 Having established a synthetic path to access enone diesters 6.1, we began optimization of 
the stereoselective addition of nitroalkanes. By screening chiral Brønsted bases known to enable 
this transformation, we identified triaryliminophosphorane C3, a bifunctional compound 
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pioneered in the Dixon laboratory, as a suitable catalyst.6 Evaluating the effect of solvent and the 
identity of the diester present in 6.1 allowed us to maximize the stereoselectivity and yield. Using 
catalyst C1 we observed poor reactivity at cryogenic temperatures (and even at room temperature; 
entries 1-2). A promising er of 13:87 was obtained with C2 at -60 ºC. The yield and 
enantioselectivity was improved by switching to C3 (entry 3). A solvent screen (entries 4-8) 
allowed us to identify diethyl ether as the optimal solvent for the reaction. Switching the ester 
groups of the substrate to tBu esters (entry 9) and using nitroethane (entry 10) allowed us into 
achieve our highest yields and stereoselectivities. 
6.3.3 Reaction Scope 
Applying the optimized conditions to the parent substrate 6.1a, the reaction proceeds with >20:1 
diastereoselection and 97:3 er, with 88% isolated yield (Table 6-2). We observed similar reaction 
outcomes with halogen-substituted arenes 6.2b-6.2d. X-ray diffraction analysis of 6.2d allowed 
us to determine the absolute stereochemical outcome of the reaction.7 Other electron-deficient 
enone diesters 6.1e-6.1g provided the desired products in high stereoselectivity and yield. When 
we turned our attention to the electron-donating substituents present in 6.1h-6.1j (4-methoxy, 3-
methoxy, piperonyl), we found similar results regardless of the specific substitution pattern. A 
study into furan (6.1k), thiophene (6.1l), and pyridine heterocycles (6.1m) also provided products 
with nearly perfect stereoselectivities and high yields. Aliphatic enones 6.1n and 6.1o performed 
well in the reaction, giving >20:1 dr, with high enantioselectivities and good yields. Finally, we 
investigated whether homologous nitroalkanes could be employed.  A nitropropane addition 
product was prepared in high stereoselectivity and chemical yield (6.2p). On 1 g scale, the reaction 
of enone diester 6.1a provided the adduct 6.2a in nearly perfect stereoselectivity with 86% isolated 
yield (Scheme 6-4). 
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Table 6-1.	Optimization of Asymmetric Conjugate Addition Reaction 
	
entry X (equiv) R solvent catalyst (equiv) 
Time 
(h) dr er Yield
a 
1 H (10.0) Et THF C1 (0.10) 21 n.a. n.a. trace 
2b H (10.0) Et THF C1 (0.10) 19 n.d. n.d. (30) 
3 H (10.0) Et THF C2 (0.10) 21 n.a. 13:87 (41) 
4 H (10.0) Et THF C3 (0.10) 21 n.a. 88:12 (62) 
5 H (10.0) Et EtOAc C3 (0.10) 21 n.a. 85.5:14.5 (45) 
6 H (10.0) Et CH2Cl2 C3 (0.10) 21 n.a. 78:22 (46) 
7 H (10.0) Et PhMe C3 (0.10) 21 n.a. 81:19 (48) 
8 H (10.0) Et Et2O C3 (0.10) 21 n.a. 89:11 (54) 
9 H (10.0) tBu Et2O C3 (0.10) 22 n.a. 93.5:6.5 (47) 
10c Me (20.0) tBu Et2O C3 (0.20) 24 >20:1 97:3 88 
a Yields in parentheses represent 1H NMR yields determined using 1,3,5-trimethoxybenzene as 
an internal standard. b Reaction was run at room temperature c The dr, er, and yield values for this 
entry are an average of two trials. n.a. = not applicable, n.d. = not determined. 
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Table 6-2.	Reaction	Scope for Asymmetric Conjugate Addition of Nitroalkanesa 
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Table 6-2, cont.	
	
a All reactions were conducted on 0.1 mmol scale, using 21.0 equiv EtNO2 or 20.2 equiv n-
PrNO2. % yields refer to isolated yields. All dr, er, and % yields are the averages of two trials. b 
er was determined by derivatization to dimethyl malonate 6.4a. 
Scheme 6-4.	Asymmetric Conjugate Addition Reaction on Gram-Scale 
	
a The reaction was conducted using 20.8 equiv EtNO2. % yield refers to isolated yield. Reaction 
was run for 24h. 
6.3.4 Synthesis of Lactam Stereotriad via Diastereotopic Group Discrimination 
 Seeking to take advantage of the diastereotopic ester groups, we developed a three-step 
local desymmetrization8 protocol that enables the formation of a new stereocenter with 
concomitant lactamization (Scheme 6-5). It was necessary to transform the di-tert-butyl malonate 
moiety into a dimethyl malonate to achieve ring closure during the nitro group reduction. The 
153 
	
final lactam 6.5a was obtained in 9.1:1 dr and 45% yield over three steps while maintaining the 
same level of enantiopurity as the starting material 6.2a. Based on the absence of a H2-H3 nOe, 
the three bond coupling constant of 7.5 Hz in CD3OD (or 8.2 Hz in CDCl3), and strong literature 
precedent,9 the benzoyl group and methyl ester were assigned as trans on the g-butyrolactam 
ring. 
Scheme 6-5. Local Desymmetrization via Transesterification and Diastereoselective 
Lactamization 
 
6.4 Conclusion 
 In summary, we have developed asymmetric organocatalytic conjugate additions of 
extended nitroalkanes to enone diester electrophiles. A chiral bifunctional iminophosphorane 
enabled the creation of two adjacent stereocenters with high levels of enantio- and 
diastereoselectivity. Through subsequent diastereotopic group selection, the establishment of a 
third stereocenter during formation of a polyfunctional lactam was demonstrated.  
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6.5 Experimental Details 
General Information: 
Methods: Infrared (IR) spectra were obtained using a Jasco 460 Plus Fourier transform infrared 
spectrometer. Proton and carbon magnetic resonance spectra (1H NMR, 13C NMR, 19F NMR) were 
recorded on a Bruker model DRX 400 or 600 (1H NMR at 400 MHz or 600 MHz, 13C NMR at 101 
MHz or 151 MHz, 19F NMR at 376 MHz with solvent resonance as the internal standard (1H 
NMR: CDCl3 at 7.26 ppm and 13C NMR: CDCl3 at 77.0 ppm). 1H NMR data are reported as 
follows: chemical shift, multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = doublet of 
doublets, t = triplet , m = multiplet), coupling constants (Hz), and integration. High resolution mass 
spectra were obtained with a Thermo Fisher Scientific FinniganTM LTQ-ICR FTTM (all samples 
prepared in methanol). Melting points were obtained using a Thomas Hoover UniMelt Capillary 
Melting Point Apparatus. Analytical thin layer chromatography was carried out using Whatman 
0.25 mm silica gel 60 plates, Sorbent Technologies 0.20 mm Silica Gel TLC plates. Visualization 
was allowed by UV light, phosphomolybdic acid in ethanol, or aqueous ceric ammonium nitrate 
solution. HPLC analysis was performed on a Perkin Elmer flexar photodiode array (PDA) system 
equipped with Daicel IA, IC, AD, and OD-H columns. Asymmetric reactions were carried out in 
a Thermo Sigma UCR-150N aluminum block UC reactor with stirring. Purification of the reaction 
products was carried out by using Siliaflash-P60 silica gel (40- 63µm) purchased from Silicycle. 
Yields refer to isolated yields after flash column chromatography; some samples contain residual 
minor diastereomers. Since all asymmetric trial results are the averages of two trials, the 
stereoisomer ratios listed in the tables may not exactly match those represented in the NMR and 
HPLC data below. 
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Materials: Diethyl ether (Et2O) was passed through a column of neutral alumina under nitrogen 
prior to use. Wittig reagents were prepared according to a literature procedure.10 
Triaryliminophosphorane catalysts C1-C3 were prepared according to literature procedures.6a 
Commercially available nitroethane and nitropropane were used as received. Raney®-Nickel 2800 
(W.R. Grace and Co. Raney®) slurry in H2O was used as received. 
General procedure for synthesis of enone diesters: 
A modified literature procedure was used.3-4 A flame-dried 100 mL round-bottomed flask 
equipped with a reflux condenser was charged with Rh2(OAc)4 (0.046 mmol, 0.02 equiv), toluene 
(10 mL), and propylene oxide (22.4 mmol, 10.0 equiv). The mixture was heated to 85 ºC in an oil 
bath for 10 min. Afterwards, a solution of di-tert-butyl 2-diazomalonate (2.25 mmol, 1.0 equiv) in 
toluene (2 mL) was added dropwise. An additional volume of toluene (1 mL) was used to 
quantitatively transfer. The reaction was stirred at 85 ºC for 1 h before removing the oil bath and 
allowing the reaction to return to room temperature. The reaction flask was then placed in an ice 
bath. MgSO4 (500 mg) was added to the reaction, followed by the appropriate Wittig reagent (3.37 
mmol, 1.5 equiv). The reaction was allowed to slowly warm to room temperature and was stirred 
for 16 h. The crude mixture was filtered through a short silica plug with CH2Cl2 and concentrated 
in vacuo. The crude materials thusly obtained were purified using flash column chromatography, 
with the gradient noted below. 
Characterization data for enone diesters: 
Di-tert-butyl 2-(2-oxo-2-phenylethylidene)malonate (6.1a): The title 
compound was prepared according to the general procedure. 35.0 mmol 
di-tert-butyl 2-diazomalonate was used and all components of the general 
procedure were scaled appropriately. The crude materials were purified using flash column 
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chromatography, with a gradient from 95:5 hexanes/EtOAc to 85:15 hexanes/EtOAc. Yellow solid 
(8.53 g), mp 89-90 °C; 1H NMR (600 MHz, CDCl3) δ 8.01-7.99 (m, 2H), 7.68 (s, 1H), 7.65-7.62 
(m, 1H), 7.53-7.51 (m, 2H), 1.57 (s, 9H), 1.49 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 189.6, 
163.7, 162.2, 138.9, 136.3, 134.0, 133.2, 128.9, 128.9, 83.3, 83.0, 27.9, 27.8. IR (thin film) n 2979, 
1724, 1673, 1450, 1369, 1278, 1257, 1156, 1069, 866 cm-1. HRMS (ESI): Calcd. For C19H24NaO5+ 
([M+Na+]): 355.1516, found 355.1509. TLC (10:90 EtOAc/Hexanes): Rf = 0.32. 
 Di-tert-butyl 2-(2-(4-fluorophenyl)-2-oxoethylidene)malonate 
(6.1b): The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column 
chromatography, with a gradient from pure hexanes to 95:5 hexanes/EtOAc. Yellow oil (544.0 
mg); 1H NMR (600 MHz, CDCl3) δ 8.04-8.02 (m, 2H), 7.64 (s, 1H), 7.20-7.18 (m, 2H), 1.56 (s, 
9H), 1.50 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 188.0, 166.3 (d, J = 256.8 Hz), 163.6, 162.1, 
139.1, 132.9, 132.8 (d, J = 3.0 Hz), 131.6 (d, J = 9.4 Hz), 116.1 (d, J = 22.1 Hz), 83.4, 83.1, 27.9, 
27.8; 19F NMR (565 MHz, CDCl3) δ -103.18. IR (thin film) n 3437, 2980, 1724, 1673, 1598, 
1541, 1369, 1279, 1155, 1070 cm-1. HRMS (ESI): Calcd. For C19H23FNaO5+ ([M+Na+]): 
373.1422, found 373.1413. TLC (10:90 EtOAc/Hexanes): Rf = 0.34. 
Di-tert-butyl 2-(2-(4-chlorophenyl)-2-oxoethylidene)malonate 
(6.1c): The title compound was prepared according to the general 
procedure. The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column chromatography, with a gradient 
from pure hexanes to 95:5 hexanes/EtOAc. Yellow solid (528.0 mg), mp 63-64 °C; 1H NMR (600 
MHz, CDCl3) δ 7.94 (d, J = 8.6 Hz, 2H), 7.63 (s, 1H), 7.49 (d, J = 8.6 Hz, 2H), 1.56 (s, 9H), 1.50 
(s, 9H); 13C NMR (151 MHz, CDCl3) δ 188.3, 163.6, 162.1, 140.6, 139.4, 134.7, 132.5, 130.2, 
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129.2, 83.5, 83.2, 27.9, 27.8. IR (thin film) n 2979, 2934, 1725, 1673, 1589, 1369, 1258, 1158, 
1092, 847 cm-1. HRMS (ESI): Calcd. For C19H23ClNaO5+ ([M+Na+]): 389.1126, found 389.1119. 
TLC (10:90 EtOAc/Hexanes): Rf = 0.34. 
 Di-tert-butyl 2-(2-(4-bromophenyl)-2-oxoethylidene)malonate 
(6.1d): The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column 
chromatography, with a gradient from pure hexanes to 95:5 hexanes/EtOAc. Light yellow solid 
(626.6 mg), mp 73-74 °C; 1H NMR (600 MHz, CDCl3) δ 7.85 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.5 
Hz, 1H), 7.62 (s, 1H), 1.56 (s, 9H), 1.50 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 188.5, 163.6, 
162.0, 139.5, 135.1, 132.4, 132.2, 130.3, 129.4, 83.5, 83.2, 27.9, 27.8. IR (thin film) n 2979, 2933, 
1725, 1672, 1586, 1569, 1369, 1278, 1159, 1071 cm-1. HRMS (ESI): Calcd. For C19H23BrNaO5+ 
([M+Na+]): 433.0621, found 433.0611. TLC (10:90 EtOAc/Hexanes): Rf = 0.38. 
Di-tert-butyl 2-(2-(4-cyanophenyl)-2-oxoethylidene)malonate 
(6.1e): The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column 
chromatography, with a gradient from pure hexanes to 90:10 hexanes/EtOAc. Yellow solid (407.2 
mg), mp 72-73 °C; 1H NMR (600 MHz, CDCl3) δ 8.08 (d, J = 8.3 Hz, 2H), 7.83 (d, J = 8.2 Hz, 
2H), 7.62 (s, 1H), 1.56 (s, 9H), 1.51 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 188.3, 163.3, 161.8, 
140.4, 139.2, 132.7, 131.6, 129.2, 117.8, 117.1, 83.7, 83.5, 27.9, 27.8. IR (thin film) n 2980, 2935, 
2232, 1725, 1677, 1370, 1279, 1158, 1071, 847 cm-1. HRMS (ESI): Calcd. For C20H23NNaO5+ 
([M+Na+]): 380.1468, found 380.1463. TLC (10:90 EtOAc/Hexanes): Rf = 0.14. 
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Di-tert-butyl 2-(2-(4-nitrophenyl)-2-oxoethylidene)malonate 
(6.1f): The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column 
chromatography, with a gradient from pure hexanes to 85:15 hexanes/EtOAc. Yellow solid (598.1 
mg), mp 77-78 °C; 1H NMR (600 MHz, CDCl3) δ 8.37 (d, J = 8.9 Hz, 2H), 8.16 (d, J = 8.9 Hz, 
2H), 7.65 (s, 1H), 1.57 (s, 9H), 1.52 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 188.0, 163.3, 161.8, 
150.7, 140.7, 140.5, 131.5, 129.8, 124.1, 83.8, 83.5, 27.9, 27.8. IR (thin film) n 2980, 2360, 1725, 
1678, 1530, 1370, 1347, 1278, 1157, 847 cm-1. HRMS (ESI): Calcd. For C19H23NNaO7+ 
([M+Na+]): 400.1367, found 400.1358. TLC (10:90 EtOAc/Hexanes): Rf = 0.28. 
Di-tert-butyl 2-(2-oxo-2-(4-
(trifluoromethyl)phenyl)ethylidene)malonate (6.1g): The title 
compound was prepared according to the general procedure. The 
crude materials were purified using flash column chromatography, with a gradient from pure 
hexanes to 90:10 hexanes/EtOAc. Yellow oil (550.6 mg); 1H NMR (600 MHz, CDCl3) δ 8.10 (d, 
J = 8.2 Hz, 2H), 7.79 (d, J = 8.2 Hz, 2H), 7.66 (s, 1H), 1.60 (s, 9H), 1.51 (s, 9H); 13C NMR (151 
MHz, CDCl3) δ 188.6, 163.4, 161.9, 140.0, 139.0, 135.1 (q, J = 32.8 Hz), 132.0, 129.1, 125.9 (m), 
123.4 (d, J = 273.0 Hz), 83.6, 83.3, 27.9, 27.8; 19F NMR (565 MHz, CDCl3) δ -63.19. IR (thin 
film) n 2981, 1726, 1678, 1370, 1326, 1279, 1258, 1161, 1067, 1032 cm-1. HRMS (ESI): Calcd. 
For C20H23F3NaO5+ ([M+Na+]): 423.1390, found 423.1383. TLC (10:90 EtOAc/Hexanes): Rf = 
0.34. 
Di-tert-butyl 2-(2-(4-methoxyphenyl)-2-
oxoethylidene)malonate (6.1h): The title compound was prepared 
according to the general procedure. The crude materials were 
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purified using flash column chromatography, with a gradient from pure hexanes to 90:10 
hexanes/EtOAc. White solid (612.8 mg), mp 93-94 °C; 1H NMR (600 MHz, CDCl3) δ 7.98 (d, J 
= 8.8 Hz, 2H), 7.67 (s, 1H), 6.98 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H), 1.56 (s, 9H), 1.50 (s, 9H); 13C 
NMR (151 MHz, CDCl3) δ 187.9, 164.3, 163.9, 162.4, 138.3, 133.5, 131.3, 129.5, 114.1, 83.2, 
82.8, 55.6, 27.9, 27.8. IR (thin film) n 2979, 1724, 1666, 1599, 1512, 1369, 1281, 1257, 1161, 847 
cm-1. HRMS (ESI): Calcd. For C20H26NaO6+ ([M+Na+]): 385.1622, found 385.1613. TLC (10:90 
EtOAc/Hexanes): Rf = 0.14. 
Di-tert-butyl 2-(2-(3-methoxyphenyl)-2-oxoethylidene)malonate 
(6.1i): The title compound was prepared according to the general 
procedure. The crude materials were purified using flash column 
chromatography, with a gradient from pure hexanes to 90:10 hexanes/EtOAc. Yellow oil (617.3 
mg); 1H NMR (600 MHz, CDCl3) δ 7.66 (s, 1H), 7.58-7.56 (m, 1H), 7.52-7.51 (m, 1H), 7.42 (t, J 
= 8.0 Hz, 1H), 7.19-7.17 (m, 1H), 3.88 (s, 3H), 1.56 (s, 9H), 1.50 (s, 9H); 13C NMR (151 MHz, 
CDCl3) δ 189.3, 163.7, 162.2, 160.0, 139.0, 137.7, 133.1, 129.8, 121.8, 121.0, 112.4, 83.3, 83.0, 
55.5, 27.9, 27.8. IR (thin film) n 2979, 1724, 1672, 1597, 1456, 1369, 1278, 1157, 1032, 848 cm-
1. HRMS (ESI): Calcd. For C20H26NaO6+ ([M+Na+]): 385.1622, found 385.1612. TLC (10:90 
EtOAc/Hexanes): Rf = 0.25. 
 Di-tert-butyl 2-(2-(benzo[d][1,3]dioxol-5-yl)-2-
oxoethylidene)malonate (6.1j): The title compound was prepared 
according to the general procedure. The crude materials were 
purified using flash column chromatography, with a gradient from pure hexanes to 80:20 
hexanes/EtOAc. Yellow solid (506.0 mg), mp 55-56 °C; 1H NMR (600 MHz, CDCl3) δ 7.62 (s, 
1H), 7.59 (d, J = 8.2, 1H), 7.48 (s, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.09 (s, 2H), 1.56 (s, 9H), 1.51 
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(s, 9H); 13C NMR (151 MHz, CDCl3) δ 187.5, 163.8, 162.3, 152.7, 148.6, 138.5, 133.4, 131.3, 
126.0, 108.1, 108.1, 102.1, 83.2, 82.9, 27.9, 27.8. IR (thin film) n 2979, 2933, 1723, 1664, 1603, 
1505, 1446, 1369, 1259, 1161 cm-1. HRMS (ESI): Calcd. For C20H24NaO7+ ([M+Na+]): 399.1414, 
found 399.1405. TLC (10:90 EtOAc/Hexanes): Rf = 0.21. 
Di-tert-butyl 2-(2-(furan-2-yl)-2-oxoethylidene)malonate (6.1k): The 
title compound was prepared according to the general procedure. The 
crude materials were purified using flash column chromatography, with a 
gradient from pure hexanes to 80:20 hexanes/EtOAc. White solid (389.0 mg), mp 67-68 °C; 1H 
NMR (600 MHz, CDCl3) δ 7.69 (m, 1H), 7.58 (s, 1H), 7.36 (d, J = 3.7 Hz, 1H), 6.62 (dd, J = 3.6 
Hz, 1.6 Hz, 1H), 1.59 (s, 9H), 1.55 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 175.8, 163.9, 162.0, 
152.7, 147.9, 140.0, 129.8, 119.6, 113.0, 83.4, 83.1, 27.9, 27.9. IR (thin film) n 2979, 1732, 1669, 
1558, 1465, 1370, 1258, 1158, 1071, 846 cm-1. HRMS (ESI): Calcd. For C17H22NaO6+ ([M+Na+]): 
345.1309, found 345.1302. TLC (10:90 EtOAc/Hexanes): Rf = 0.17. 
Di-tert-butyl 2-(2-oxo-2-(thiophen-2-yl)ethylidene)malonate (6.1l): 
The title compound was prepared according to the general procedure. The 
crude materials were purified using flash column chromatography, with a 
gradient from pure hexanes to 90:10 hexanes/EtOAc. Off-white solid (485.8 mg), mp 84-85 °C; 
1H NMR (600 MHz, CDCl3) δ 7.83 (dd, J = 3.9, 1.0 Hz, 1H), 7.76 (dd, J = 4.9, 1.0 Hz, 1H), 7.58 
(s, 1H), 7.19 (dd, J = 4.9, 3.8 Hz, 1H), 1.56 (s, 18H); 13C NMR (151 MHz, CDCl3) δ 180.7, 163.7, 
162.1, 144.2, 139.4, 135.8, 133.7, 131.2, 128.6, 83.4, 83.1, 27.9, 27.9. IR (thin film) n 2979, 1726, 
1656, 1516, 1415, 1369, 1282, 1257, 1156, 1066 cm-1. HRMS (ESI): Calcd. For C17H22NaO5S+ 
([M+Na+]): 361.1080, found 361.1073. TLC (10:90 EtOAc/Hexanes): Rf = 0.18. 
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 Di-tert-butyl 2-(2-oxo-2-(pyridin-4-yl)ethylidene)malonate (6.1m): 
The title compound was prepared according to the general procedure, but 
best results were obtained on larger scale. 12.4 mmol di-tert-butyl 2-
diazomalonate was used and all components of the general procedure were scaled appropriately. 
The crude materials were purified using flash column chromatography, with a gradient from 95:5 
hexanes/EtOAc to 40:60 hexanes/EtOAc. Low-melting red-brown solid (2.23 g); 1H NMR (600 
MHz, CDCl3) δ 8.87 (br s, 2H), 7.78 (br s, 2H), 7.61 (s, 1H), 1.57 (s, 9H), 1.52 (s, 9H); 13C NMR 
(151 MHz, CDCl3) δ 188.8, 163.3, 161.8, 151.2, 142.1, 140.7, 130.9, 121.4, 83.8, 83.5, 27.9, 27.8. 
IR (thin film) n 2979, 1725, 1682, 1370, 1279, 1223, 1158, 1072, 1032, 847 cm-1. HRMS (ESI): 
Calcd. For C18H23NNaO5+ ([M+Na+]): 356.1468, found 356.1452. TLC (40:60 EtOAc/Hexanes): 
Rf = 0.35. 
 Di-tert-butyl 2-(2-oxopropylidene)malonate (6.1n): The title compound 
was prepared according to the general procedure. The crude materials were 
purified using flash column chromatography, with a gradient from pure hexanes to 95:5 
hexanes/EtOAc. Clear oil (282.4 mg); 1H NMR (600 MHz, CDCl3) δ 6.97 (s, 1H), 2.35 (s, 3H), 
1.58 (s, 9H), 1.52 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.4, 163.9, 162.0, 138.1, 133.5, 83.4, 
83.1, 30.8, 27.9 (2C). IR (thin film) n 2980, 2935, 1730, 1703, 1369, 1274, 1254, 1159, 1075, 848 
cm-1. HRMS (ESI): Calcd. For C14H22NaO5+ ([M+Na+]): 293.1359, found 293.1356. TLC (10:90 
EtOAc/Hexanes): Rf = 0.24. 
 Di-tert-butyl 2-(2-cyclopropyl-2-oxoethylidene)malonate (6.1o): The 
title compound was prepared according to the general procedure. The crude 
materials were purified using flash column chromatography, with a gradient from pure hexanes to 
95:5 hexanes/EtOAc. Clear oil (342.4 mg); 1H NMR (600 MHz, CDCl3) δ 7.11 (s, 1H), 2.14-2.09 
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(m, 1H), 1.56 (s, 9H), 1.53 (s, 9H), 1.22-1.19 (m, 2H), 1.07-1.04 (m, 2H); 13C NMR (151 MHz, 
CDCl3) δ 198.7, 164.0, 162.2, 137.4, 133.6, 83.2, 82.9, 27.9, 27.9, 22.2, 12.6. IR (thin film) n 
2979, 1729, 1686, 1391, 1369, 1256, 1159, 1087, 1062, 917 cm-1. HRMS (ESI): Calcd. For 
C16H24NaO5+ ([M+Na+]): 319.1516, found 319.1510. TLC (10:90 EtOAc/Hexanes): Rf = 0.29. 
General procedure for asymmetric conjugate addition of nitroalkanes: 
A flame-dried test tube was charged sequentially with enone diester (0.1 mmol, 1.0 equiv), Et2O 
(1.0 mL), and nitroethane (2.1 mmol, 21.0 equiv). The reaction was stirred at -60 ºC in a cryogenic 
cooling apparatus for 15 min, then triaryliminophosphorane catalyst C1 (0.02 mmol, 0.20 equiv) 
was added. The reaction was then stirred at -60 ºC for 24 h. After this period, the reaction was 
quenched with a TFA solution in toluene (50 µL, 0.5 M solution) at the same temperature. 
Additional Et2O was used to flush the reaction through a short plug of silica and the filtrate was 
concentrated in vacuo. The crude materials thusly obtained were purified using flash column 
chromatography with a gradient from 97.5:2.5 hexanes/EtOAc to 90:10 hexanes/EtOAc unless 
otherwise noted. 
Gram scale asymmetric conjugate addition reaction: 
A flame-dried 100 mL round-bottomed flask was charged sequentially with enone diester 1a (1.00 
g, 3.01 mmol, 1.0 equiv), Et2O (30.0 mL), and nitroethane (4.50 mL, 62.6 mmol, 20.8 equiv). The 
reaction was stirred at -60 ºC in a cryogenic cooling apparatus for 15 min, then 
triaryliminophosphorane catalyst C1 (401.7 mg, 0.60 mmol, 0.20 equiv) was added. The reaction 
was then stirred at -60 ºC for 24 h. After this period, the reaction was quenched with a TFA solution 
in toluene (1.5 mL, 0.5 M solution) at the same temperature. Additional Et2O was used to flush 
the reaction through a short plug of silica and the filtrate was concentrated in vacuo. The crude 
materials thusly obtained were purified using flash column chromatography with a gradient from 
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97.5:2.5 hexanes/EtOAc to 90:10 hexanes/EtOAc, yielding 1.05 g (86%) 6.2a as a white solid in 
>20:1 dr and >99.5:0.5 er. 
Characterization data for conjugate addition products: 
Di-tert-butyl 2-(3-nitro-1-oxo-1-phenylbutan-2-yl)malonate (6.2a): 
The title compound was prepared according to the general procedure. No 
minor diastereomer was observed in the crude 1H NMR. White solid (34.7 
mg), mp 93-94 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 7.99 (d, J = 7.4 Hz, 2H), 7.61 (t, 7.4 
Hz, 1H), 7.5 (t, J = 7.8 Hz, 2H), 4.92-4.86 (m, 2H), 3.87 (d, J = 9.8 Hz, 1H), 1.52 (s, 9H), 1.47 (d, 
6.7 Hz, 3H), 1.35 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  197.3, 166.8, 166.2, 137.1, 133.9, 128.8, 
128.6, 83.2, 83.0, 82.4, 55.0, 46.5, 27.8, 27.7, 15.3. IR (thin film) n 2979, 1729, 1682, 1557, 1370, 
1257, 1143, 842, 734, 692 cm-1. HRMS (ESI): Calcd. For C21H29NNaO7+ ([M+Na+]): 430.1842, 
found 430.1831. HPLC Derivatized to 4a for determination of enantiopurity. TLC (10:90 
EtOAc/Hexanes): Rf = 0.25. [a]D = +80.2 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(4-fluorophenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2b): The title compound was prepared according to 
the general procedure. The diastereomeric ratio was determined by 1H 
NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances at δ 
3.92 (minor diastereomer) and δ 3.86 (major diastereomer). The crude materials were purified 
using flash column chromatography, with a gradient from 97.5:2.5 hexanes/EtOAc to 95:5 
hexanes/EtOAc. White solid (34.9 mg), mp 89-90 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 
8.02 (dd, J = 8.8, 5.3 Hz, 2H), 7.17 (t, J = 8.6 Hz, 2H), 4.88-4.83 (m, 2H), 3.87 (d, J = 9.9 Hz, 
1H), 1.53 (s, 9H), 1.48 (d, J = 6 Hz, 3H), 1.36 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  195.7, 
166.7, 166.2, 166.2 (d, J = 256.7 Hz), 133.6, 131.3 (d, J = 9.1 Hz), 116.0 (d, J = 21.14 Hz), 83.29, 
164 
	
83.06, 82.37, 54.9, 46.4, 27.8, 27.8, 15.0; 19F NMR (565 MHz, CDCl3) δ -103.8. IR (thin film) n 
2980, 1729, 1683, 1599, 1557, 1394, 1370, 1257, 1158, 848 cm-1. HRMS (ESI): Calcd. For 
C21H28FNNaO7+ ([M+Na+]): 448.1748, found 448.1729. HPLC Chiralpak AD column, 
Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, 9.0 min (minor isomer), 16.4 min (major 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.16. [a]D = +75.2 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(4-chlorophenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2c): The title compound was prepared according to 
the general procedure. The diastereomeric ratio was determined by 
1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances at 
δ 3.92 (minor diastereomer) and δ 3.87 (major diastereomer). The crude materials were purified 
using flash column chromatography, with a gradient from 97.5:2.5 hexanes/EtOAc to 95:5 
hexanes/EtOAc. White solid (39.0 mg), mp 83-84 °C (decomp); 1H NMR (400 MHz, CDCl3) δ 
7.92 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 4.89-4.81 (m, 2H), 3.86 (d, J = 9.9 Hz, 1H), 1.52 
(s, 9H), 1.47 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.1, 166.6, 166.2, 
140.4, 135.5, 130.0, 129.1, 83.3, 83.1, 82.4, 55.0, 46.4, 27.8, 27.7, 15.1. IR (thin film) n 2980, 
1728, 1683, 1557, 1370, 1258, 1163, 1093, 846, 736 cm-1. HRMS (ESI): Calcd. For 
C21H28ClNNaO7+ ([M+Na+]): 464.1452, found 464.1435. HPLC Chiralpak AD column, 
Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, 9.1 min (minor isomer), 21.8 min (major 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.28. [a]D = +68.6 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(4-bromophenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2d): The title compound was prepared according to 
the general procedure. The diastereomeric ratio was determined by 
1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances at 
165 
	
δ 3.92 (minor diastereomer) and δ 3.86 (major diastereomer). Some residual minor diastereomer 
was still present in the isolated material. The crude materials were purified using flash column 
chromatography, with a gradient from 97.5:2.5 hexanes/EtOAc to 95:5 hexanes/EtOAc. White 
solid (41.1 mg), mp 80-81 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 7.85 (d, J = 8.5 Hz, 2H), 
7.64 (d, J = 8.5 Hz, 2H), 4.88-4.81 (m, 2H), 3.86 (d, J = 10.1 Hz, 1H), 1.52 (s, 9H), 1.48 (d, J = 
6.7 Hz, 3H), 1.36 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.4, 166.6, 166.2, 135.9, 132.1, 130.1, 
129.3, 83.3, 83.1, 82.4, 55.0, 46.4, 27.8, 27.7, 15.1. IR (thin film) n 2979, 1728, 1683, 1557, 1370, 
1258, 1144, 1072, 845, 738 cm-1. HRMS (ESI): Calcd. For C21H28BrNNaO7+ ([M+Na+]): 
508.0947, found 508.0928. HPLC Chiralpak AD column, Hex/iPrOH = 98:2, flow rate = 1.0 
mL/min, λ = 210 nm, 12.9 min (minor isomer), 32.9 min (major isomer). TLC (10:90 
EtOAc/Hexanes): Rf = 0.31. [a]D = +61.4 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(4-cyanophenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2e): The title compound was prepared according to 
the general procedure. No minor diastereomer was observed in the 
crude 1H NMR. White solid (41.3 mg), mp 116-117 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 
8.07 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 4.86-4.81 (m, 2H), 3.89 (d, J = 10.1 Hz, 1H), 
1.54 (s, 9H), 1.50 (d, J = 6.7 Hz, 3H), 1.37 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.5, 166.4, 
166.3, 140.1, 132.6, 128.9, 117.9, 116.8, 83.6, 83.4, 82.3, 55.1, 46.4, 27.8, 27.7, 14.8. IR (thin 
film) n 2980, 2360, 1727, 1688, 1557, 1370, 1294, 1257, 1143, 848 cm-1. HRMS (ESI): Calcd. 
For C22H28N2NaO7+ ([M+Na+]): 455.1794, found 455.1782. HPLC Chiralpak IC column, 
Hex/iPrOH = 99:1, flow rate = 1.0 mL/min, λ = 254 nm, 41.1 min (minor isomer), 43.2 min (major 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.11. [a]D = +47.5 (c = 1.5, CHCl3). 
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Di-tert-butyl 2-(3-nitro-1-(4-nitrophenyl)-1-oxobutan-2-
yl)malonate (6.2f): The title compound was prepared according to 
the general procedure. No minor diastereomer was observed in the 
crude 1H NMR. White solid (42.1 mg), mp 109-110 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 
8.34 (d, J = 8.8 Hz, 2H), 8.14 (d, J = 8.7 Hz, 2H), 4.86 (d, J = 8.8 Hz, 2H), 3.90 (d, J = 10.1 Hz, 
1H), 1.54 (s, 9H), 1.52 (d, J = 6.7 Hz, 3H), 1.38 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.4, 
166.4, 166.3, 150.5, 141.6, 129.6, 123.9, 83.6, 83.5, 82.3, 55.1, 46.7, 27.8, 27.7, 14.8. IR (thin 
film) n 2980, 2936, 2349, 1727, 1530, 1346, 1258, 1144, 850, 734 cm-1. HRMS (ESI): Calcd. For 
C21H28N2NaO9+ ([M+Na+]): 475.1693, found 475.1681. HPLC Chiralpak OD-H column, 
Hex/iPrOH = 99:1, flow rate = 1.0 mL/min, λ = 254 nm, 11.8 min (major isomer), 13.9 min (major 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.28. [a]D = +47.2 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(3-nitro-1-oxo-1-(4-
(trifluoromethyl)phenyl)butan-2-yl)malonate (6.2g): The title 
compound was prepared according to the general procedure. No 
minor diastereomer was observed in the crude 1H NMR. Yellow solid (46.0 mg), mp 68-69 °C 
(decomp); 1H NMR (600 MHz, CDCl3) δ 8.09 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 8.16 Hz, 2H), 4.87 
(d, J = 7.7 Hz, 2H), 3.89 (d, 9.8 Hz, 1H), 1.53 (s, 9H), 1.50 (d, J = 6.1 Hz, 3H), 1.37 (s, 9H); 13C 
NMR (151 MHz, CDCl3) δ  196.7, 166.5, 166.3, 139.8, 134.8 (q, J = 33.2 Hz), 128.9, 125.8 (q, J 
= 3 Hz), 123.5 (q, J = 273.3 Hz), 83.4, 83.3, 82.3, 55.0, 46.6, 27.8, 27.7, 15.0; 19F NMR (565 
MHz, CDCl3) δ -63.2. IR (thin film) n 2981, 2937, 1728, 1689, 1558, 1371, 1325, 1169, 1067, 
850 cm-1. HRMS (ESI): Calcd. For C22H28F3NNaO7+ ([M+Na+]): 498.1716, found 498.1696. 
HPLC Chiralpak AD column, Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 215 nm, 6.5 min 
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(minor isomer), 20.0 min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.29. [a]D = +67.1 
(c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(4-methoxyphenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2h): The title compound was prepared according 
to the general procedure. The diastereomeric ratio was determined 
by 1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances 
at δ 5.05-4.99 (minor diastereomer) and δ 4.90-4.83 (major diastereomer). Some residual minor 
diastereomer was still present in the isolated material. White solid (37.6 mg), mp 63-64 °C 
(decomp); 1H NMR (600 MHz, CDCl3) δ 7.97 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.89-
4.84 (m, 2H), 3.89 (s, 3H), 3.86 (d, J = 9.7 Hz, 1H), 1.52 (s, 9H), 1.47 (d, J = 6.5 Hz, 3H), 1.34 (s, 
9H); 13C NMR (151 MHz, CDCl3) δ  195.3, 166.9, 166.2, 164.2, 131.0, 130.1, 114.0, 83.1, 82.8, 
82.6, 55.5, 54.9, 46.3, 27.8, 27.7, 15.2. IR (thin film) n 2979, 2360, 1729, 1672, 1601, 1556, 1263, 
1168, 1030, 846 cm-1. HRMS (ESI): Calcd. For C22H31NNaO8+ ([M+Na+]): 460.1948, found 
460.1926. HPLC Chiralpak AD column, Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, 
20.3 min (minor isomer), 29.0 min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.17. [a]D 
= +77.9 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(3-methoxyphenyl)-3-nitro-1-oxobutan-2-
yl)malonate (6.2i): The title compound was prepared according to 
the general procedure. No minor diastereomer was observed in the 
crude 1H NMR. White solid (37.1 mg), mp 80-81 °C (decomp); 1H NMR (400 MHz, CDCl3) δ 
7.58 (d, J = 7.8 Hz, 1H), 7.49 (s, 1H), 7.40 (t, J = 8.0 Hz, 1H), 7.15 (dd, J = 8.2, 2.0 Hz, 1H), 4.91-
4.84 (m, 2H), 3.88 (s, 3H), 3.85 (d, signal overlap prevents J value calculation, 1H), 1.52 (s, 9H), 
1.47 (d, J = 6.6 Hz, 3H), 1.35 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  196.9, 166.8, 166.2, 159.8, 
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138.3, 129.8, 121.4, 120.6, 112.5, 83.2, 83.0, 82.4, 55.5, 55.0, 46.7, 27.8, 27.7, 15.4. IR (thin film) 
n 2979, 2937, 1729, 1683, 1557, 1456, 1370, 1270, 1144, 840 cm-1. HRMS (ESI): Calcd. For 
C22H31NNaO8+ ([M+Na+]): 460.1948, found 460.1926. HPLC Chiralpak OD-H column, 
Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 205 nm, 25.3 min (major isomer), 50.5 min (minor 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.17. [a]D = +38.3 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-(benzo[d][1,3]dioxol-5-yl)-3-nitro-1-oxobutan-
2-yl)malonate (6.2j): The title compound was prepared according to 
the general procedure. The diastereomeric ratio was determined by 
1H NMR spectroscopic analysis of the crude reaction mixture by comparison of the resonances at 
δ 3.93 (minor diastereomer) and δ 3.85 (major diastereomer). White solid (35.8 mg), mp 91-92 °C 
(decomp); 1H NMR (600 MHz, CDCl3) δ 7.61 (dd, J = 8.3, 1.7 Hz, 1H), 7.45 (d, J = 1.6 Hz, 1H), 
6.88 (d, J = 8.2 Hz, 1H), 6.08 (s, 2H), 4.88-4.83 (m, 1H), 4.79 (dd, J = 10.2, 5.3 Hz, 1H), 3.85 (d, 
J = 10.2 Hz, 1H), 1.52 (s, 9H), 1.47 (d, J = 6.8 Hz, 3H), 1.37 (s, 9H); 13C NMR (151 MHz, CDCl3) 
δ  194.9, 166.8, 166.2, 152.6, 148.4, 131.9, 125.4, 108.2, 108.1, 102.1, 83.2, 82.9, 82.5, 55.0, 46.4, 
27.8, 27.7, 15.2. IR (thin film) n 3443, 2937, 2349, 1728, 1673, 1556, 1444, 1260, 1144, 1038 cm-
1. HRMS (ESI): Calcd. For C22H29NNaO9+ ([M+Na+]): 474.1740, found 474.1717. HPLC 
Chiralpak AD column, Hex/iPrOH = 96:4, flow rate = 1.0 mL/min, λ = 205 nm, 13.9 min (minor 
isomer), 18.5 min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.22. [a]D = +77.5 (c = 1.5, 
CHCl3). 
Di-tert-butyl 2-(1-(furan-2-yl)-3-nitro-1-oxobutan-2-yl)malonate 
(6.2k): The title compound was prepared according to the general 
procedure. The diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture by comparison of the resonances at δ 3.93 
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(minor diastereomer) and δ 3.81 (major diastereomer). White solid (38.0 mg), mp 88-89 °C 
(decomp); 1H NMR (600 MHz, CDCl3) δ 7.65 (app s, 1H), 7.31 (d, J = 3.6 Hz, 1H), 6.59 (dd, J = 
3.5, 2.7 Hz, 1H), 4.91-4.86 (m, 1H), 4.62 (dd, J = 10.4, 5.1 Hz, 1H), 3.82 (d, J = 10.4 Hz, 1H), 
1.52 (d, signal overlap prevents J value calculation, 3H), 1.51 (s, 9H), 1.37 (s, 9H); 13C NMR (151 
MHz, CDCl3) δ  184.6, 166.5, 166.0, 152.5, 147.6, 118.9, 112.9, 83.2, 83.0, 82.3, 54.2, 47.6, 27.8, 
27.7, 15.0. IR (thin film) n 2980, 2359, 1730, 1674, 1558, 1466, 1296, 1144, 842, 768 cm-1. HRMS 
(ESI): Calcd. For C19H27NNaO8+ ([M+Na+]): 420.1635, found 420.1623. HPLC Chiralpak AD 
column, Hex/iPrOH = 96:4, flow rate = 1.0 mL/min, λ = 210 nm, 10.4 min (minor isomer), 11.8 
min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.15. [a]D = +65.2 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(3-nitro-1-oxo-1-(thiophen-2-yl)butan-2-yl)malonate 
(6.2l): The title compound was prepared according to the general 
procedure. The diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture by comparison of the resonances at δ 3.93 
(minor diastereomer) and δ 3.83 (major diastereomer). White solid (39.4 mg), mp 100-101 °C 
(decomp); 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J = 3.8, 0.8 Hz, 1H), 7.72 (dd, J = 4.9, 0.9 Hz, 
1H), 7.16 (dd, J = 4.8, 4.0 Hz, 1H), 4.94-4.87 (m, 1H), 4.66 (dd, J = 10.2, 5.3 Hz, 1H), 3.82 (d, J 
= 10.2 Hz, 1H), 1.53 (d, J = 7.2 Hz, 3H), 1.51 (s, 9H), 1.35 (s, 9H); 13C NMR (151 MHz, CDCl3) 
δ  189.0, 166.6, 165.9, 144.4 135.7, 133.5, 128.6, 83.3, 83.0, 82.5, 54.6, 48.6, 27.8, 27.6, 15.2. IR 
(thin film) n 2980, 1730, 1660, 1557, 1415, 1370, 1256, 1144, 838, 733 cm-1. HRMS (ESI): Calcd. 
For C19H27NNaO7S+ ([M+Na+]): 436.1406, found 436.1394. HPLC Chiralpak AD column, 
Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 215 nm, 14.1 min (minor isomer), 22.6 min (major 
isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.23. [a]D = +80.6 (c = 1.5, CHCl3). 
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Di-tert-butyl 2-(3-nitro-1-oxo-1-(pyridin-4-yl)butan-2-yl)malonate 
(6.2m): The title compound was prepared according to the general 
procedure. No minor diastereomer was observed in the crude 1H NMR. 
The crude materials were purified using flash column chromatography with a gradient from 90:10 
hexanes/EtOAc to 60:40 hexanes/EtOAc. White solid (35.3 mg), mp 95-96 °C (decomp); 1H NMR 
(600 MHz, CDCl3) δ 8.84 (d, J = 4.6 Hz, 2H), 7.76 (d, J = 4.6 Hz, 2H), 4.88-4.84 (m, 1H), 4.79 
(dd, J = 10.3, 5.0 Hz, 1H), 3.88 (d, J = 10.4 Hz, 1H), 1.53 (s, 9H), 1.51 (d, J = 6.9 Hz, 3H), 1.37 
(s, 9H); 13C NMR (151 MHz, CDCl3) δ  197.3, 166.4, 166.2, 151.0, 143.0, 121.3, 83.5 (2C), 82.3, 
55.1, 46.4, 27.8, 27.7, 15.1. IR (thin film) n 3438, 2980, 2935, 1727, 1696, 1557, 1370, 1257, 
1144, 845 cm-1. HRMS (ESI): Calcd. For C20H29N2O7+ ([M+H+]): 409.1974, found 409.1958. 
HPLC Chiralpak IC column, Hex/iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 225 nm, 12.1 min 
(minor isomer), 18.3 min (major isomer). TLC (20:80 EtOAc/Hexanes): Rf = 0.19. [a]D = +55.5 
(c = 1.5, CHCl3). 
Di-tert-butyl 2-(2-nitro-4-oxopentan-3-yl)malonate (6.2n): The title 
compound was prepared according to the general procedure. The 
diastereomeric ratio was determined by 1H NMR spectroscopic analysis of 
the crude reaction mixture by comparison of the resonances at δ 3.66 (minor diastereomer) and δ 
3.60 (major diastereomer). The crude materials were purified using flash column chromatography, 
with a gradient from 97.5:2.5 hexanes/EtOAc to 95:5 hexanes/EtOAc. Low-melting white solid 
(26.3 mg); 1H NMR (600 MHz, CDCl3) δ 4.73-4.69 (m, 1H), 4.02 (dd, J = 10.3, 4.7 Hz, 1H), 3.62 
(d, J = 10.4 Hz, 1H), 2.30 (s, 3H), 1.50 (s, 12H), 1.45 (s, 9H); 13C NMR (151 MHz, CDCl3) δ  
205.5, 166.6, 166.4, 83.2, 83.0, 82.0, 54.6, 52.0, 32.5, 27.8 (2C), 14.7. IR (thin film) n 2980, 1724, 
1557, 1477, 1458, 1395, 1316, 1144, 1256, 847 cm-1. HRMS (ESI): Calcd. For C16H27NNaO7+ 
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([M+Na+]): 368.1685, found 368.1671. HPLC Chiralpak AD column, Hex/iPrOH = 99:1, flow 
rate = 1.0 mL/min, λ = 210 nm, 6.3 min (minor isomer), 10.2 min (major isomer). TLC (10:90 
EtOAc/Hexanes): Rf = 0.34. [a]D = +30.8 (c = 1.5, CHCl3). 
Di-tert-butyl 2-(1-cyclopropyl-3-nitro-1-oxobutan-2-yl)malonate 
(6.2o): The title compound was prepared according to the general 
procedure. The diastereomeric ratio was determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture by comparison of the resonances at δ 3.77 
(minor diastereomer) and δ 3.62 (major diastereomer). The crude materials were purified using 
flash column chromatography, with a gradient from 97.5:2.5 hexanes/EtOAc to 95:5 
hexanes/EtOAc. White solid (33.3 mg), mp 64-65 °C (decomp); 1H NMR (600 MHz, CDCl3) δ 
4.76-4.72 (m, 1H), 4.32 (dd, J = 10.6, 4.7 Hz, 1H), 3.64 (d, J = 10.7 Hz, 1H), 2.02-1.98 (m, 1H), 
1.50 (s, 9H), 1.48 (d, J = 6.9 Hz, 3H), 1.44 (s, 9H), 1.17-1.12 (m, 1H), 1.05-1.01 (m, 2H), 0.98-
0.95 (m, 1H); 13C NMR (151 MHz, CDCl3) δ  207.2 166.7, 166.3, 83.1, 82.7, 81.7, 54.2, 53.3, 
27.8 (2C), 22.7, 14.6, 13.3, 12.9. IR (thin film) n 2980, 2359, 1730, 1556, 1393, 1370, 1294, 1256, 
1146, 843 cm-1. HRMS (ESI): Calcd. For C18H29NNaO7+ ([M+Na+]): 394.1842, found 394.1826. 
HPLC Chiralpak AD column, Hex/iPrOH = 99:1, flow rate = 1.0 mL/min, λ = 210 nm, 7.9 min 
(minor isomer), 30.1 min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.36. [a]D = +36.5 
(c = 1.5, CHCl3). 
Di-tert-butyl 2-(3-nitro-1-oxo-1-phenylpentan-2-yl)malonate (6.2p): 
The title compound was prepared according to the general procedure. No 
minor diastereomer was observed in the crude 1H NMR. White solid (41.7 
mg), mp 99-100 °C (decomp); 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 7.4 Hz, 2H), 7.62 (t, J 
= 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 4.79 (dd, J = 9.4, 6.0 Hz, 1H), 4.73-4.68 (m, 1H), 3.87 (d, 
172 
	
J = 9.4 Hz, 1H), 1.94-1.82 (m, 1H), 1.78-1.68 (m, 1H), 1.51 (s, 9H), 1.35 (s, 9H), 0.88 (t, J = 7.2 
Hz, 3H); 13C NMR (151 MHz, CDCl3) δ  197.3, 166.7, 166.2, 137.2, 133.8, 128.8, 128.6, 89.9, 
83.1, 83.0, 55.2, 46.4, 27.8, 27.7, 23.5, 10.8. IR (thin film) n 2979, 1741, 1683, 1556, 1370, 1258, 
1144, 845, 735, 692 cm-1. HRMS (ESI): Calcd. For C22H31NNaO7+ ([M+Na+]): 444.1999, found 
444.1981. HPLC Chiralpak AD column, Hex/iPrOH = 98:2, flow rate = 1.0 mL/min, λ = 210 nm, 
11.1 min (minor isomer), 14.1 min (major isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.27. [a]D 
= +78.3 (c = 1.5, CHCl3). 
Procedure for transesterification of 6.2a: 
A one dram vial with a stir bar was charged with di-tert-butyl ester 6.2a (0.058 mmol, 1.0 equiv) 
and trifluoroacetic acid (0.5 mL). The reaction was stirred for 30 min, then placed under a stream 
of nitrogen to evaporate volatiles. The residue was dissolved in 3:2 toluene:MeOH (1 mL, 0.06 M) 
and cooled in an ice bath. A solution of TMSCHN2 (2.0 M in Et2O) was added dropwise until a 
yellow color persisted. The reaction was stirred for 30 min at room temperature then quenched 
dropwise with glacial acetic acid; the acid was added until the yellow color disappeared. After 
stirring for 30 min, ethyl acetate was used to dilute the crude reaction and the organic layer was 
washed with an aqueous saturated sodium bicarbonate solution. The aqueous layer was extracted 
twice with ethyl acetate. The combined organic layers were dried with sodium sulfate, filtered, and 
concentrated in vacuo. The crude materials thusly obtained were purified using flash column 
chromatography with a gradient from 97.5:2.5 hexanes/EtOAc to 90:10 hexanes/EtOAc. 
Dimethyl 2-(3-nitro-1-oxo-1-phenylbutan-2-yl)malonate (6.4a): The 
diastereomeric ratio of the isolated material was determined by 1H NMR 
spectroscopic analysis by comparison of the resonances at δ 4.22 (minor 
diastereomer) and δ 4.08 (major diastereomer). Clear oil (16.4 mg); 1H NMR (600 MHz, CDCl3) 
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δ 8.02 (d, J = 7.3 Hz, 2H), 7.65-7.63 (m, 1H), 7.54-7.51 (m, 2H), 4.98 (dd, J = 9.2, 6.5 Hz, 1H), 
4.96-4.91 (m, 1H), 4.08 (d, J = 9.2 Hz, 1H), 3.80 (s, 3H), 3.69 (s, 3H), 1.47 (d, J = 6.8 Hz, 3H); 
13C NMR (151 MHz, CDCl3) δ  197.3, 167.8, 167.7, 136.8, 134.1, 128.9, 128.7, 82.3, 53.3, 53.2, 
52.6, 46.7, 16.5. IR (thin film) n 2956, 1738, 1682, 1596, 1579, 1437, 1281, 1198, 968, 698 cm-1. 
HRMS (ESI): Calcd. For C15H17NNaO7+ ([M+Na+]): 346.0897, found 346.0893. HPLC Chiralpak 
IC column, Hex/iPrOH = 97:3, flow rate = 1.0 mL/min, λ = 210 nm, 27.3 min (major isomer), 44.1 
min (minor isomer). TLC (10:90 EtOAc/Hexanes): Rf = 0.07. [a]D = +58.8 (c = 0.5, CHCl3). 
Local desymmetrization sequence for transesterification/lactamization of 6.2a: 
A scintillation vial with a stir bar was charged with di-tert-butyl ester 6.2a (0.25 mmol, 1.0 equiv) 
and cooled in an ice bath. Trifluoroacetic acid (1.25 mL) was added slowly and the reaction was 
stirred for 30 min in the ice bath. The reaction was then placed under a stream of nitrogen to 
evaporate volatiles. The residue was dissolved in 3:2 toluene:MeOH (2.5 mL, 0.1 M) and cooled 
in an ice bath. A solution of TMSCHN2 (2.0 M in Et2O) was added dropwise until a yellow color 
persisted. The reaction was stirred for 30 min at room temperature and then cooled in an ice bath 
while it was quenched dropwise with glacial acetic acid; the acid was added until the yellow color 
disappeared. The reaction was allowed to return to room temperature and stir for 30 min. Ethyl 
acetate was used to dilute the crude reaction and the organic layer was washed with an aqueous 
saturated sodium bicarbonate solution. The aqueous layer was extracted twice with ethyl acetate 
and the combined organic layers were dried with sodium sulfate, filtered, and concentrated in 
vacuo. 1H NMR analysis of this crude material indicated that it was >20:1 dr. The material was 
concentrated into a scintillation vial, where it was dissolved in EtOH (2.0 mL) and treated with 
Raney®-Nickel 2800 slurry in H2O (250 mg). The reaction was placed in a high pressure Parr 
reactor under H2 (60 psi); the vessel was filled and purged three times before finally refilling and 
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allowing the reaction to stir for 24 h at room temperature. The crude reaction was flowed through 
a Celite® plug with EtOH and concentrated in vacuo. The diastereomeric ratio could not be 
discerned from the crude 1H NMR. The crude materials were purified using flash column 
chromatography, with a gradient from 60:40 hexanes/EtOAc to 40:60 hexanes/EtOAc to obtain 
the lactam product.  
Methyl 4-benzoyl-5-methyl-2-oxopyrrolidine-3-carboxylate (6.5a): 
The title compound was prepared according to the above procedure. The 
diastereoselectivity could not be determined from the crude 1H NMR. Once 
isolated, the product was found to be 9.1:1 dr, which was determined by compared the signals in 
the 1H NMR at δ 1.38 (major) and δ 1.34 (minor). Clear oil (29.3 mg); 1H NMR (600 MHz, 
CD3OD) δ 8.01 (d, J = 7.6 Hz, 2H), 7.70-7.67 (m, 1H), 7.58-5.55 (m, 2H), 4.38 (dd, J = 7.4, 6.0 
Hz, 1H), 3.89 (d, J = 7.5 Hz, 1H), 3.88-3.85 (m, 1H), 3.75 (s, 3H), 1.38 (d, J = 6.2 Hz, 3H); 13C 
NMR (151 MHz, CD3OD) δ  197.8, 171.1, 169.8, 135.9, 133.7, 128.7, 128.4, 52.0, 51.9, 51.7, 
51.7, 20.3. IR (thin film) n 3231, 2954, 2359, 1705, 1596, 1448, 1381, 1264, 1219, 697 cm-1. 
HRMS (ESI): Calcd. For C14H15NNaO4+ ([M+Na+]): 284.0893, found 284.0895. HPLC Chiralpak 
IA column, Hex/iPrOH = 92:8, flow rate = 1.0 mL/min, λ = 210 nm, 16.8 min (minor isomer), 22.7 
min (major isomer). TLC (50:50 EtOAc/Hexanes): Rf = 0.19. [a]D = +3.15 (c = 1.25, CHCl3). 
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